



Office de la Propriété
Intellectuelle
du Canada

Un organisme
d'Industrie Canada

Canadian
Intellectual Property
Office

An agency of
Industry Canada

CA 2751758 A1 2010/08/19

(21) **2 751 758**

(12) **DEMANDE DE BREVET CANADIEN
CANADIAN PATENT APPLICATION**

(13) **A1**

(86) Date de dépôt PCT/PCT Filing Date: 2010/02/11
(87) Date publication PCT/PCT Publication Date: 2010/08/19
(85) Entrée phase nationale/National Entry: 2011/08/05
(86) N° demande PCT/PCT Application No.: US 2010/023939
(87) N° publication PCT/PCT Publication No.: 2010/093820
(30) Priorité/Priority: 2009/02/11 (US61/207,450)

(51) Cl.Int./Int.Cl. *C12Q 1/68* (2006.01),
C12P 19/34 (2006.01), *C07K 14/65* (2006.01),
C40B 30/04 (2006.01), *C40B 40/06* (2006.01)

(71) Demandeur/Applicant:
ORION GENOMICS LLC, US

(72) Inventeurs/Inventors:
ORDWAY, JARED, US;
MALONEY, REBECCA, US;
LAKEY, NATHAN, US;
BUDIMAN, MUHAMMAD A., US

(74) Agent: FETHERSTONHAUGH & CO.

(54) Titre : COMBINAISONS DE POLYMORPHISMES DESTINEES A DETERMINER L'EXPRESSION SPECIFIQUE DES ALLELES D'IGF2

(54) Title: COMBINATIONS OF POLYMORPHISMS FOR DETERMINING ALLELE-SPECIFIC EXPRESSION OF IGF2

(57) Abrégé/Abstract:

Combinations of SNPs and reagents for detecting such SNPs, as well as methods of detecting IGF loss-of-imprinting as provided.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
19 August 2010 (19.08.2010)

(10) International Publication Number
WO 2010/093820 A3

(51) International Patent Classification:
C12Q 1/68 (2006.01)

(21) International Application Number:
PCT/US2010/023939

(22) International Filing Date:
11 February 2010 (11.02.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/207,450 11 February 2009 (11.02.2009) US

(71) Applicant (for all designated States except US): **ORION GENOMICS LLC** [US/US]; 4041 Forest Park Avenue, St. Louis, Missouri 63108 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ORDWAY, Jared** [US/US]; 4266 Castleman Avenue, St. Louis, Missouri 63110 (US). **MALONEY, Rebecca** [US/US]; 13581 Lavender Mist Lane, Centreville, Virginia 20120 (US). **LAKEY, Nathan** [US/US]; 2040 Wilson Ridge Lane, Chesterfield, Missouri 63005 (US). **BUDIMAN, Muhammad A.** [ID/US]; 144 Spruce Tree Lane, Manchester, Missouri 63124 (US).

(74) Agents: **LOCKYER, Jean M.** et al.; Townsend and Townsend and Crew LLP, Two Embarcadero Center, 8th Floor, San Francisco, California 94111-3834 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(88) Date of publication of the international search report:
14 October 2010

(54) Title: COMBINATIONS OF POLYMORPHISMS FOR DETERMINING ALLELE-SPECIFIC EXPRESSION OF IGF2

(57) Abstract: Combinations of SNPs and reagents for detecting such SNPs, as well as methods of detecting IGF loss-of-imprinting as provided.



WO 2010/093820 A3

COMBINATIONS OF POLYMORPHISMS FOR DETERMINING ALLELE-SPECIFIC EXPRESSION OF IGF2

CROSS-REFERENCE TO RELATED APPLICATIONS

5 [0001] This application claims benefit of U.S. provisional application no. 61/207,450, filed February 11, 2009, which application is herein incorporated by reference.

BACKGROUND OF THE INVENTION

[0002] The gene for insulin-like growth factor 2, or *IGF2*, is located in a cluster of imprinted genes on human chromosome 11p15.5. Genomic imprinting is an important
10 mechanism of gene regulation where one copy of the gene is normally expressed and the other copy is silenced through an epigenetic mark of parental origin. *IGF2* is normally maternally imprinted in human tissues and therefore, expressed only from the paternally inherited copy of the gene (DeChiara TM, et al. *Cell* **64**, 849-859 (1991); Rainier S, et al., *Nature* **362**, 747-749 (1993); Ogawa, et al, *Nature* **362**, 749-751 (1993)). Loss of
15 imprinting of *IGF2* (referred to as loss of imprinting, or LOI) has been strongly linked to several cancer types (over 20 tumor types reviewed in Falls, et al. 1999, *AJP* 154, 635-647). Furthermore, mounting evidence indicates that individuals displaying LOI of *IGF2* may be at elevated risk for developing colorectal cancer (Kinochi et al., 1996, *Cancer Letters* 107, 105-108 (1996); Nishihara S. 2000, *Int. Jour. Oncol.* 17, 317-322; Cui H 1998, *Nature*
20 *Medicine* 4-11, 1276-1280; Nakagawa H 2001, *PNAS* 98-2, 591-596). LOI of *IGF2* can be detected in normal tissues of cancer patients including peripheral blood and normal colonic mucosa (Kinochi et al., 1996, *Cancer Letters* 107, 105-108 (1996); Ogawa, et al, *Nature Genetics* **5**, 408-412 (1993); Cui H, *Science* 299, 1753 (2003)) and in the normal tissues of people believed to be cancer free (Cui H, et al. *Nature Medicine* 4-11, 1276-1280 (1998);
25 Cui H, *Science* 299, 1753 (2003); Woodson K et al., *JNCI* 96, 407-410 (2004); Cruz-Correa Met al., *Gastroenterology* 126, 964-970 (2004)).

[0003] Several studies of peripheral blood of general populations report that between 7-10% of people display loss of imprinting of *IGF2* in colonic mucosa tissue. Three retrospective studies report that the odds of colorectal cancer patients displaying LOI of
30 *IGF2* in either peripheral blood or colonic mucosa are significantly higher (between 2-21 fold) than the odds of an age matched cancer free control group displaying LOI. These

studies suggest that LOI of *IGF2* may predispose otherwise healthy individuals to colorectal cancer. Therefore, a risk test based on the detection of LOI of *IGF2* may have a future clinical benefit, (Cui H, et al. *Nature Medicine* 4-11, 1276-1280 (1998); Cui H, *Science* 14, 1753-1755 (2003); Woodson K 2004, *JNCI* 96, 407-410; Cruz-Correa M, *Gastroenterology* 5 126, 964-970 (2004)). These studies show that people with LOI of *IGF2* (also referred to as the *IGF2* biomarker) may be up to 20 times more likely to develop colorectal cancer than individuals without the *IGF2* biomarker.

[0004] Detection of LOI of *IGF2* is based on a quantitative allele specific gene expression assay, where transcripts from both copies of the *IGF2* gene are each quantified. The 10 quantities are then compared to one another to determine an allelic gene expression ratio, which is subsequently compared to a threshold value. If the concentration of the lesser abundant allele is “relatively similar” to the concentration of the more abundant allele, then the *IGF2* imprint is determined to be lost. If the concentration of the lesser abundant allele is “relatively dissimilar” to the concentration of the more abundant allele, then the *IGF2* 15 imprint is determined to be present. One method of measuring the imprinting status of *IGF2* in a sample is to first determine the genotype(s) of one or more polymorphic sites in the transcribed region of the *IGF2* gene. Heterozygous markers in the transcribed region of the gene provide for convenient molecular handles by which the individual alleles of the *IGF2* gene can be distinguished from one another in a sample. RNA transcription from each 20 of the two copies of the *IGF2* gene may be independently measured with quantitative allele specific assays. Comparison of the amount of expression of one allele to the amount of expression of the other allele can therefore be made and the imprinting status of the *IGF2* gene can be determined (see Figure 2).

[0005] *IGF2* has four promoters, each driving expression of alternatively spliced 25 transcripts, in a tissue specific manner (Figure 1). Exons 7, 8, and 9 are present in all transcripts, while exons 1-6 have been reported to be expressed in a promoter specific fashion. Exon 9 includes a short stretch of protein-coding sequence followed by a considerably longer 3' UTR. Polymorphic markers in exons 7, 8, and 9 are therefore useful in the determination of *IGF2* imprinting status by enabling the detection of allele specific 30 expression of *IGF2* transcription driven from any of the four *IGF2* promoters.

[0006] Four allele-specific expression assays measuring *IGF2* imprinting status are known to those skilled in the art. Woodson, *et al.* measured imprinting status of *IGF2* with

a combination of two SNP based assays (rs680 and rs2230949) (Woodson K 2004, JNCI 96, 407-410). Both SNPs are in exon 9 of IGF2 but are reported by Woodson *et al.* to be in minimal linkage disequilibrium. Therefore attempts to measure LOI of an individual with such a combination of markers increases the probability that the individual will be

heterozygous for at least one of the two SNPs, and thereby increase the likelihood that the LOI status of the individual can be determined. The authors demonstrated that the first SNP, the second SNP, or both SNPs were informative (*i.e.*, were heterozygous and, therefore, permitted measurement of LOI of *IGF2*) in 48 of 106 patients evaluated (or 45%). Cui *et al.* measured *IGF2* imprinting with a combination of two assays, one targeting a SNP (rs680) and a second measuring restriction fragment length polymorphisms of a simple sequence repeat within exon 9 of IGF2. The authors demonstrated that the SNP, the repeat, or both markers were informative in 191 of 421 (or 45%) patients evaluated (Cui H, et al. *Nature Medicine* 4-11, 1276-1280 (1998)).

[0007] Previous studies have demonstrated that use of these polymorphisms result in a low combined frequency of heterozygosity in patient populations and, therefore, a large number of individuals in these populations were “uninformative” such that their *IGF2* imprinting status could not be determined. The present application describes newly discovered SNPs in *IGF2* exon 9, and the discovery of useful combinations of SNPs, which enable successful LOI measurements in an increased proportion of the human population.

The ability to measure LOI using these polymorphisms in the general population will have a profound medical benefit, serving as the basis for various molecular diagnostic and therapeutic tests.

[0008] The informativity of a given SNP for detection of LOI is based on the frequency of heterozygosity of the SNP within a population. Furthermore, the optimal informativity of a combination of different SNPs is dependent upon the linkage among the different markers. For example, if two SNPs fall within a common haplotype block, the combined use of the two SNPs provides a minimal increase in informativity relative to the use of either of the two SNPs alone. However, if two SNPs are not on the same haplotype block (*i.e.*, are in minimal linkage disequilibrium), the combined use of the two SNPs provides an effective increase in informativity relative to the use of either of the two SNPs alone.

BRIEF SUMMARY OF THE INVENTION

[0009] The present invention provides methods of determining loss-of-imprinting in the Insulin Growth Factor-2 (IGF2) gene of an individual. In some embodiments, the method comprises,

5 detecting the SNP genotype of the IGF2 gene in the individual, wherein the genotype of at least three SNPs selected from the group consisting of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and 16 is determined, thereby determining whether the individual is heterozygous or homozygous at each of the at least three SNPs;

quantifying in a sample from the individual the amount of RNA comprising
10 two polymorphic options of at least one heterozygous SNP;

determining a ratio of the amount of RNA comprising two polymorphic options of at least one heterozygous SNP; and

correlating the RNA ratio to loss of imprinting of the IGF2 gene.

[0010] In some embodiments, at least one SNP in the detecting step is selected from the
15 group consisting of SEQ ID NO:1, 2, 3, 4, 5, and 6.

[0011] In some embodiments, the correlating step further comprises correlating the relative amount of RNA comprising the polymorphic options of the at least one heterozygous SNP to an increased risk of cancer, a diagnosis or prognosis of cancer, or a prediction of efficacy of a drug for ameliorating, treating or preventing cancer.

20 [0012] In some embodiments, at least two of the detected SNPs are heterozygous and the quantifying step comprises quantifying the amount of RNA comprising two polymorphic options at the at least two heterozygous SNPs.

[0013] In some embodiments, the sample is a blood, stool, cell scrape or tissue sample.

[0014] In some embodiments, the RNA is reverse transcribed into cDNA and the quantity
25 of cDNA comprising each polymorphic option is used to determine the amount of RNA comprising the two polymorphic options. In some embodiments, the amount of allele-specific cDNA is quantified in a method comprising contacting the cDNA with at least one allele-specific detection polynucleotide. In some embodiments, the method comprises contacting the cDNA with a sufficient number of allele-specific detection polynucleotides
30 such that the polymorphic option for each heterozygous SNP from the group is determined. In some embodiments, the method comprises contacting the cDNA with a number of different allele-specific detection polynucleotides, wherein the number is equal to or greater

than the number of heterozygous SNPs in the group such that at least one different allele-specific detection polynucleotide is used to detect each different heterozygous SNP. In some embodiments, the at least one allele-specific detection polynucleotide is hybridized to the cDNA and extended in a template-dependent manner through the polymorphic position
 5 of the SNP in the cDNA.

[0015] In some embodiments, the at least one allele-specific detection polynucleotide comprises at least 8 (e.g., at least 10, 12, 15) contiguous nucleotides at the 3' end of the allele-specific detection polynucleotide, wherein the at least 8 contiguous nucleotides are either:

- 10 100% complementary to at least 8 (e.g., at least 10, 12, 15) nucleotides directly 3' (or is 2 or 3 nucleotides 3') of the polymorphic position of the SNP region set forth in the SEQ ID NO:; or
- 100% identical to at least 8 (e.g., at least 10, 12, 15) nucleotides directly 5' (or is 2 or 3 nucleotides 5') of the polymorphic position of the SNP region set forth in the
- 15 SEQ ID NO: [or, e.g., 100% identical to at least 8 (e.g., at least 10, 12, 15, 20) nucleotides directly 3' (or is 2 or 3 nucleotides 3') of the polymorphic position of the complement of the SNP region].

[0016] In some embodiments, the at least one allele-specific detection polynucleotide comprises a sequence 100% identical to at least 8 (e.g., at least 10, 12, 15) contiguous
 20 nucleotides, or the complement thereof, of at least one heterozygous SNP, and the sequence consists of at least 8 (e.g., at least 10, 12, 15) contiguous nucleotides, or the complement thereof, of the SNP, wherein one of the positions of the sequence corresponds to the variable position of the SNP.

[0017] In some embodiments, the detecting step comprises detecting the SNP genotype of
 25 each polymorphic option of each of:

SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and 16; or

SEQ ID NOs: 1, 5, 8, 9, 10, 11, 14, 15, and 16; or

SEQ ID NOs: 1, 5, 8, 9, 10, 11, 12, 14, 15, and 16; or

SEQ ID NOs: 1, 2, 4, 5, 8, 9, 10, 12, 13, 14, 15, and 16.

30 **[0018]** In some embodiments, the detecting step comprises detecting at least 4 (e.g., 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15) SNPs selected from the group.

[0019] In some embodiments, the detecting step comprises contacting the sample with a first, second and third polynucleotides as described herein (e.g., below with regard to reaction mixtures or kits).

5 [0020] In some embodiments, the method further comprises providing a risk classification of cancer, diagnosis of cancer, or prognosis based on the correlating step, and/or submitting the individual to a disease screening procedure (e.g., colonoscopy) based on the correlating step, and/or submitting a sample from the individual to further diagnostic or prognostics assays based on the correlating step and/or changing a drug or other treatment regimen of the individual based on the correlating step.

10 [0021] The present invention also provides reaction mixtures. In some embodiments, the reaction mixture comprises,

a first polynucleotide of between 8-100 nucleotides, wherein the first polynucleotide distinguishes between one polymorphic option of a first SNP (or complement thereof) and the other polymorphic option of the first SNP (or complement thereof) in a hybridization reaction,

a second polynucleotide of between 8-100 nucleotides, wherein the second polynucleotide distinguishes between one polymorphic option of a second SNP (or complement thereof) and the other polymorphic option of the second SNP (or complement thereof) in a hybridization reaction, and

20 a third polynucleotide of between 8-100 nucleotides, wherein the third polynucleotide distinguishes between one polymorphic option of a third SNP (or complement thereof) and the other polymorphic option of the third SNP (or complement thereof) in a hybridization reaction, wherein the first and second and third SNP is selected from the group consisting of SEQ ID NOs:1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and 25 16, wherein at least one SNP is 1, 2, 3, 4, 5, or 6.

[0022] In some embodiments, at least one, at least two, or three of the first, second, and third polynucleotide comprise a sequence 100% identical to at least 8 (e.g., at least 10, 12, 15, 20) contiguous nucleotides, or the complement thereof, of the SEQ ID NO: corresponding to the first and second and third SNP, respectively.

30 [0023] In some embodiments, the sequence consists of at least 8 (e.g., at least 10, 12, 15, 20) contiguous nucleotides, or the complement thereof, of the SNP, wherein one of the positions of the sequence corresponds to the variable position of the SNP.

[0024] In some embodiments, the reaction mixture further comprises a sample comprising nucleic acids from a human.

[0025] In some embodiments, the reaction mixture further comprises a polymerase.

[0026] In some embodiments, the polymerase is a thermostable polymerase.

5 [0027] In some embodiments, at least one of the first and second and third polynucleotides are detectably labeled. In some embodiments, the detectable label is a fluorescent label. In some embodiments, the first and second and third polynucleotides are detectably labeled with different labels such that the different labels can be differentially detected based on different wavelength of fluorescence of the labels or different mass of the
10 labels.

[0028] In some embodiments, the reaction mixture comprises a plurality of different allele-specific detection polynucleotide of between 8-100 nucleotides, such that at least one polynucleotide of the plurality distinguishes between one allele of a SNP (or complement thereof) and the other allele of the SNP (or complement thereof) in a hybridization reaction
15 for each of:

SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and 16; or

SEQ ID NOs: 1, 5, 8, 9, 10, 11, 14, 15, and 16; or

SEQ ID NOs: 1, 5, 8, 9, 10, 11, 12, 14, 15, and 16; or

SEQ ID NOs: 1, 2, 4, 5, 8, 9, 10, 12, 13, 14, 15, and 16.

20 [0029] In some embodiments, the reaction mixture comprises
a first allele-specific detection polynucleotide of between 8-100 nucleotides,
a second allele-specific detection polynucleotide of between 8-100
nucleotides,
a third allele-specific detection polynucleotide of between 8-100 nucleotides,
25 wherein each of the first, second, and third polynucleotides comprise at least
8 (e.g., at least 10, 12, 15, 20) contiguous nucleotides at the 3' end of the allele-specific
detection polynucleotide, wherein the at least 8 contiguous nucleotides are either:
100% complementary to at least 8 (e.g., at least 10, 12, 15, 20) nucleotides
directly 3' (or is 2 or 3 nucleotides 3') of the polymorphic position of a SNP region; or
30 100% identical to at least 8 (e.g., at least 10, 12, 15, 20) nucleotides directly
5' (or is 2 or 3 nucleotides 5') of the polymorphic position of a SNP region,

wherein the SNP region corresponding to each of the first, second, and third polynucleotides is different and the SNP regions are selected from the group consisting of SEQ ID NOs:1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and 16, wherein at least one SNP region is SEQ ID NO:1, 2, 3, 4, 5, or 6.

5 [0030] In some embodiments, the reaction mixture further comprises a sample comprising nucleic acids from a human.

[0031] In some embodiments, the reaction mixture further comprises a polymerase. In some embodiments, the polymerase is a thermostable polymerase.

10 [0032] In some embodiments, at least one of the first and second and third polynucleotides are detectably labeled. In some embodiments, the detectable label is a fluorescent label. In some embodiments, the first and second and third polynucleotides are detectably labeled with different labels such that the different labels can be differentially detected based on different wavelength of fluorescence of the labels or different mass of the labels.

15 [0033] In some embodiments, the reaction mixture comprises a plurality of different allele-specific detection polynucleotides, wherein each of the plurality of polynucleotides comprise at least 8 (e.g., at least 10, 12, 15, 20) contiguous nucleotides at the 3' end of the allele-specific detection polynucleotide, wherein the at least 8 contiguous nucleotides are either:

20 100% complementary to at least 8 (e.g., at least 10, 12, 15, 20) nucleotides directly 3' (or is 2 or 3 nucleotides 3') of the polymorphic position of a SNP region; or
100% identical to at least 8 (e.g., at least 10, 12, 15, 20) nucleotides directly 5' (or is 2 or 3 nucleotides 5') of the polymorphic position of a SNP region,

wherein the plurality includes a sufficient number of polynucleotides such at
25 least one polynucleotide corresponds to each of the following SNP regions:

SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and 16; or

SEQ ID NOs: 1, 5, 8, 9, 10, 11, 14, 15, and 16; or

SEQ ID NOs: 1, 5, 8, 9, 10, 11, 12, 14, 15, and 16; or

SEQ ID NOs: 1, 2, 4, 5, 8, 9, 10, 12, 13, 14, 15, and 16.

30 [0034] The present invention also provides kits useful for performing the methods of the invention. In some embodiments, the kit comprises

a first polynucleotide of between 8-100 nucleotides, wherein the first polynucleotide distinguishes between one polymorphic option of a first SNP (or complement thereof) and the other polymorphic option of the first SNP (or complement thereof) in a hybridization reaction,

5 a second polynucleotide of between 8-100 nucleotides, wherein the second polynucleotide distinguishes between one polymorphic option of a second SNP (or complement thereof) and the other polymorphic option of the second SNP (or complement thereof) in a hybridization reaction,

10 a third polynucleotide of between 8-100 nucleotides, wherein the third polynucleotide distinguishes between one polymorphic option of a third SNP (or complement thereof) and the other polymorphic option of the third SNP (or complement thereof) in a hybridization reaction, wherein the first and second and third SNP is selected from the group consisting of SEQ ID NOs:1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and 16, wherein at least one SNP is selected from SEQ ID NO:1, 2, 3, 4, 5, or 6.

15 **[0035]** In some embodiments, at least one, at least two, or three of the first, second, and third polynucleotide comprise a sequence 100% identical to at least 8 (e.g., at least 10, 12, 15, 20) contiguous nucleotides, or the complement thereof, of the SEQ ID NO: corresponding to the first and second and third SNP, respectively.

20 **[0036]** In some embodiments, the sequence consists of at least 8 (e.g., at least 10, 12, 15, 20) contiguous nucleotides, or the complement thereof, of the SNP, wherein one of the positions of the sequence corresponds to the variable position of the SNP.

[0037] In some embodiments, the kit further comprises a polymerase. In some embodiments, the polymerase is a thermostable polymerase.

25 **[0038]** In some embodiments, at least one of the first and second and third polynucleotides are detectably labeled. In some embodiments, the detectable label is a fluorescent label. In some embodiments, the first and second and third polynucleotides are detectably labeled with different labels such that the different labels can be differentially detected based on different wavelength of fluorescence of the labels or different mass of the labels.

30 **[0039]** In some embodiments, the kit comprises a plurality of different allele-specific detection polynucleotide of between 8-100 nucleotides, such that at least one polynucleotide

of the plurality distinguishes between one allele of a SNP (or complement thereof) and the other allele of the SNP (or complement thereof) in a hybridization reaction for each of:

SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and 16; or

SEQ ID NOs: 1, 5, 8, 9, 10, 11, 14, 15, and 16; or

5 SEQ ID NOs: 1, 5, 8, 9, 10, 11, 12, 14, 15, and 16; or

SEQ ID NOs: 1, 2, 4, 5, 8, 9, 10, 12, 13, 14, 15, and 16.

[0040] In some embodiments, the kit comprises:

a first allele-specific detection polynucleotide of between 8-100 nucleotides,

a second allele-specific detection polynucleotide of between 8-100

10 nucleotides,

a third allele-specific detection polynucleotide of between 8-100 nucleotides,

wherein each of the first, second, and third polynucleotides comprise at least 8 (e.g., at least 10, 12, 15, 20) contiguous nucleotides at the 3' end of the allele-specific detection polynucleotide, wherein the at least 8 contiguous nucleotides are either:

15 100% complementary to at least 8 (e.g., at least 10, 12, 15, 20) nucleotides directly 3' (or is 2 or 3 nucleotides 3') of the polymorphic position of a SNP region; or

100% identical to at least 8 (e.g., at least 10, 12, 15, 20) nucleotides directly 5' (or is 2 or 3 nucleotides 5') of the polymorphic position of a SNP region [or, e.g., 100% identical to at least 8 (e.g., at least 10, 12, 15, 20) nucleotides directly 3' (or is 2 or 3

20 nucleotides 3') of the polymorphic position of the complement of the SNP region],

wherein the SNP region corresponding to each of the first, second, and third polynucleotides is different and the SNP regions are selected from the group consisting of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and 16, wherein at least one SNP region is SEQ ID NO: 1, 2, 3, 4, 5, or 6.

25 **[0041]** In some embodiments, the kit further comprises a sample comprising nucleic acids from a human.

[0042] In some embodiments, the kit further comprises a polymerase. In some embodiments, the polymerase is a thermostable polymerase.

[0043] In some embodiments, at least one of the first and second and third
30 polynucleotides are detectably labeled. In some embodiments, the detectable label is a fluorescent label. In some embodiments, the first and second and third polynucleotides are detectably labeled with different labels such that the different labels can be differentially

detected based on different wavelength of fluorescence of the labels or different mass of the labels.

[0044] In some embodiments, the kit comprises a plurality of different allele-specific detection polynucleotides, wherein each of the plurality of polynucleotides comprise at least 8 (e.g., at least 10, 12, 15, 20) contiguous nucleotides at the 3' end of the allele-specific detection polynucleotide, wherein the at least 8 contiguous nucleotides are either:

100% complementary to at least 8 (e.g., at least 10, 12, 15, 20) nucleotides directly 3' (or is 2 or 3 nucleotides 3') of the polymorphic position of a SNP region; or

100% identical to at least 8 (e.g., at least 10, 12, 15, 20) nucleotides directly 5' (or is 2 or 3 nucleotides 5') of the polymorphic position of a SNP region,

wherein the plurality includes a sufficient number of polynucleotides such at least one polynucleotide corresponds to each of the following SNP regions:

SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and 16; or

SEQ ID NOs: 1, 5, 8, 9, 10, 11, 14, 15, and 16; or

15 SEQ ID NOs: 1, 5, 8, 9, 10, 11, 12, 14, 15, and 16; or

SEQ ID NOs: 1, 2, 4, 5, 8, 9, 10, 12, 13, 14, 15, and 16.

[0045] The present invention also provides computer-implemented methods for determining loss-of-imprinting in the Insulin Growth Factor-2 (IGF2) gene. In some embodiments, the method comprises:

20 (a) receiving, at a host computer, genotype values for at least three SNPs selected from the group consisting of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and 16, wherein the genotype is determined from a sample from an individual; and

(b) receiving, at a host computer, a value representing the amount of RNA comprising each polymorphic option of at least one heterozygous SNP selected from the group consisting of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and 16, wherein the RNA is from a sample from an individual; and

(c) determining, at a host computer, a ratio of the amount of RNA comprising two polymorphic options of at least one heterozygous SNP; and

(d) outputting to a human the RNA ratio or correlating in the host computer, the RNA ratio to loss of imprinting of the IGF2 gene, and optionally outputting to a human the result of the correlating step.

[0046] In some embodiments, at least one SNP is selected from SEQ ID NO: 1, 2, 3, 4, 5, or 6. In some embodiments, the correlating step further comprises correlating the relative amount of RNA comprising the polymorphic options of the at least one heterozygous SNP to an increased risk of cancer, a diagnosis or prognosis of cancer, or a prediction of efficacy of a drug for ameliorating, treating or preventing cancer.

[0047] In some embodiments, the receiving step (a) comprises receiving a value representing the amount of RNA having each polymorphic option of each of

SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and 16; or

SEQ ID NOs: 1, 5, 8, 9, 10, 11, 14, 15, and 16; or

10 SEQ ID NOs: 1, 5, 8, 9, 10, 11, 12, 14, 15, and 16; or

SEQ ID NOs: 1, 2, 4, 5, 8, 9, 10, 12, 13, 14, 15, and 16.

[0048] In some embodiments, the receiving step (a) comprises receiving a value representing the amount of RNA having each polymorphic option of each of at least 4 (e.g., 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15) SNPs selected from the group.

15 [0049] The present invention provides a computer program product for determining loss-of-imprinting in the Insulin Growth Factor-2 (IGF2) gene. In some embodiments, the computer readable product comprises:

a computer readable medium encoded with program code, the program code including:

20 program code for receiving genotype values for at least three SNPs selected from the group consisting of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and 16, wherein the genotype is determined from a sample from an individual;

program code for receiving a value representing the amount of RNA comprising each polymorphic option of at least one heterozygous SNP selected from the group consisting of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and 16, wherein the RNA is from a sample from an individual;

program code for determining a ratio of the amount of RNA comprising two polymorphic options of at least one heterozygous SNP; and

optionally, program code for correlating in the host computer, the RNA ratio to loss of imprinting of the IGF2 gene.

[0050] In some embodiments, at least one SNP is selected from SEQ ID NO: 1, 2, 3, 4, 5, or 6.

[0051] In some embodiments, the program code for correlating the relative amount of RNA comprises the polymorphic options of the at least one heterozygous SNP to an increased risk of cancer, a diagnosis or prognosis of cancer, or a prediction of efficacy of a drug for ameliorating, treating or preventing cancer.

5 [0052] In some embodiments, program code includes program code for receiving information representing the presence or absence of each polymorphic option of the at least three SNPs in genomic DNA in the sample; and program code for determining whether the individual is heterozygous for the at least two SNPs.

[0053] In some embodiments, program code includes program code for receiving a value
10 representing the amount of RNA having each polymorphic option of each of

SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and 16; or

SEQ ID NOs: 1, 5, 8, 9, 10, 11, 14, 15, and 16; or

SEQ ID NOs: 1, 5, 8, 9, 10, 11, 12, 14, 15, and 16; or

SEQ ID NOs: 1, 2, 4, 5, 8, 9, 10, 12, 13, 14, 15, and 16.

15 [0054] In some embodiments, the program code includes program code for receiving a genotype value representing for each of at least 4 (e.g., 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15) SNPs selected from the group.

[0055] In a further aspect, the invention also provide a pair of control isolated nucleic acid members, substantially free of cellular nucleic acids, wherein both members of the pair
20 comprise at least two Insulin Growth Factor-2 (IGF2) single nucleotide polymorphism (SNP) sequences, wherein:

(a) one member of the pair comprises a polynucleotide that comprises one allele of the at least two *IGF2* SNPs, wherein the 3' nucleic acid sequence directly adjacent to the first SNP site is substantially identical to at least 15 contiguous nucleotides (e.g., at least 20, 25,
25 or 50 contiguous nucleotides) of the corresponding region of SEQ ID NO:17, 18, 21, or 23; and the 3' nucleic acid sequence directly adjacent to the second SNP site is substantially identical to at least 15 contiguous nucleotides (e.g., at least 20, 25, or 50 contiguous nucleotides) of the corresponding region of SEQ ID NO:17, 18, 21, or 23; and

(b) the second member of the pair comprises a polynucleotide comprising an alternate
30 allele of the at least two *IGF2* SNPs; wherein the 3' nucleic acid sequence directly adjacent to the first SNP site is substantially identical to at least 15 contiguous nucleotides (e.g., at least 20, 25, or 50 contiguous nucleotides) of the corresponding region of SEQ ID NO:17,

18, 21, or 23 and the 3' nucleic acid sequence directly adjacent to the second SNP site is substantially identical to at least 15 contiguous nucleotides (e.g., at least 20, 25, or 50 contiguous nucleotides) of the corresponding region of SEQ ID NO:17, 18, 21, or 23.

5 [0056] In some embodiments of the pair, at least one of the SNPs is selected from the group consisting of the SNP as shown in SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and 16. In some embodiments, at least two of the SNPs are selected from the group consisting of the SNP as shown in SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and 16. In some embodiments, at least one of the SNPs is selected from the group consisting of the SNP as shown in SEQ ID NOs: 1, 2, 3, 4, 5, and

10 [0057] In some embodiments of the pair at least two IGF2 SNPs comprise three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen or sixteen IGF2 SNPs.

[0058] In some embodiments of the pair of control nucleic acids, the SNPs comprise the SNPs as shown in:

15 SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and 16;
 SEQ ID NOs: 1, 5, 8, 9, 10, 11, 14, 15, and 16;
 SEQ ID NOs. 1, 5, 8, 9, 10, 11, 12, 14, 15, and 16; or
 SEQ ID NOs. 1, 2, 4, 5, 8, 9, 10, 12, 13, 14, 15, and 16.

[0059] In some embodiment of the control pair, the first member of the pair comprises a
 20 polynucleotide that has at least 8 contiguous nucleotides (e.g., at least 10, 12, 15, 20, or 25 contiguous nucleotides) of one allele of SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16, or the complement thereof; and the second member of the pair comprises a polynucleotide that has at least 8 contiguous nucleotides (e.g., at least 10, 12, 15, 20, or 25 contiguous nucleotides) of the alternative allele of SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 10,
 25 11, 12, 13, 14, 15, or 16, or the complement thereof.

[0060] In some embodiments, one of the members of the pair comprises at least two minor alleles of the SNPs.

[0061] In some embodiments, the pair of isolated nucleic acid members are RNA.

[0062] In some embodiments, the pair of isolated nucleic acid members are DNA.

[0063] In some embodiments, the polynucleotide of one member of the pairs is operably linked to a promoter and the polynucleotide of the second member of the pair is operably linked to a promoter.

5 [0064] In some embodiments, the members of the pair comprise less than 500 nucleotides of the sequence set forth in SEQ ID NO:22.

[0065] In some embodiments, the members of the pair are separated. Alternatively, the members of the pair are in a mix together.

10 [0066] The invention also provides a mixture comprising a pair of isolated control nucleic acid members as described herein, *e.g.*, a pair of nucleic acids described herein above. In some embodiments, the members of the pair are present in equimolar amounts.

[0067] In some embodiments, the mixture further comprises a second pair of isolated nucleic acids, substantially free of cellular nucleic acids, wherein both members of the second pair comprise at least one *IGF2* SNP sequence and wherein the at least one *IGF2* SNP sequence in the second pair is different from the *IGF2* SNPs in the first pair; and
15 (c) one member of the second pair comprises one allele of the at least one *IGF2* SNP, wherein the 3' nucleic acid sequence directly adjacent to the SNP site is substantially identical to at least 15 contiguous nucleotides (*e.g.*, at least 20, 25, or 50 contiguous nucleotides) of the corresponding region of SEQ ID NO:17, 18, 21, or 23 of the corresponding region of SEQ ID NO:17, 18, 21, or 23; and
20 (d) the other member of the second pair comprises an alternate allele of the at least one *IGF2* SNP; wherein the 3' nucleic acid sequence directly adjacent to the SNP site is substantially identical to at least 15 contiguous nucleotides (*e.g.*, at least 20, 25, or 50 contiguous nucleotides) of the corresponding region of SEQ ID NO:17, 18, 21, or 23.

25 [0068] The invention additionally comprises a kit comprising the pair of isolated nucleic acid members of any one of a control pair of nucleic acids as described herein, *e.g.*, the pairs described herein above. In some embodiments, one member of the pair is in a separate container without the second member of the pair. In some embodiments, a kit of the invention comprises a mixture comprising at least one control pair of nucleic acids.

30 [0069] In some embodiments, the kit further comprises a second pair of isolated nucleic acids, substantially free of cellular nucleic acids, wherein both members of the second pair

comprise at least one *IGF2* SNP sequences and wherein the at least one *IGF2* SNP sequence in the second pair is different from the *IGF2* SNPs in the first pair; and

(c) one member of the second pair comprises one allele of the at least one *IGF2* SNP, wherein the 3' nucleic acid sequence directly adjacent to the SNP site is substantially

5 identical to at least 15 contiguous nucleotides (e.g., at least 20, 25, or 50 contiguous nucleotides) of the corresponding region of SEQ ID NO:17, 18, 21, or 23; and

(d) the other member of the second pair comprises an alternate allele of the at least one *IGF2* SNP; wherein the 3' nucleic acid sequence directly adjacent to the SNP site is substantially identical to at least 15 contiguous nucleotides (e.g., at least 20, 25, or 50

10 contiguous nucleotides) of the corresponding region of SEQ ID NO:17, 18, 21, or 23. In some embodiments, the second pair of isolated nucleic acids is a separate container from the first pair of nucleic acids.

[0070] The invention also provides a method of determining loss-of-imprinting (LOI) in an *IGF2* gene from an individual, the method comprising,

15 (a) quantifying in a sample from the individual, the amount of maternal (first) and paternal (second) copy of *IGF2* RNA, wherein the quantifying step comprises contacting the sample RNA, or a sample cDNA thereof, with one or more oligonucleotides that distinguish between a first possible SNP allele and a second possible SNP allele in the first and second copy, respectively; and

20 (b) providing a control mix comprising a known ratio of a control pair of nucleic acids as described herein that comprise polynucleotides having the first possible SNP allele and the second possible SNP allele in step (a);

(c) quantifying in the control mix the amount of each member of the pair of nucleic acids;

(d) comparing the ratio of the pair of nucleic acids present in the control mix measured in
25 step (c) to the amounts in the sample measured in step (a) of the first and second copy of *IGF2* RNA, or a sample cDNA thereof, thereby determining the presence or absence of *IGF2* LOI.

[0071] The invention additionally provides a method of providing a control standard in an *IGF2* loss-of-imprinting (LOI) assay to confirm the viability of the reaction conditions, the
30 method comprising,

providing a control mix comprising a known ratio of a control pair of nucleic acids described herein; and

quantifying in the control mix the measured ratio of each member of the pair of nucleic acid, thereby confirming viability of the reaction conditions of the assay.

DEFINITIONS

5 [0072] A “thermostable polymerase” refers to a polymerase useful for PCR applications. A thermostable polymerase can generally be heated to 75° C repeatedly (e.g., at least 20 times for a minute each time) and retain at least 80% of its original activity. Examples of such polymerases include, but are not limited to, *Taq* polymerase.

10 [0073] A “single nucleotide polymorphism” or “SNP” refers to a site of one nucleotide that varies between alleles.

[0074] An “allele” refers to one member of a pair or set of different forms of a gene. In a diploid organism, an individual has two copies of each autosomal gene. For a single nucleotide polymorphism, an individual has two different alleles of the polymorphic nucleotide if the genotype at the polymorphic nucleotide is different on one copy of the
15 gene than the other copy of the gene (*i.e.* the individual is heterozygous for the polymorphic nucleotide). If an individual has the same genotype at the polymorphic nucleotide on both copies of the gene (*i.e.* the individual is homozygous for the polymorphic nucleotide), then the individual has two copies of the same allele of the polymorphic nucleotide. A given individual can be homozygous for one polymorphic nucleotide within a gene (two copies of
20 the same allele of the polymorphic nucleotide) and heterozygous for a different polymorphic nucleotide within the same gene (two different alleles of the polymorphic nucleotide).

[0075] “Hybridization” refers to the formation of a duplex structure by two single stranded nucleic acids due to complementary base pairing. Hybridization can occur
25 between exactly complementary nucleic acid strands or between nucleic acid strands that contain minor regions of mismatch.

[0076] “Target sequence” or “target region” refers to a region of a nucleic acid that is to be analyzed and comprises the polymorphic site of interest.

30 [0077] As used herein, the terms “nucleic acid,” “polynucleotide” and “oligonucleotide” refer to nucleic acid regions, nucleic acid segments, primers, probes, amplicons and oligomer fragments. The terms are not limited by length and are generic to linear polymers

of polydeoxyribonucleotides (containing 2-deoxy-D-ribose), polyribonucleotides (containing D-ribose), and any other N-glycoside of a purine or pyrimidine base, or modified purine or pyrimidine bases. These terms include double- and single-stranded DNA, as well as double- and single-stranded RNA.

5 [0078] A nucleic acid, polynucleotide or oligonucleotide can comprise, for example, phosphodiester linkages or modified linkages including, but not limited to phosphotriester, phosphoramidate, siloxane, carbonate, carboxymethylester, acetamidate, carbamate, thioether, bridged phosphoramidate, bridged methylene phosphonate, phosphorothioate, methylphosphonate, phosphorodithioate, bridged phosphorothioate or sulfone linkages, and
10 combinations of such linkages.

[0079] A nucleic acid, polynucleotide or oligonucleotide can comprise the five biologically occurring bases (adenine, guanine, thymine, cytosine and uracil) and/or bases other than the five biologically occurring bases. For example, a polynucleotide of the invention can contain one or more modified, non-standard, or derivatized base moieties,
15 including, but not limited to, N⁶-methyl-adenine, N⁶-tert-butyl-benzyl-adenine, imidazole, substituted imidazoles, 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl)uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-
20 methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-methyladenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6- isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-
25 methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, uracil-5- oxyacetic acidmethylester, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, 2,6- diaminopurine, and 5-propynyl pyrimidine. Other examples of modified, non-standard, or derivatized base moieties may be found in U.S. Patent Nos. 6,001,611; 5,955,589; 5,844,106; 5,789,562; 5,750,343; 5,728,525; and 5,679,785.

30 [0080] Furthermore, a nucleic acid, polynucleotide or oligonucleotide can comprise one or more modified sugar moieties including, but not limited to, arabinose, 2-fluoroarabinose, xylulose, and a hexose.

[0081] “Haplotype block” refers to a region of a chromosome that contains one or more polymorphic sites (e.g., 1-10) that tend to be inherited together. In other words, combinations of polymorphic forms at the polymorphic sites within a block cosegregate in a population more frequently than combinations of polymorphic sites that occur in different
 5 haplotype blocks. Polymorphic sites within a haplotype block tend to be in linkage disequilibrium with each other. Often, the polymorphic sites that define a haplotype block are common polymorphic sites. Some haplotype blocks contain a polymorphic site that does not cosegregate with adjacent polymorphic sites in a population of individuals.

[0082] “Linkage disequilibrium” refers to the preferential segregation of a particular
 10 polymorphic form with another polymorphic form at a different chromosomal location more frequently than expected by chance. Linkage disequilibrium can also refer to a situation in which a phenotypic trait displays preferential segregation with a particular polymorphic form or another phenotypic trait more frequently than expected by chance.

15 BRIEF DESCRIPTION OF THE DRAWINGS

[0083] Figure 1 illustrates the structure of the *IGF2* gene. The scale bar above the gene diagram is drawn in 1 Kb increments and depicts the location of *IGF2* on chromosome 11 (NCBI build 36). The scale bar is also present in Figure 4. Arrows in Figure 1A, represent the four promoters of *IGF2*. Exons 1 to 9 are indicated below the gene diagram. Black
 20 shaded exons 1 to 6 are not protein-coding in most transcripts of *IGF2*. The white exons 7 and 8 are protein-coding, as is the small white region of exon 9. The black shaded region of exon 9 is the 3' UTR.

[0084] Figure 2 illustrates a basic strategy for determining LOI of *IGF2* in a biological sample. Genomic DNA and total or polyadenylated RNA are isolated from a biological
 25 sample (for example, peripheral blood, peripheral blood mononuclear cells, colonic biopsy or cell scrape, stool, etc.) from an individual. The genomic DNA sample is used for genotyping of one or more polymorphic markers (DNA SNP Assay). This step determines whether the individual is heterozygous for a specific SNP or combination of SNPs. Any SNP, or combination of SNPs, determined to be heterozygous may be utilized for analysis
 30 of allele-specific expression of the *IGF2* gene in the matched RNA sample (RNA SNP assay). In the example shown, an individual was determined by an allele-discriminating DNA genotyping assay to be homozygous for hypothetical SNPs 1, 3, 4 and 6 and

heterozygous for hypothetical SNPs 2 and 5. cDNA is amplified from the relevant region of the *IGF2* transcript using standard reverse transcriptase and PCR methods such that PCR products including at least SNPs 2 and 5 are amplified. Expression from each of the two copies of the *IGF2* gene is independently measured using the generated cDNA with a quantitative allele specific gene expression assay, and which can sufficiently discriminate between the two alleles of the gene. A comparison between the amount of expression of one allele relative to the amount of expression of the other allele is made and the imprinting status of the *IGF2* gene is determined. Assays that discriminate SNPs 2 and 5 may be performed simultaneously, and allele specific expression ratios obtained for each assay can be compared to improve accuracy.

[0085] Figure 3 illustrates the informativity of combinations of SNPs in *IGF2* exon 9.

The percentage of individuals that are heterozygous (informative) for one SNP (open bars), two SNPs (gray bars) or more than two SNPs (black bars) are plotted for the African American panel of samples (AA) genotyped for a first panel of SNPs, the Caucasian panel of samples (CAU) genotyped for a second panel of SNPs, the Mexican descent panel of samples (MEX) genotyped for a third panel of SNPs, the Japanese panel of samples (JPN) genotyped for a fourth panel of SNPs and the Chinese panel of samples (CHI) genotyped for a fifth panel of SNPs. A total of 96 African American panel samples, 207 Caucasian panel samples, 96 Mexican descent panel samples, 88 Japanese panel samples and 84 Chinese panel samples were genotyped. Only samples that were successfully genotyped by a single nucleotide primer extension assay for all SNPs are included in the calculation of percent informativity. The number of samples included in each ethnic group is indicated below the x-axis (n). Error bars indicate the 95% confidence interval. The combinations of SNPs for each ethnic population included SNPs represented by SEQ ID NOs: 1, 2, 3, 4, 12, 13, 15 and 16 for the first panel of SNPs genotyped in the African American panel of samples; SEQ ID NOs: 5, 8, 9, 10, 12, 15 and 16 for the second panel of SNPs genotyped in the Caucasian panel of samples; SEQ ID NOs: 1, 7, 9, 10, 11, 12, 14, 15 and 16 for the third panel of SNPs genotyped in the Mexican descent panel of samples; SEQ ID NOs: 10, 12, 14 and 16 for the fourth panel of SNPs genotyped in the Japanese panel of samples; and SEQ ID NOs: 6, 8, 12 and 16 for the fifth panel of SNPs genotyped in the Chinese panel of samples.

[0086] Figure 4 illustrates the informativity of various optimal combinations of SNPs in *IGF2* exon9. The percentage of individuals that are heterozygous (informative) for one or

more SNP within each combination of SNPs are plotted for the African American sample panel (AA), the Caucasian sample panel (CAU), the Mexican descent sample panel (MEX), the Japanese sample panel (JPN), the Chinese sample panel (CHI) and all genotyped samples combined (Overall). Only samples that were successfully genotyped by a single
 5 nucleotide primer extension assay for all SNPs are included in the calculation of percent informativity. Panels of SNPs were selected based on identification of SNPs common to all maximal informativity combinations of 15, 14, 13, 12, 11 or 10 SNPs across all samples (overall). All percentages are provided in Table 4. The SEQ ID NOs for SNPs included in each panel are listed in Table 5.

10 **[0087]** Figure 5 illustrates the use of a restriction enzyme based assay for genotyping the SNP corresponding to SEQ ID NO: 8. The polymorphic nucleotide is located within the recognition sequence of two restriction enzymes. *Apa I* recognizes and cleaves the sequence when the “G” allele is present, and *Ava II* recognizes and cleaves the sequence when the “A” allele is present. A PCR amplicon including SEQ ID NO: 8 was amplified
 15 from three independent genomic DNA samples derived from three individuals (Samples A, B and C). Amplicons were digested with *Apa I* or *Ava II* or a combination of both enzymes (Double). Digestion by *Apa I* only indicates that the individual is homozygous for the G allele (Sample B), digestion by *Ava II* only indicates that the individual is homozygous for the A allele (Sample C), and digestion by both enzymes indicates that the individual is
 20 heterozygous for the SNP (Sample A).

[0088] Figure 6 illustrates the use of a restriction enzyme based method for detecting LOI of *IGF2*. Total RNA was extracted from three individuals that are heterozygous for SEQ ID NO: 8. The region of the 3' UTR of exon 9 of the *IGF2* gene, which includes SEQ ID NO: 8 was RT-PCR amplified from each sample. cDNA amplicons were digested with *Apa I* or
 25 *Ava II* or a combination of both enzymes, as indicated above each lane. Digested products were resolved on an Agilent Bioanalyzer, and concentrations of cut and uncut fragments were determined. The quantity of fragments cut by *Apa I* represents the proportion of cDNA including the “G” allele. The quantity of fragments cut by *Ava II* represents the proportion of cDNA including the “A” allele. Therefore, the ratio of *Apa I* cut fragments to
 30 *Ava II* cut fragments indicates the relative ratio of expression of the two alleles in the original RNA sample. The calculated G:A ratio is shown below each triplet of lanes representing each sample. Sample 2 expresses exclusively the “A” allele and therefore the imprint of *IGF2* was present. Sample 1 expresses both copies of the *IGF2* gene, with a G:A

ratio of 0.53 and therefore displays LOI of *IGF2*. Sample 3 expresses detectible amounts of both copies of the *IGF2* gene, with a G:A ratio of 0.27, which could be considered a borderline call for imprinting status (close to the threshold of 0.33 ratio for determining LOI).

5 [0089] Figure 7 diagrams a method for allele-specific detection of a SNP using a single nucleotide primer extension strategy. The SNP represented by SEQ ID NO: 8 and its surrounding DNA sequence are shown as an example ("PCR amplicon sequence"). The nucleotide position of SEQ ID NO: 8 is indicated by the arrow labeled "SEQ ID NO: 8". The sequence of the polynucleotide used for single nucleotide primer extension is indicated
10 by the bracket labeled "Primer". The PCR DNA amplicon (or, alternatively a RT-PCR cDNA amplicon) including the sequence of interest is amplified from the genomic DNA or RNA sample to be assayed. A primer is added to the purified PCR (or, alternatively RT-PCR) product that anneals with its 3' terminal nucleotide complimentary to the template nucleotide 1 base to the 3' side of the polymorphic nucleotide to be genotyped. Single
15 nucleotide primer extension is carried out using a thermostable DNA polymerase and differentially fluorescently labeled ddNTPs. In this example, either dR110 labeled ddGTP or dR6G labeled ddATP is added to the 3' end of the primer. These labeled polynucleotides are then resolved and the peak areas representative of each possible incorporated nucleotide are calculated. Peak areas are compared to determine the genotype of the individual at that
20 SNP position (or, alternatively to determine the allele-specific gene expression ratio).

[0090] Figure 8 illustrates the use of the single nucleotide primer extension assay described in Figure 7 to genotype three individuals for SEQ ID NO: 8. The same three individuals that were assayed for LOI of *IGF2* by the restriction enzyme based assay shown in Figure 6, were genotyped. The figure shows the resulting chromatograms for each
25 sample following electrophoretic resolution and peak detection using an ABI 3730XL Genetic Analyzer and Gene Mapper software. As expected, peaks representing both alleles of SEQ ID NO: 8 are obtained in relatively equal proportions, confirming that the three individuals are heterozygous for SEQ ID NO: 8 and demonstrating the concordance between results obtained by the restriction enzyme based method and the single nucleotide
30 primer extension based method.

[0091] Figure 9 illustrates the application of the single nucleotide primer extension based method for detecting LOI of *IGF2*. The region including SEQ ID NO: 8 was RT-PCR

amplified from a total RNA sample derived from each of the three individuals genotyped in Figure 8. The cDNA products obtained were purified and analyzed as diagrammed in Figure 7. The figure shows the resulting chromatograms for each sample following electrophoretic resolution and peak detection using an ABI 3730XL Genetic Analyzer and Gene Mapper software. For each sample, peak areas representing each of the two possible alleles were calculated and compared to each other. The calculated G:A ratios are indicated to the right of each chromatogram. Consistent with the results shown in Figure 6, Samples 1 and 3 were determined to show LOI of *IGF2*, and Sample 2 was determined to show normal imprinting of *IGF2*.

[0092] Figure 10 illustrates the quantitative analytical linearity of single nucleotide primer extension assays developed for 8 independent SNPs: SEQ ID NO: 8 (A), SEQ ID NO: 2 (B), SEQ ID NO: 9 (C), SEQ ID NO:10 (D), SEQ ID NO:5 (E), SEQ ID NO:7 (F), SEQ ID NO:15 (G) and SEQ ID NO:16 (H). For each assay of the 8 assays, two PCR amplicons targeting the 3' UTR of exon 9 of the *IGF2* gene were separately amplified from genomic DNA samples from two individuals; one homozygous for one allele of the SNP and the other homozygous for the other allele of the SNP (*i.e.* a total of 16 amplicons representing 8 allele pairs were obtained). The 16 PCR products were purified and quantified. For each of the 8 SNPs, two PCR products (one containing one allele (allele 1) and the other containing the other allele (allele 2) of a particular SNP) were combined in the following 11 ratios (or dilution points) of allele 1 to allele 2; 1:10, 1:6, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1, 6:1, and 10:1. For each of the 8 SNPs, the single nucleotide primer extension assay was performed in triplicate on each dilution point. Ratios of peak areas representing each of the two possible alleles were calculated for each dilution point (y-axis) and compared to the known input ratio of each allele pair (x-axis). Values are plotted on a log₁₀ scale. The R² and slope for each assay are shown in Table 6.

[0093] Figure 11 illustrates the quantitative analytical linearity of single nucleotide primer extension assays developed for 5 independent SNPs: SEQ ID NO: 3 (A), SEQ ID NO:4 (B), SEQ ID NO:6 (C), SEQ ID NO:11 (D) and SEQ ID NO:14 (E). For each assay, PCR products were separately amplified from genomic DNA samples derived from two individuals; one homozygous for one allele of the SNP and the other homozygous for the other allele of the SNP. The PCR products were purified and quantified. For each of the 8 SNPs, two PCR products (one amplified from the DNA sample homozygous for one allele and the other amplified from the DNA sample homozygous for the other allele) were

combined in the following ratios of allele 1 to allele 2; 1:10, 1:6, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1, 6:1, and 10:1. For each of the 8 SNPs, the single nucleotide primer extension assay was performed in triplicate on each dilution point. Ratios of peak areas representing each of the two possible alleles were calculated (y-axis) and compared to the known input ratio of each allele pair (x-axis). Values are plotted on a log10 scale. The R^2 and slope for each assay are shown in Table 6.

[0094] Figure 12 illustrates the use of a multiplexed assay for determining the genotype and imprinting status of *IGF2*. Figure 12 A shows a chromatogram generated by GeneMapper software for a multiplexed genotyping assay of PCR products generated from genomic DNA derived from a blood sample from one individual (Sample A in Table 7). The assay determines the genotype and imprinting status at SNP positions represented by SEQ ID NOs: 1, 2, 3, 7, 8, 10, 11, 12, 15 and 16. In the figure, peaks are labeled by a corresponding SEQ ID NO, followed by the represented single nucleotide sequence in parentheses. For example, peaks labeled 12 (C) and 12 (T) indicate that the sample is heterozygous (C/T) for the SNP represented by SEQ ID NO: 12. The sample is heterozygous, and therefore is informative, at SNP positions represented by SEQ ID NO: 3, 11 and 12. Peaks representing these heterozygous positions are highlighted by brackets below the chromatogram in Figure 12 A. Figure 12 B shows a chromatogram generated by GeneMapper for a multiplexed imprinting assay of PCR products generated from cDNA amplified from total RNA derived from a blood sample from the same individual as in Figure 12 A (Sample A in Table 7). Peaks are labeled as in Figure 12 A. The sample is found to display normal imprinting (*i.e.* monoallelic expression) of *IGF2* because only a single peak is detected for the SNP positions represented by SEQ ID NOs: 3, 11 and 12. For example, the C allele of SEQ ID NO: 12 is detected, but the T allele is not detected.

Figure 13. Diagram of *IGF2* LOI Assay Details as Related to Synth1 and Synth2 Controls. 13 A. Diagram of the *IGF2* gene. Potential promoters are indicated by arrows labeled Promoter 1, P0, P2, P3 or P4. Potential transcribed exons are indicated by block arrows connected by a hashed line that represents intronic sequence regions. Untranslated exonic sequence regions are indicated by filled block arrows, and translated exonic sequence regions are indicated by open block arrows. The scale bar at the top of diagram is shown in 1000 base pair (Kb) increments. 13 B. Expanded view of the Synth1 (or Synth2) nucleic acid region. The Synth1 (or Synth2) nucleic acid sequence includes the 3'-most 21 base pairs of exon 8 followed immediately by the sequence of exon 9. The 5' and 3' ends of

Synth1 (or Synth2) include Not I restriction enzyme recognition sequences that were included to allow ligation of the sequences into a transcription vector. The CA repeat-rich sequence region present in IGF2 exon 9 was omitted from the Synth1 (or Synth2) sequence. The annealing sites of four primers within the Synth1 (or Synth2) region (or optionally, within the IGF2 mRNA region) are indicated by arrow heads (RT primers). These RT primers are used to reverse transcribe first strand cDNA from the Synth1 or Synth2 IVT RNAs (or optionally, from total RNA derived from a human biological sample). The scale bar is shown in 500 base pair increments. 13 C. The first strand cDNA molecules generated by these RT reactions are indicated by hashed lines. 13 D. Following reverse transcription, the first strand cDNA is used as template for first round PCR amplification of four independent amplicons. The annealing sites of four primer pairs relative to the generated first strand cDNA are indicated by arrow heads. Solid lines connecting the primer pairs represent the PCR amplicon produced in each first round PCR amplification reaction. The primer highlighted by the open box includes the exon 8-9 splice junction spanning sequence. 13 E. The amplicons produced in the first round PCR amplification are used as template for amplification of four independent nested amplicons. The annealing sites of the four primer pairs relative to the generated first strand cDNA are indicated by arrow heads. Solid lines connecting the primer pairs represent the PCR amplicon produced in each second round PCR amplification reaction. 13 F. Each of the four amplicons generated by the second round PCR reaction includes one or more of the SNP positions represented by SEQ ID NOs.:1-16. The position of each SNP is indicated by a diamond.

[0095] Figure 14. Use of DNA Controls to Determine the Quantitative Linearity of an *IGF2* LOI Assay. Mixtures of pEZ-Synth1 and pEZ-Synth2 were made in the following ratios: 8:1, 6:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:6 and 1:8 (Synth1:Synth2). Four non-overlapping PCR amplicons were designed to amplify the transcribed regions of IGF2 exon 9 including the 16 SNP nucleotides. Amplicons derived from the Synth1/Synth2 ratio mixtures were used as template for the multiplexed single-nucleotide primer extension assay described in Example 1. Assays were performed in triplicate, and average peak areas for each peak were calculated. The known input ratio of Synth1:Synth2 template is plotted on the x-axis. The average measured ratio of peak areas representing the Synth 1 allele: the Synth2 allele is plotted on the y-axis. Error bars indicate plus and minus one standard deviation across the triplicate measurements. All average data point values were multiplied by a common normalization factor that adjusts the measured value for the known 1:1 input

data point to equal exactly 1.0. Results of assays utilizing the SNPs represented by SEQ ID NO: 7 within Amplicon 1 (A), SEQ ID NO: 5 within Amplicon 2 (B), SEQ ID NO: 1 within Amplicon 3 (C) and SEQ ID NO: 13 within Amplicon 4 (D) are shown.

[0096] Figure 15. Use of RNA Controls to Determine the Quantitative Linearity of an *IGF2* LOI Assay. IVT RNA derived from pEZ-Synth1 was mixed with IVT RNA derived from pEZ-Synth2 in ratios including 8:1, 6:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:6 and 1:8 (Synth1:Synth2). A total of 120 pg of Synth1:Synth2 IVT RNA mixture (i.e. the amount of IVT control RNA derived from pEZ-Synth1 plus the amount of IVT control RNA derived from pEZ-Synth2 equaled 120 pg) was spiked into 500 ng of yeast RNA. This RNA mixture was used as template for RT-PCR amplification of the four amplicons described in Figure 13E. Amplicons derived from the Synth1/Synth2 ratio mixtures were used as template for the multiplexed single-nucleotide primer extension assay described in Example 1. Assays were performed in triplicate, and average peak areas for each peak were calculated. The known input ratio of Synth1:Synth2 IVT RNA template is plotted on the x-axis. The average measured ratio of peak area representing the Synth 1 allele: the Synth2 allele is plotted on the y-axis. Error bars indicate plus and minus one standard deviation across the triplicated measurements. All average data point values were multiplied by a common normalization factor that adjusts the measured value for the known 1:1 input data point to equal exactly 1.0. Results of assays utilizing the SNPs represented by SEQ ID NO: 7 within Amplicon 1 (A), SEQ ID NO: 5 within Amplicon 2 (B), SEQ ID NO: 1 within Amplicon 3 (C) SEQ ID NO: 13 within Amplicon 4 (D), SEQ ID NO: 4 within Amplicon 2 (E) and SEQ ID NO: 14 within Amplicon 4 (F) are shown.

DETAILED DESCRIPTION OF THE INVENTION

I. Introduction

[0097] The present invention provides methods of detecting LOI of *IGF2*. The inventors have found that specific combinations of *IGF2* SNPs, selected from numerous possible known and newly discovered SNPs, represent optimal ways to detect for LOI of *IGF2* in heterogeneous human populations. Detection of LOI relies on the ability to detect both alleles of *IGF* carried by an individual and therefore requires that there be at least one detectable difference between the two *IGF* alleles carried by the individual. Any particular *IGF2* SNP therefore is a potential marker to measure LOI, but it is only useful to measure LOI in individuals that are heterozygous at that particular SNP. The inventors have now identified a very small number of *IGF2* SNPs, which when used in various combinations or

sub-combinations, are highly likely to have at least one, and generally two or more SNPs that are heterozygous for any particular individual assayed. Past studies typically were only successful in measuring imprinting status of *IGF2* in 40-50% of the patients tested. The present invention, for the first time, makes it possible to determine the imprinting status of *IGF2* in a high proportion of human subjects from diverse backgrounds. As shown in the examples, the combinations of SNPs described herein can be used effectively with a variety of different ethnic backgrounds and thus are also effective for use in the human population at large (being a combination of the different ethnic groups).

10 II. *IGF2* SNPs

[0098] The following SNPs can be detected in combinations, or subcombinations as described herein to achieve optimal detection of LOI across a variety of ethnic groups with a minimum number of markers: SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and 16. The sequence identifiers correspond to the sequence including and surrounding the SNP are provided in Table 1, with the polymorphic position (and polymorphic options) provided in brackets in the sequence. When an individual carries a copy of *IGF2* having a polymorphic option, that copy is referred to as an “allele” of the SNP.

[0099] The present invention allows for detection of all of the above SNPs (e.g., as represented in SEQ ID NOs: 1-16, or subcombinations thereof). For example, in some embodiments, SNPs comprising or consisting of SEQ ID NOs: 1, 5, 8, 9, 10, 11, 14, 15 and 16 are detected. As shown in the Examples below, this particular subcombination provides a very high rate of heterozygosity across ethnic groups and thus represents a useful combination of markers for detecting LOI. In some embodiments, at least one, two three, or more (e.g., all) SNP consisting of SEQ ID NOs: 1, 5, 8, 9, 10, 11, 12, 14, 15 and 16 is detected. In some embodiments, at least one, two three, or more (e.g., all) SNP consisting of SEQ ID NOs: 1, 2, 4, 5, 8, 9, 10, 12, 13, 14, 15 and 16 is detected. In some embodiments, at least one, two three, or more (e.g., all) SNP consisting of SEQ ID NOs: 1, 2, 3, 4, 5, and 6 is detected. In some embodiments, SNPs comprising or consisting of SEQ ID NOs: 1, 5, 8, 9, 10, 11, 12, 14, 15 and 16 is detected. In some embodiments, SNPs comprising or consisting of SEQ ID NOs: 1, 2, 4, 5, 8, 9, 10, 12, 13, 14, 15 and 16 are detected. In some embodiments, SNPs comprising or consisting of SEQ ID NOs: 1-16 are detected. SNPs can be detected for genotyping, LOI determination, or both as discussed below.

[0100] In some embodiments, the individual assayed is of African descent (e.g., African or African-American) and at least one (e.g., 2, 3, 4, 5, 6, 7, or 8) SNP detected is selected from SEQ ID NOs: 1, 2, 3, 4, 12, 13, 15 and 16. In some embodiments, the individual assayed is Caucasian and at least one (e.g., 2, 3, 4, 5, 6, or 7) SNP detected is selected from
5 SEQ ID NOs: 5, 8, 9, 10, 12, 15 and 16. In some embodiments, the individual assayed is Mexican or of Mexican descent and at least one (e.g., 2, 3, 4, 5, 6, 7, 8 or 9) SNP detected is selected from SEQ ID NOs: 1, 7, 9, 10, 11, 12, 14, 15 and 16. In some embodiments, the individual assayed is of Japanese descent (e.g., Japanese or Japanese-American) and at least one (e.g., 2, 3, or 4) SNP detected is selected from SEQ ID NOs: 10, 12, 14 and 16. In
10 some embodiments, the individual assayed is of Chinese descent (e.g., Chinese-American) and at least one (e.g., 2, 3 or 4) SNP detected is selected from SEQ ID NOs: 6, 8, 12 and 16.

[0101] The present invention provides for combinations, and uses thereof, of polynucleotides that distinguish between two alleles of a first and second (or more) SNP as set forth in the combinations presented herein (e.g., as listed above). For example, a
15 combination of a number of different polynucleotides can be used, where each polynucleotide is capable of distinguishing a different SNP. Thus, for example, one can use at least one polynucleotide that distinguishes between two or more alleles of each of the following SNP combination. In some embodiments, the combinations comprise 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 SNPs selected from the group consisting of SEQ ID
20 NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and 16.

[0102] For example, the present invention provides for combinations of polynucleotides, wherein the combination comprises different polynucleotides, wherein each of the different polynucleotides hybridize to a first allele of a particular different SNP, but does not significantly hybridize to the second allele of the SNP. "Does not significantly hybridize"
25 means that in the presence of equal amounts of both alleles in a sample, the polynucleotide is able to detect the presence of the first allele but does not detect the presence of the second allele to such an extent so as to interfere with the interpretation of the assay. In some embodiments, in the presence of equal amounts of both alleles in a sample, the polynucleotide provides a signal for a sample having the first allele that is at least, e.g.,
30 about 10, 100; 1,000; 10,000; 100,000 times or more than the signal generated by the polynucleotide for a sample having an equal amount of the second allele. "Signal" refers to any output indicative of hybridization of the polynucleotide to a complementary sequence. In some embodiments, at least 70%, 80%, 90%, 95% of the sequence of any, a subset, or all

of the polynucleotides in the group for detection of the combinations of SNPs is complementary to one (or more, depending on the number of polynucleotides) SNP selected from SEQ ID NOs: 1-16. In some embodiments, the polynucleotides are, e.g., 8-200, 8-100, 8-50, 10-50, 115-100, 20-200 nucleotides long. In some embodiments, the

5 polynucleotides comprise, for example, at least 8, 10, 15, 20, 30, 40 or 50 complementary nucleotides. A plurality of allele-specific detection polynucleotides can be used to detect a plurality of different SNPs. For example, in some embodiments, the plurality of polynucleotides includes a sufficient number of polynucleotides to detect one of the following combinations:

- 10 SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and 16; or
 SEQ ID NOs: 1, 5, 8, 9, 10, 11, 14, 15, and 16; or
 SEQ ID NOs: 1, 5, 8, 9, 10, 11, 12, 14, 15, and 16; or
 SEQ ID NOs: 1, 2, 4, 5, 8, 9, 10, 12, 13, 14, 15, and 16.

- 15 The plurality of polynucleotides can be designed, for example, such that there is one polynucleotide that is complementary to one allele of each of the SNPs in the combination. Accordingly, a sufficient number of polynucleotides such at least one polynucleotide corresponds to “each” of the following SNP regions means that the plurality in sum correspond to all of the SNP regions, not necessarily that one polynucleotide corresponds to
- 20 all SNP regions.

- [0103] Alternatively, any, a subset, or all polynucleotides in a group can distinguish between two alleles of a SNP by acting as a primer in a template-specific primer extension reaction. In these embodiments, the polynucleotides do not generally encompass the polymorphic nucleotide but instead hybridize to the genomic DNA or cDNA such that 3'
- 25 extension of the polynucleotide occurs at the polymorphic nucleotide. Thus, in some embodiments, the 3' end of the polynucleotide is complementary to a nucleotide within 1000, 100, 10, 5, 3, 2, or 1 nucleotide(s) upstream from the polymorphic nucleotide. In some embodiments, the polynucleotides are complementary over at least 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of the polynucleotides length to an IGF2 genomic
- 30 DNA or cDNA (or complement thereof). In some embodiments, the polynucleotide comprises at its 3' end, at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, or more contiguous nucleotides that are at least at least 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% complementary to an IGF2 genomic DNA or cDNA (or complement thereof) (e.g., NM_000612 (SEQ ID NO: 17) or ENST00000300632 (SEQ ID NO: 18) or

ENSG00000167244 (SEQ ID NO: 19)). Optionally, the 5' end of the polynucleotide will comprise a sequence tag or other sequence not complementary to an IGF2 genomic DNA or cDNA. As is well known in the art, a variety of primer extension methods can be employed to detect SNPs.

5 [0104] Allele-specific detection polynucleotides useful for primer extension reactions include those having at least 8 (e.g., at least 10, 12, 15, 20) contiguous nucleotides at the 3' end of the allele-specific detection polynucleotide, wherein the at least 8 contiguous nucleotides are either:

10 100% complementary to at least 8 (e.g., at least 10, 12, 15, 20) nucleotides directly 3' (or is 2 or 3 nucleotides 3') of the polymorphic position of a SNP region (as set forth in SEQ ID NOs: 1-16); or

15 100% identical to at least 8 (e.g., at least 10, 12, 15, 20) nucleotides directly 5' (or is 2 or 3 nucleotides 5') of the polymorphic position of the SNP region [or, e.g., 100% identical to at least 8 (e.g., at least 10, 12, 15, 20) nucleotides directly 3' (or is 2 or 3 nucleotides 3') of the polymorphic position of the complement of the SNP region].

[0105] This configuration allows for the 3' end of the polynucleotide to form Watson-Crick base pairing with the region just upstream of the polymorphic position (from either strand), allowing for a primer extension reaction to take place to determine which allele is in a cDNA or genomic DNA of an individual. "100% complementary" means that the
20 designated (e.g., the "at least 8") contiguous nucleotides of the polynucleotide are completely complementary to the designated sequences in the SNP region, i.e., there are no mismatches. It will be appreciated that the polynucleotides can include non-naturally-occurring nucleotides that retain Watson-Crick base pairing. The polynucleotides can include further nucleotides at the 5' end that are either complementary to the SNP region or
25 not as desired.

[0106] Combinations of such polynucleotides can be used to detect particular combinations of SNPs as described herein. For example, a plurality of allele-specific detection polynucleotides can be designed with the above features such that one polynucleotide can prime a separate extension reaction whereby the plurality detects one of
30 the following combinations:

SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and 16; or
SEQ ID NOs: 1, 5, 8, 9, 10, 11, 14, 15, and 16; or

SEQ ID NOs: 1, 5, 8, 9, 10, 11, 12, 14, 15, and 16; or
SEQ ID NOs: 1, 2, 4, 5, 8, 9, 10, 12, 13, 14, 15, and 16.

[0107] In some embodiments, the polynucleotides that distinguish between the two alleles
5 are at least 4, 6, 8, 10, 12, 15, 20, 30, 50, or more nucleotides in length. In some
embodiments, the polynucleotides are no more than 1000, 500, 200, 100, 80, 50, 40, 30, or
25 nucleotides in length. For example, the polynucleotides can be, e.g., 8-25, 8-30, 8-50, 8-
100, 10-25, 10-50, 10-100, nucleotides, etc. The polynucleotides that distinguish between
the two alleles will typically include a nucleotide that corresponds (i.e., aligns with) and is
10 complementary to one of the polymorphic nucleotides of the SNP. In some embodiments,
the ultimate or penultimate 3' nucleotide of the polynucleotide is complementary to a
nucleotide at the polymorphic position of the SNP. Such embodiments can be particularly
useful in SNP detection methods employing the polynucleotides as primers or probes, for
example in amplification-based assays such as those involving the polymerase chain
15 reaction.

[0108] The polynucleotides of the invention can be detectably labeled. Detectable labels
suitable for use in the present invention include any composition detectable by
spectroscopic, photochemical, biochemical, immunochemical, electrical, optical or chemical
means. Useful labels in the present invention include biotin for staining with labeled
20 streptavidin conjugate, magnetic beads (e.g., DynabeadsTM), fluorescent dyes (e.g.,
fluorescein, Texas red, rhodamine, green fluorescent protein, and the like, *see, e.g.*,
Molecular Probes, Eugene, Oregon, USA), radiolabels (e.g., ³H, ¹²⁵I, ³⁵S, ¹⁴C, or ³²P),
enzymes (e.g., horse radish peroxidase, alkaline phosphatase and others commonly used in
an ELISA), and colorimetric labels such as colloidal gold (e.g., gold particles in the 40 -80
25 nm diameter size range scatter green light with high efficiency) or colored glass or plastic
(e.g., polystyrene, polypropylene, latex, etc.) beads. Patents teaching the use of such labels
include U.S. Patent Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149;
and 4,366,241. Where two or more alleles and or multiple SNPs or polynucleotides are to
be detected, it can be useful to have each polynucleotide be labeled with a different
30 fluorescent or other label. Optionally, where primer extension is used, the free nucleotides
can be detectably, and optionally differentially, labeled, thereby allowing for detecting of
incorporation of a particular nucleotide.

[0109] Hybridization reaction conditions can vary depending on the assay that is used to
detect the SNPs. Stringent, sequence-specific hybridization conditions, under which an

oligonucleotide will hybridize only to the exactly complementary target sequence, are well known in the art. Stringent conditions are sequence dependent and will be different in different circumstances. In some embodiments, stringent conditions are selected to be about 5°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength and pH) at which 50% of the base pairs have dissociated. Relaxing the stringency of the hybridizing conditions will allow sequence mismatches to be tolerated; the degree of mismatch tolerated can be controlled by suitable adjustment of the hybridization conditions.

[0110] For Southern-type hybridization, exemplary conditions are: 50% formamide, 5X SSC, and 1% SDS, incubating at 42°C, or 5X SSC, 1% SDS, incubating at 65°C, with wash in 0.2X SSC, and 0.1% SDS at 55°C, 60°C, or 65°C. Such washes can be performed for 5, 15, 30, 60, 120, or more minutes. For PCR applications (involving hybridization and/or extension of primers and/or probes), hybridization conditions comprising annealing and extension condition are well known, e.g., as described in *PCR Protocols: A Guide to Methods and Applications* (Innis *et al.*, eds., 1990).

[0111] The present invention relies on routine techniques in the field of recombinant genetics. Basic texts disclosing the general methods of use in this invention include Sambrook *et al.*, *Molecular Cloning, A Laboratory Manual* (3rd ed. 2001); Kriegler, *Gene Transfer and Expression: A Laboratory Manual* (1990); and *Current Protocols in Molecular Biology* (Ausubel *et al.*, eds., 1994)).

III. Methods for Measuring Loss of Imprinting and Cancer Predisposition

[0112] Detection of LOI is based on a comparison of the amount of expression derived from each of the two copies of the *IGF2* gene within a biological sample from an individual. Thus, if an individual has two different alleles of the *IGF2* gene, then allele-specific detection can be used to quantify expression of each copy of the gene. If imprinting is functioning, then one copy of the gene (typically the maternal copy) will not be expressed in spite of the presence of a genomic copy of the gene. However, if LOI has occurred, then expression will occur from both the maternal and paternal copies of the *IGF2* gene. Accordingly, it is useful to generate a ratio of the amount of RNA having each allele or otherwise determine their relative amounts. Because expression levels are not always exactly equal when LOI has occurred, in some embodiments, a sample is determined to display LOI of *IGF2* if the quantified proportion of the lesser abundant allele is greater than

or equal to 33.3% the quantified proportion of the more abundant allele in heterozygous individuals (*i.e.* a 3:1 ratio of the more abundantly expressed allele to the less abundantly expressed allele). Expression of the lesser abundant allele at a level lower than 33.3% the quantified portions of the more abundant allele may also indicate loss of imprinting of the *IGF2* gene and be associated with increased cancer risk. Therefore, in some embodiments, a sample is determined to display LOI of *IGF2* if the quantified proportion of the lesser abundant allele is greater than or equal to, for example, 10%, 15%, 20%, 25% or 30% the quantified proportion of the more abundant allele in heterozygous individuals (*i.e.* a ratio of the more abundantly expressed allele to the less abundantly expressed allele of 10.00:1, 6.67:1, 5.00:1, 4.00:1 or 3.33:1, respectively). In some embodiments, a sample is determined to display LOI of *IGF2* if the quantified proportion of the lesser abundant allele is greater than or equal to, for example, a ratio of 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, or 4:1 to the more abundant allele in heterozygous individuals (*i.e.* 10%, 11.11%, 12.50%, 14.29% or 16.67%, 20.00%, or 25.00% the quantified proportion of the more abundant allele, respectively).

[0113] It is generally desirable to know whether an individual is heterozygous for a particular SNP. Thus in some embodiments, both DNA (*i.e.*, genomic DNA) and RNA from a sample are obtained. The genomic DNA is assayed to determine whether the individual is heterozygous for a particular SNP. If the individual is heterozygous for one or more SNP of the combination of SNPs genotyped, then it is possible to measure loss of imprinting by detecting RNA having either of the two or more possible SNP alleles selected from the heterozygous SNPs and then comparing their expression. This is illustrated in Figure 2. In some embodiments, one detects the genotype of a combination of SNPs as set forth herein, and then LOI is determined for one or more of the SNPs determined to be heterozygous.

[0114] In some circumstances, however, it may be beneficial to detect only RNA without previously knowing whether the individual is a heterozygote for a particular SNP. In this circumstance, observing relatively similar quantities of expression of two alleles indicates LOI, while detecting expression of one allele is not informative because it will not be known if the negative result is due to imprinting or homozygosity of the particular SNP. However, by increasing the number of different SNPs detected, it is possible to design an assay such that the chance of an individual being homozygous for every SNP would be low. As explained herein, the combinations of SNPs provided make it unlikely that a particular

individual would be homozygous for each SNP in the combination. Moreover, because imprinting is not generally fully complete, it is possible to determine the genotype of an individual by measuring RNA quantity alone if one uses a sensitive enough assay such that one can distinguish between an imprinted allele (which will still generate an extremely
 5 small amount of transcript, thus indicating a heterozygote), and a homozygote (which does not make any transcript for a second allele).

[0115] In some embodiments, one set of SNPs can be selected to allow for the greatest chance of assaying for a heterozygous SNP regardless of race. Thus, in some embodiments, a panel of SNPs selected from Table 5 is used.

10 **IV. Methods of SNP Detection**

[0116] Detection techniques for evaluating nucleic acids for the presence of a SNP involve procedures well known in the field of molecular genetics. Further, many of the methods involve amplification of nucleic acids. Ample guidance for performing SNP detection is provided in the art. Exemplary references include manuals such as PCR
 15 Technology: Principles and Applications for DNA Amplification (ed. H. A. Erlich, Freeman Press, NY, N.Y., 1992); PCR Protocols: A Guide to Methods and Applications (eds. Innis, et al., Academic Press, San Diego, Calif., 1990); Current Protocols in Molecular Biology, Ausubel, 1994-1999, including supplemental updates through April 2004; Sambrook & Russell, *Molecular Cloning, A Laboratory Manual* (3rd Ed, 2001).

20 [0117] Although the methods typically employ PCR steps, other amplification or non-amplification-based protocols may also be used. Suitable amplification methods include ligase chain reaction (*see, e.g.*, Wu & Wallace, *Genomics* 4:560-569, 1988); strand displacement assay (*see, e.g.*, Walker *et al.*, *Proc. Natl. Acad. Sci. USA* 89:392-396, 1992; U.S. Pat. No. 5,455,166); and several transcription-based amplification systems, including
 25 the methods described in U.S. Pat. Nos. 5,437,990; 5,409,818; and 5,399,491; the transcription amplification system (TAS) (Kwoh *et al.*, *Proc. Natl. Acad. Sci. USA* 86:1173-1177, 1989); and self-sustained sequence replication (3SR) (Guatelli *et al.*, *Proc. Natl. Acad. Sci. USA* 87:1874-1878, 1990; WO 92/08800). Alternatively, methods that amplify the probe to detectable levels can be used, such as Q β -replicase amplification (Kramer &
 30 Lizardi, *Nature* 339:401-402, 1989; Lomeli *et al.*, *Clin. Chem.* 35:1826-1831, 1989). A review of known amplification methods is provided, for example, by Abramson and Myers in *Current Opinion in Biotechnology* 4:41-47, 1993.

[0118] Typically, detecting SNPs in an individual is performed using oligonucleotide primers and/or probes. Oligonucleotides can be prepared by any suitable method, usually chemical synthesis. Oligonucleotides can be synthesized using commercially available reagents and instruments. Alternatively, they can be purchased through commercial sources. Methods of synthesizing oligonucleotides are well known in the art (*see, e.g.*, Narang *et al.*, *Meth. Enzymol.* 68:90-99, 1979; Brown *et al.*, *Meth. Enzymol.* 68:109-151, 1979; Beaucage *et al.*, *Tetrahedron Lett.* 22:1859-1862, 1981; and the solid support method of U.S. Pat. No. 4,458,066). In addition, modifications to the above-described methods of synthesis may be used to desirably impact enzyme behavior with respect to the synthesized oligonucleotides. For example, incorporation of modified phosphodiester linkages (e.g., phosphorothioate, methylphosphonates, phosphoramidate, or boranophosphate) or linkages other than a phosphorous acid derivative into an oligonucleotide may be used to prevent cleavage at a selected site. In addition, the use of 2'-amino modified sugars tends to favor displacement over digestion of the oligonucleotide when hybridized to a nucleic acid that is also the template for synthesis of a new nucleic acid strand.

[0119] The amount and/or presence of an allele of a SNP of the invention in a sample from an individual can be determined using many detection methods that are well known in the art. A number of SNP assay formats entail one of several general protocols: hybridization using allele-specific oligonucleotides, primer extension, allele-specific ligation, sequencing, or electrophoretic separation techniques, *e.g.*, singled-stranded conformational polymorphism (SSCP) and heteroduplex analysis. Exemplary assays include 5' nuclease assays, template-directed dye-terminator incorporation, molecular beacon allele-specific oligonucleotide assays, single-base extension assays, and SNP scoring by real-time pyrophosphate sequences. Analysis of amplified sequences can be performed using various technologies such as microchips, fluorescence polarization assays, and matrix-assisted laser desorption ionization (MALDI) mass spectrometry. Two methods that can also be used are assays based on invasive cleavage with Flap nucleases and methodologies employing padlock probes.

[0120] Determining the presence or absence of a particular SNP allele is generally performed by analyzing a nucleic acid sample that is obtained from a biological sample from the individual to be analyzed. While the amount and/or presence of a SNP allele can be directly measured using RNA from the sample, often times the RNA in a sample will be

reverse transcribed, optionally amplified, and then the SNP allele will be detected in the resulting cDNA.

[0121] Frequently used methodologies for analysis of nucleic acid samples to measure the amount and/or presence of an allele of a SNP are briefly described. However, any method known in the art can be used in the invention to measure the amount and/or presence of single nucleotide polymorphisms.

Allele Specific Hybridization

[0122] This technique, also commonly referred to as allele specific oligonucleotide hybridization (ASO) (*e.g.*, Stoneking et al., *Am. J. Hum. Genet.* 48:70–382, 1991; Saiki et al., *Nature* 324, 163-166, 1986; EP 235,726; and WO 89/11548), relies on distinguishing between two DNA molecules differing by one base by hybridizing an oligonucleotide probe that is specific for one of the variants to an amplified product obtained from amplifying the nucleic acid sample. In some embodiments, this method employs short oligonucleotides, *e.g.*, 15-20 bases in length. The probes are designed to differentially hybridize to one variant versus another. Principles and guidance for designing such probe is available in the art, *e.g.*, in the references cited herein. Hybridization conditions should be sufficiently stringent that there is a significant difference in hybridization intensity between alleles, and preferably an essentially binary response, whereby a probe hybridizes to only one of the alleles. Some probes are designed to hybridize to a segment of target DNA or cDNA such that the polymorphic site aligns with a central position (*e.g.*, within 4 bases of the center of the oligonucleotide, for example, in a 15-base oligonucleotide at the 7 position; in a 16-based oligonucleotide at either the 8 or 9 position) of the probe (*e.g.*, a polynucleotide of the invention distinguishes between two SNP alleles as set forth herein), but this design is not required.

[0123] The amount and/or presence of an allele is determined by measuring the amount of allele-specific oligonucleotide that is hybridized to the sample. Typically, the oligonucleotide is labeled with a label such as a fluorescent label. For example, an allele-specific oligonucleotide is applied to immobilized oligonucleotides representing potential SNP sequences. After stringent hybridization and washing conditions, fluorescence intensity is measured for each SNP oligonucleotide.

[0124] In one embodiment, the nucleotide present at the polymorphic site is identified by hybridization under sequence-specific hybridization conditions with an oligonucleotide probe exactly complementary to one of the polymorphic alleles in a region encompassing the polymorphic site. The probe hybridizing sequence and sequence-specific hybridization conditions are selected such that a single mismatch at the polymorphic site destabilizes the hybridization duplex sufficiently so that it is effectively not formed. Thus, under sequence-specific hybridization conditions, stable duplexes will form only between the probe and the exactly complementary allelic sequence. Thus, oligonucleotides from about 10 to about 35 nucleotides in length, e.g., from about 15 to about 35 nucleotides in length, which are exactly complementary to an allele sequence in a region which encompasses the polymorphic site are within the scope of the invention (e.g., one of SEQ ID NOs: 1-16).

[0125] In an alternative embodiment, the amount and/or presence of the nucleotide at the polymorphic site is identified by hybridization under sufficiently stringent hybridization conditions with an oligonucleotide substantially complementary to one of the SNP alleles in a region encompassing the polymorphic site, and exactly complementary to the allele at the polymorphic site. Because mismatches that occur at non-polymorphic sites are mismatches with both allele sequences, the difference in the number of mismatches in a duplex formed with the target allele sequence and in a duplex formed with the corresponding non-target allele sequence is the same as when an oligonucleotide exactly complementary to the target allele sequence is used. In this embodiment, the hybridization conditions are relaxed sufficiently to allow the formation of stable duplexes with the target sequence, while maintaining sufficient stringency to preclude the formation of stable duplexes with non-target sequences. Under such sufficiently stringent hybridization conditions, stable duplexes will form only between the probe and the target allele. Thus, oligonucleotides from about 10 to about 35 nucleotides in length, preferably from about 15 to about 35 nucleotides in length, which are substantially complementary to an allele sequence in a region which encompasses the polymorphic site, and are exactly complementary to the allele sequence at the polymorphic site, are within the scope of the invention.

[0126] The use of substantially, rather than exactly, complementary oligonucleotides may be desirable in assay formats in which optimization of hybridization conditions is limited. For example, in a typical multi-target immobilized-probe assay format, probes for each target are immobilized on a single solid support. Hybridizations are carried out simultaneously by contacting the solid support with a solution containing target DNA or

cDNA. As all hybridizations are carried out under identical conditions, the hybridization conditions cannot be separately optimized for each probe. The incorporation of mismatches into a probe can be used to adjust duplex stability when the assay format precludes adjusting the hybridization conditions. The effect of a particular introduced mismatch on duplex stability is well known, and the duplex stability can be routinely both estimated and empirically determined, as described above. Suitable hybridization conditions, which depend on the exact size and sequence of the probe, can be selected empirically using the guidance provided herein and well known in the art. The use of oligonucleotide probes to detect single base pair differences in sequence is described in, for example, Conner et al., 1983, Proc. Natl. Acad. Sci. USA 80:278-282, and U.S. Pat. Nos. 5,468,613 and 5,604,099, each incorporated herein by reference.

[0127] The proportional change in stability between a perfectly matched and a single-base mismatched hybridization duplex depends on the length of the hybridized oligonucleotides. Duplexes formed with shorter probe sequences are destabilized proportionally more by the presence of a mismatch. In practice, oligonucleotides between about 15 and about 35 nucleotides in length are preferred for sequence-specific detection. Furthermore, because the ends of a hybridized oligonucleotide undergo continuous random dissociation and re-annealing due to thermal energy, a mismatch at either end destabilizes the hybridization duplex less than a mismatch occurring internally. Preferably, for discrimination of a single base pair change in target sequence, the probe sequence is selected which hybridizes to the target sequence such that the polymorphic site occurs in the interior region of the probe.

[0128] The above criteria for selecting a probe sequence that hybridizes to a particular SNP apply to the hybridizing region of the probe, i.e., that part of the probe which is involved in hybridization with the target sequence. A probe may be bound to an additional nucleic acid sequence, such as a poly-T tail used to immobilize the probe, without significantly altering the hybridization characteristics of the probe. One of skill in the art will recognize that for use in the present methods, a probe bound to an additional nucleic acid sequence which is not complementary to the target sequence and, thus, is not involved in the hybridization, is essentially equivalent to the unbound probe.

[0129] Suitable assay formats for detecting hybrids formed between probes and target nucleic acid sequences in a sample are known in the art and include the immobilized target (dot-blot) format and immobilized probe (reverse dot-blot or line-blot) assay formats. Dot

blot and reverse dot blot assay formats are described in U.S. Pat. Nos. 5,310,893; 5,451,512; 5,468,613; and 5,604,099; each incorporated herein by reference.

5 [0130] In a dot-blot format, amplified target DNA or cDNA is immobilized on a solid support, such as a nylon membrane. The membrane-target complex is incubated with labeled probe under suitable hybridization conditions, unhybridized probe is removed by washing under suitably stringent conditions, and the membrane is monitored for the presence of bound probe.

10 [0131] In the reverse dot-blot (or line-blot) format, the probes are immobilized on a solid support, such as a nylon membrane or a microtiter plate. The target DNA or cDNA is labeled, typically during amplification by the incorporation of labeled primers. One or both of the primers can be labeled. The membrane-probe complex is incubated with the labeled amplified target DNA or cDNA under suitable hybridization conditions, unhybridized target DNA or cDNA is removed by washing under suitably stringent conditions, and the membrane is monitored for the presence of bound target DNA or cDNA.

15 [0132] An allele-specific probe that is specific for one of the polymorphism variants is often used in conjunction with the allele-specific probe for the other polymorphism variant. In some embodiments, the probes are immobilized on a solid support and the target sequence in an individual is analyzed using both probes simultaneously. Examples of nucleic acid arrays are described by WO 95/11995. The same array or a different array can
20 be used for analysis of characterized polymorphisms. WO 95/11995 also describes subarrays that are optimized for detection of variant forms of a pre-characterized polymorphism.

Allele-Specific Primers

25 [0133] The amount and/or presence of an allele is also commonly detected using allele-specific amplification or primer extension methods. These reactions typically involve use of primers that are designed to specifically target a polymorphism via a mismatch at the 3' end of a primer. The presence of a mismatch affects the ability of a polymerase to extend a primer when the polymerase lacks error-correcting activity. For example, to detect an allele sequence using an allele-specific amplification- or extension-based method, a primer
30 complementary to the polymorphic nucleotide of a SNP is designed such that the 3' terminal nucleotide hybridizes at the polymorphic position. The presence of the particular allele can

be determined by the ability of the primer to initiate extension. If the 3' terminus is mismatched, the extension is impeded. If a primer matches the polymorphic nucleotide at the 3' end, the primer will be efficiently extended.

[0134] Typically, the primer is used in conjunction with a second primer in an amplification reaction. The second primer hybridizes at a site unrelated to the polymorphic position. Amplification proceeds from the two primers leading to a detectable product signifying the particular allelic form is present. Allele-specific amplification- or extension-based methods are described in, for example, WO 93/22456; U.S. Pat. Nos. 5,137,806; 5,595,890; 5,639,611; and U.S. Pat. No. 4,851,331.

[0135] Using allele-specific amplification-based methods, identification and/or quantification of the alleles require detection of the presence or absence of amplified target sequences. Methods for the detection of amplified target sequences are well known in the art. For example, gel electrophoresis and probe hybridization assays described are often used to detect the presence of nucleic acids.

[0136] In an alternative probe-less method, the amplified nucleic acid is detected by monitoring the increase in the total amount of double-stranded DNA in the reaction mixture, is described, *e.g.*, in U.S. Pat. No. 5,994,056; and European Patent Publication Nos. 487,218 and 512,334. The detection of double-stranded target DNA or cDNA relies on the increased fluorescence various DNA-binding dyes, *e.g.*, SYBR Green, exhibit when bound to double-stranded DNA.

[0137] As appreciated by one in the art, allele-specific amplification methods can be performed in reactions that employ multiple allele-specific primers to target particular alleles. Primers for such multiplex applications are generally labeled with distinguishable labels or are selected such that the amplification products produced from the alleles are distinguishable by size. Thus, for example, both alleles in a single sample can be identified and/or quantified using a single amplification by various methods.

[0138] As in the case of allele-specific probes, an allele-specific oligonucleotide primer may be exactly complementary to one of the polymorphic alleles in the hybridizing region or may have some mismatches at positions other than the 3' terminus of the oligonucleotide, which mismatches occur at non-polymorphic sites in both allele sequences.

5'-nuclease assay

[0139] The amount and/or presence of an allele can also be determined using a "TaqMan®" or "5'-nuclease assay", as described in U.S. Pat. Nos. 5,210,015; 5,487,972; and 5,804,375; and Holland *et al.*, 1988, *Proc. Natl. Acad. Sci. USA* 88:7276-7280. In the
5 TaqMan® assay, labeled detection probes that hybridize within the amplified region are added during the amplification reaction. The probes are modified so as to prevent the probes from acting as primers for DNA synthesis. The amplification is performed using a DNA polymerase having 5' to 3' exonuclease activity. During each synthesis step of the amplification, any probe which hybridizes to the target nucleic acid downstream from the
10 primer being extended is degraded by the 5' to 3' exonuclease activity of the DNA polymerase. Thus, the synthesis of a new target strand also results in the degradation of a probe, and the accumulation of degradation product provides a measure of the synthesis of target sequences.

[0140] The hybridization probe can be an allele-specific probe that discriminates between
15 the SNP alleles. Alternatively, the method can be performed using an allele-specific primer and a labeled probe that binds to amplified product.

[0141] Any method suitable for detecting degradation product can be used in a 5' nuclease assay. Often, the detection probe is labeled with two fluorescent dyes, one of which is capable of quenching the fluorescence of the other dye. The dyes are attached to the probe,
20 preferably one attached to the 5' terminus and the other is attached to an internal site, such that quenching occurs when the probe is in an unhybridized state and such that cleavage of the probe by the 5' to 3' exonuclease activity of the DNA polymerase occurs in between the two dyes. Amplification results in cleavage of the probe between the dyes with a concomitant elimination of quenching and an increase in the fluorescence observable from
25 the initially quenched dye. The accumulation of degradation product is monitored by measuring the increase in reaction fluorescence. U.S. Pat. Nos. 5,491,063 and 5,571,673, both incorporated herein by reference, describe alternative methods for detecting the degradation of probe which occurs concomitant with amplification.

DNA Sequencing and single base or other primer extensions

[0142] The amount and/or presence of an allele can also be determined by direct sequencing. Methods include *e.g.*, dideoxy sequencing-based methods and other methods such as Maxam and Gilbert sequence (*see, e.g.*, Sambrook and Russell, *supra*).

5 [0143] Other detection methods include Pyrosequencing™ of oligonucleotide-length products. Such methods often employ amplification techniques such as PCR. For example, in pyrosequencing, a sequencing primer is hybridized to a single stranded, PCR-amplified, DNA or cDNA template; and incubated with the enzymes, DNA polymerase, ATP
10 sulfurylase, luciferase and apyrase, and the substrates, adenosine 5' phosphosulfate (APS) and luciferin. The first of four deoxynucleotide triphosphates (dNTP) is added to the reaction. DNA polymerase catalyzes the incorporation of the deoxynucleotide triphosphate into the DNA strand, if it is complementary to the base in the template strand. Each incorporation event is accompanied by release of pyrophosphate (PPi) in a quantity equimolar to the amount of incorporated nucleotide. ATP sulfurylase quantitatively
15 converts PPi to ATP in the presence of adenosine 5' phosphosulfate. This ATP drives the luciferase-mediated conversion of luciferin to oxyluciferin that generates visible light in amounts that are proportional to the amount of ATP. The light produced in the luciferase-catalyzed reaction is detected by a charge coupled device (CCD) camera and seen as a peak in a pyrogram™. Each light signal is proportional to the number of nucleotides
20 incorporated. Apyrase, a nucleotide degrading enzyme, continuously degrades unincorporated dNTPs and excess ATP. When degradation is complete, another dNTP is added.

[0144] Another similar method for characterizing SNPs does not require use of a complete PCR, but typically uses only the extension of a primer by a single nucleotide,
25 which is complementary to any of the allelic options of the SNP, and in some cases which is modified so as to be easily detected. Modifications of ddNTPs can include, but are not limited to, fluorescent labeling or mass modification. The incorporated nucleotide at the polymorphic site can then be identified via detection of a primer that has been extended by one base and is fluorescently labeled or mass modified (*e.g.*, Kobayashi *et al*, *Mol. Cell.*
30 *Probes*, 9:175-182, 1995). Of course extension products can also be detected based on other types of labels, or by mass-spectrometry, as desired.

[0145] In a similar method, PCR amplified target DNA or RT-PCR amplified target cDNA may be used as template for a single nucleotide primer extension reaction whereby a single fluorescently labeled ddNTP complementary to the polymorphic nucleotide is incorporated on the 3' end of a single primer. Each specific ddNTP can be labeled with a different fluorescent dye (*e.g.* ddATP labeled with dR6G, ddCTP labeled with dTAMRATM, ddGTP labeled with dR110 and ddTTP or ddUTP labeled with dROXTM). Therefore, single nucleotide extension of the initially unlabeled primer tags the primer with a specific fluorescent dye that identifies the base that was added to the 3' end of the unlabeled primer. Extended primers can be resolved and analyzed to determine the presence and relative quantity of each specific dye-tagged primer, representing the relative quantities of each allele in the target DNA or target cDNA template.

Restriction Fragment Length Polymorphism Analysis

[0146] In other embodiments, the amount and/or presence of an allele of a SNP can be determined by differential digestion of amplified target DNA or cDNA when the polymorphic nucleotide of interest lies within the recognition sequence of a restriction enzyme. In one case, one allele of the SNP (the first allele) maintains the recognition sequence of the restriction enzyme and the other allele (the second allele) does not. In this case, the restriction enzyme will cleave the target DNA or cDNA including the first allele, but not the target DNA or cDNA including the second allele. In another case, one allele (the first allele) of the SNP maintains the recognition sequence of a restriction enzyme (the first restriction enzyme) and the other allele (the second allele) maintains the recognition sequence of a different restriction enzyme (the second restriction enzyme). In this case, the first restriction enzyme will cleave the target DNA or cDNA including the first allele, but not the target DNA or cDNA including the second allele. The second restriction enzyme will cleave the target DNA or cDNA including the second allele, but not the target DNA or cDNA including the first allele. The amount and/or presence of alleles can be determined by various methods including, but not limited to, Southern blot hybridization to immobilized restricted fragments and quantification of band intensities, resolution and visualization of restriction fragments by gel electrophoresis, resolution and quantification of restriction fragments by capillary electrophoresis (such as performed using an Agilent BioAnalyzer), or differential quantitative PCR amplification of cleaved versus uncleaved template DNA or cDNA.

Denaturing Gradient Gel Electrophoresis

[0147] Amplification products generated using the polymerase chain reaction can be analyzed by the use of denaturing gradient gel electrophoresis. Different alleles can be identified based on the different sequence-dependent melting properties and electrophoretic migration of DNA in solution (*see, e.g.*, Erlich, ed., PCR Technology, Principles and Applications for DNA Amplification, W. H. Freeman and Co, New York, 1992, Chapter 7).

Single-Strand Conformation Polymorphism Analysis

[0148] Alleles of target sequences can be differentiated using single-strand conformation polymorphism analysis, which identifies base differences by alteration in electrophoretic migration of single stranded PCR products, as described, *e.g.* in Orita *et al.*, *Proc. Nat. Acad. Sci.* 86, 2766-2770 (1989). Amplified PCR or RT-PCR products can be generated as described above, and heated or otherwise denatured, to form single stranded amplification products. Single-stranded nucleic acids may refold or form secondary structures which are partially dependent on the base sequence. The different electrophoretic mobilities of single-stranded amplification products can be related to base-sequence difference between alleles of target

[0149] SNP detection methods often employ labeled oligonucleotides. Oligonucleotides can be labeled by incorporating a label detectable by spectroscopic, photochemical, biochemical, immunochemical, or chemical means. Useful labels include fluorescent dyes, radioactive labels, *e.g.*, ^{32}P , electron-dense reagents, enzyme, such as peroxidase or alkaline phosphatase, biotin, or haptens and proteins for which antisera or monoclonal antibodies are available. Labeling techniques are well known in the art (*see, e.g.*, *Current Protocols in Molecular Biology*, *supra*; Sambrook & Russell, *supra*).

V. Methods for Quantifying RNA

[0150] The presence and quantity of RNA corresponding to a particular SNP can be readily determined according to any method for quantifying RNA. Various methods involving linkage of RNA to a solid support and probing the RNA (*e.g.*, northern blots, dot blots, etc.) can be used.

[0151] In some embodiments, the target RNA is first reverse transcribed (*e.g.*, with reverse transcriptase) and then the resulting cDNA is quantified by any methods known in the art (blot hybridization, RT-PCR, etc.) as a surrogate for RNA quantity. Various

methods of reverse transcription are known and described, e.g., in Sambrook *et al.*, *Molecular Cloning, A Laboratory Manual* (3rd ed. 2001); Kriegler, *Gene Transfer and Expression: A Laboratory Manual* (1990); and *Current Protocols in Molecular Biology* (Ausubel *et al.*, eds., 1994)), and can involve reverse transcription using either specific or non-specific primers.

[0152] In some embodiments, RT-PCR or other quantitative amplification techniques are used to quantify the target RNA. Amplification of cDNA using reactions is well known (see U.S. Patents 4,683,195 and 4,683,202; PCR PROTOCOLS: A GUIDE TO METHODS AND APPLICATIONS (Innis *et al.*, eds, 1990)).

[0153] Sequences amplified by the methods of the invention can be further evaluated, detected, cloned, sequenced, and the like, either in solution or after binding to a solid support, by any method usually applied to the detection of a specific DNA sequence such as PCR, oligomer restriction (Saiki, *et al.*, *Bio/Technology* 3:1008-1012 (1985)), allele-specific oligonucleotide (ASO) probe analysis (Conner, *et al.*, *PNAS USA* 80:278 (1983)), oligonucleotide ligation assays (OLAs) (Landegren, *et al.*, *Science* 241:1077, (1988)), and the like. Molecular techniques for DNA analysis have been reviewed (Landegren, *et al.*, *Science* 242:229-237 (1988)).

[0154] Methods of quantitative amplification are disclosed in, e.g., U.S. Patent Nos. 6,180,349; 6,033,854; and 5,972,602, as well as in, e.g., Gibson *et al.*, *Genome Research* 6:995-1001 (1996); DeGraves, *et al.*, *Biotechniques* 34(1):106-10, 112-5 (2003); Deiman B, *et al.*, *Mol Biotechnol.* 20(2):163-79 (2002). Amplifications may be monitored in "real time."

[0155] In general, quantitative amplification is based on the monitoring of the signal (e.g., fluorescence of a probe) representing copies of the template in cycles of an amplification (e.g., PCR) reaction. In the initial cycles of the PCR, a very low signal is observed because the quantity of the amplicon formed does not support a measurable signal output from the assay. After the initial cycles, as the amount of formed amplicon increases, the signal intensity increases to a measurable level and reaches a plateau in later cycles when the PCR enters into a non-logarithmic phase. Through a plot of the signal intensity versus the cycle number, the specific cycle at which a measurable signal is obtained from the PCR reaction can be deduced and used to back-calculate the quantity of the target before the start of the PCR. The number of the specific cycles that is determined by this method is typically referred to as the cycle threshold (Ct). Exemplary methods are described in, e.g., Heid *et al.* *Genome Methods* 6:986-94 (1996) with reference to hydrolysis probes.

[0156] One method for detection of amplification products is the 5'-3' exonuclease "hydrolysis" PCR assay (also referred to as the TaqMan™ assay) (U.S. Pat. Nos. 5,210,015 and 5,487,972; Holland *et al.*, *PNAS USA* 88: 7276-7280 (1991); Lee *et al.*, *Nucleic Acids Res.* 21: 3761-3766 (1993)). This assay detects the accumulation of a specific PCR product by hybridization and cleavage of a doubly labeled fluorogenic probe (the "TaqMan™" probe) during the amplification reaction. The fluorogenic probe consists of an oligonucleotide labeled with both a fluorescent reporter dye and a quencher dye. During PCR, this probe is cleaved by the 5'-exonuclease activity of DNA polymerase if, and only if, it hybridizes to the segment being amplified. Cleavage of the probe generates an increase in the fluorescence intensity of the reporter dye.

[0157] Another method of detecting amplification products that relies on the use of energy transfer is the "beacon probe" method described by Tyagi and Kramer, *Nature Biotech.* 14:303-309 (1996), which is also the subject of U.S. Patent Nos. 5,119,801 and 5,312,728. This method employs oligonucleotide hybridization probes that can form hairpin structures. On one end of the hybridization probe (either the 5' or 3' end), there is a donor fluorophore, and on the other end, an acceptor moiety. In the case of the Tyagi and Kramer method, this acceptor moiety is a quencher, that is, the acceptor absorbs energy released by the donor, but then does not itself fluoresce. Thus, when the beacon is in the open conformation, the fluorescence of the donor fluorophore is detectable, whereas when the beacon is in hairpin (closed) conformation, the fluorescence of the donor fluorophore is quenched. When employed in PCR, the molecular beacon probe, which hybridizes to one of the strands of the PCR product, is in "open conformation," and fluorescence is detected, while those that remain unhybridized will not fluoresce (Tyagi and Kramer, *Nature Biotechnol.* 14: 303-306 (1996)). As a result, the amount of fluorescence will increase as the amount of PCR product increases, and thus may be used as a measure of the progress of the PCR. Those of skill in the art will recognize that other methods of quantitative amplification are also available.

[0158] Various other techniques for performing quantitative amplification of nucleic acids are also known. For example, some methodologies employ one or more probe oligonucleotides that are structured such that a change in fluorescence is generated when the oligonucleotide(s) is hybridized to a target nucleic acid. For example, one such method involves is a dual fluorophore approach that exploits fluorescence resonance energy transfer (FRET), *e.g.*, LightCycler™ hybridization probes, where two oligo probes anneal to the amplicon. The oligonucleotides are designed to hybridize in a head-to-tail orientation with

the fluorophores separated at a distance that is compatible with efficient energy transfer. Other examples of labeled oligonucleotides that are structured to emit a signal when bound to a nucleic acid or incorporated into an extension product include: Scorpions™ probes (*e.g.*, Whitcombe *et al.*, *Nature Biotechnology* 17:804-807, 1999, and U.S. Pat. No. 6,326,145),

5 Sunrise™ (or Amplifluor™) probes (*e.g.*, Nazarenko *et al.*, *Nuc. Acids Res.* 25:2516-2521, 1997, and U.S. Pat. No. 6,117,635), and probes that form a secondary structure that results in reduced signal without a quencher and that emits increased signal when hybridized to a target (*e.g.*, Lux probes™).

[0159] In other embodiments, intercalating agents that produce a signal when intercalated

10 in double stranded DNA may be used. Exemplary agents include SYBR GREEN™ and SYBR GOLD™. Since these agents are not template-specific, it is assumed that the signal is generated based on template-specific amplification. This can be confirmed by monitoring signal as a function of temperature because melting point of template sequences will generally be much higher than, for example, primer-dimers, *etc.*

15 VI. Kits

[0160] The invention also provides kits comprising useful components for practicing the methods. In some embodiments, the kit may comprise one or both allele-specific detection polynucleotides (*e.g.*, primers or probes) for any of the combinations of SNPs described

20 herein. Such polynucleotides can optionally be fixed to an appropriate support membrane. In some embodiments, the kits comprise a sufficient number of polynucleotides to detection a combination of SNPs as described herein. In some embodiments, the first and second SNP is selected from the group consisting of SEQ ID NOs:1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and 16, optionally wherein at least one SNP is 1, 2, 3, 4, 5, or 6.

25 [0161] In some embodiments, the kit comprises one or both allele-specific detection polynucleotides (*e.g.*, primers or probes) for each of SEQ ID NOs: 1, 5, 8, 9, 10, 11, 14, 15 and 16. In some embodiments, the kit comprises one or both allele-specific detection polynucleotides (*e.g.*, primers or probes) for each of SEQ ID NOs: 1, 5, 8, 9, 10, 11, 12, 14, 15 or 16. In some embodiments, the kit comprises one or both allele-specific detection

30 polynucleotides (*e.g.*, primers or probes) for each of SEQ ID NOs: 1, 2, 4, 5, 8, 9, 10, 12, 13, 14, 15 or 16. In some embodiments, the kit comprises one or both allele-specific detection polynucleotides (*e.g.*, primers or probes) for each of SEQ ID NOs: 1-16.

[0162] In some embodiments, one, some or all of the polynucleotides for detection of the combination of SNPs comprise a sequence 100% identical to at least 8 (e.g., at least 10, 12, 15) contiguous nucleotides, or the complement thereof, of the SNPs to be detected. For example, if three SNPs are to be detected (arbitrarily designated A, B, and C), a kit can
5 comprise at least three polynucleotides wherein:

the first polynucleotide detects (and optionally comprises a sequence 100% identical to at least 8 (e.g., at least 10, 12, 15) contiguous nucleotides, or the complement thereof, of SNP A;

the second polynucleotide detects (and optionally comprises a sequence 100% identical to at least 8 (e.g., at least 10, 12, 15) contiguous nucleotides, or the complement thereof, of SNP B;

the third polynucleotide detects (and optionally comprises a sequence 100% identical to at least 8 (e.g., at least 10, 12, 15) contiguous nucleotides, or the complement thereof, of SNP C.

[0163] In some embodiments, the sequence of the allele-specific detection polynucleotide comprises or consists of at least 8 (e.g., at least 10, 12, 15) contiguous nucleotides directly 5' (or is 2 or 3 nucleotides 5') from the variable position of the target SNP and the sequence is at the 3' end of the polynucleotide. Such options are conveniently used for, e.g., primer extension reactions. In some embodiments, the sequence comprises or consists of the
20 complement of at least 8 (e.g., at least 10, 12, 15) contiguous nucleotides directly 3' (or is 2 or 3 nucleotides 3') from the variable position of the SNP and the sequence is at the 3' end of the polynucleotide. Such options are also conveniently used for, e.g., primer extension reactions.

[0164] In some embodiments, the sequence consists of at least 8 (e.g., at least 10, 12, 15) contiguous nucleotides, or the complement thereof, of the SNP, wherein one of the positions of the sequence corresponds to the variable position of the SNP. Such embodiments are useful, for example, for assays where differential hybridization to SNP alleles is involved.

[0165] Such a kit can also contain amplification primers for amplifying a region of the *IGF2* locus encompassing the polymorphic site. Alternatively, useful kits can contain a set
30 of primers comprising an allele-specific primer for the specific amplification of the polymorphic alleles. Such a kit may also comprise probes for the detection of amplification

products. Alternatively, useful kits can contain a set of primers complementary to sequences 5' to but not including the SNP positions of interest (or complements thereof) for use in primer extension methods as described above.

5 [0166] Other optional components of the kits include additional reagents used for genotyping patients and/or quantifying the relative amount of specific alleles present. For example, a kit can contain a polymerase, labeled or unlabeled substrate nucleoside triphosphates (optionally, where some or each different nucleotides are labeled with a different, distinguishable label, means for labeling and/or detecting nucleic acid, appropriate buffers for amplification or hybridization reactions, and/or instructions for carrying out the
10 present method.

[0167] Optionally kit will comprise control nucleic acid samples, e.g., a sample comprising only one possible allele and optionally a control having two (or, where appropriate, all three) possible alleles of a particular SNP. Controls can include at least one control nucleic acid or mixture of nucleic acids for each SNP (e.g., having one or both
15 alleles). Negative and other controls can also be included.

VII. Reaction Mixtures

[0168] The present invention provides for reaction mixtures for carrying out the invention. In some embodiments, the reaction mixtures may comprise one or both allele-specific detection polynucleotides (e.g., primers or probes) for any of the combinations of
20 SNPs described herein. Such polynucleotides can optionally be fixed to an appropriate support membrane. In some embodiments, the reaction mixtures comprise a sufficient number of polynucleotides to detect a combination of SNPs as described herein. For example, in some embodiments, the reaction mixtures can comprise a first polynucleotide of between 8-100 nucleotides, wherein the first polynucleotide distinguishes between one
25 allele of a first SNP (or complement thereof) and the other allele of the first SNP (or complement thereof) in a hybridization reaction, a second polynucleotide of between 8-100 nucleotides, wherein the second polynucleotide distinguishes between one allele of a second SNP (or complement thereof) and the other allele of the second SNP (or complement thereof) in a hybridization reaction, wherein the first and second SNP is selected from the
30 group consisting of SEQ ID NOs:1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and 16, optionally wherein at least one SNP is selected from SEQ ID NO:s 1, 2, 3, 4, 5, or 6. Exemplary combinations include, but are not limited to:

SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and 16; or

SEQ ID NOs: 1, 5, 8, 9, 10, 11, 14, 15, and 16; or

SEQ ID NOs: 1, 5, 8, 9, 10, 11, 12, 14, 15, and 16; or

SEQ ID NOs: 1, 2, 4, 5, 8, 9, 10, 12, 13, 14, 15, and 16.

5 [0169] In some embodiments, the reaction mixture comprises one or both allele-specific detection polynucleotides (e.g., primers or probes) for each of SEQ ID NOs: 1, 5, 8, 9, 10, 11, 14, 15 and 16. In some embodiments, the reaction mixture comprises one or both allele-specific detection polynucleotides (e.g., primers or probes) for each of SEQ ID NOs: 1, 5, 8, 9, 10, 11, 12, 14, 15 or 16. In some embodiments, the reaction mixture comprises one or both allele-specific detection polynucleotides (e.g., primers or probes) for each of SEQ ID NOs: 1, 2, 4, 5, 8, 9, 10, 12, 13, 14, 15 or 16. In some embodiments, the reaction mixture comprises one or both allele-specific detection polynucleotides (e.g., primers or probes) for each of SEQ ID NOs: 1-16.

[0170] In some embodiments, one, some or all of the polynucleotides for detection of the combination of SNPs comprise a sequence 100% identical to at least 8 (e.g., at least 10, 12, 15) contiguous nucleotides, or the complement thereof, of the SNPs to be detected. For example, if three SNPs are to be detected (arbitrarily designated A, B, and C), a kit can comprise at least three polynucleotides wherein:

the first polynucleotide detects (and optionally comprises a sequence 100% identical to at least 8 (e.g., at least 10, 12, 15) contiguous nucleotides, or the complement thereof, of SNP A;

the second polynucleotide detects (and optionally comprises a sequence 100% identical to at least 8 (e.g., at least 10, 12, 15) contiguous nucleotides, or the complement thereof, of SNP B;

25 the third polynucleotide detects (and optionally comprises a sequence 100% identical to at least 8 (e.g., at least 10, 12, 15) contiguous nucleotides, or the complement thereof, of SNP C.

[0171] In some embodiments, the sequence comprises or consists of at least 8 (e.g., at least 10, 12, 15) contiguous nucleotides directly 5' (or is 2 or 3 nucleotides 5') from the variable position of the target SNP and the sequence is at the 3' end of the polynucleotide. Such options are conveniently used for, e.g., primer extension reactions. In some embodiments, the sequence comprises or consists of the complement of at least 8 (e.g., at

least 10, 12, 15) contiguous nucleotides directly 3' (or is 2 or 3 nucleotides 3') from the variable position of the SNP and the sequence is at the 3' end of the polynucleotide. Such options are also conveniently used for, e.g., primer extension reactions.

5 [0172] In some embodiments, the sequence consists of at least 8 (e.g., at least 10, 12, 15) contiguous nucleotides, or the complement thereof, of the SNP, wherein one of the positions of the sequence corresponds to the variable position of the SNP. Such embodiments are useful, for example, for assays where differential hybridization to SNP alleles is involved.

10 [0173] Such reaction mixtures can also contain amplification primers for amplifying a region of the *IGF2* locus encompassing the polymorphic site. Alternatively, reaction mixtures can contain a set of primers comprising an allele-specific primer for the specific amplification of the polymorphic alleles. Such a reaction mixtures may also comprises probes for the detection of amplification products. Alternatively, useful reaction mixtures can contain a set of primers complementary to sequences 5' to but not including the SNP positions of interest (or complements thereof) for use in primer extension methods as
15 described above.

[0174] Other optional components of the reaction mixtures include additional reagents used for genotyping patients and/or quantifying the relative amount of specific alleles present. For example, a kit can contain a polymerase, labeled or unlabeled substrate nucleoside triphosphates (optionally, where some or each different nucleotides are labeled
20 with a different, distinguishable label, means for labeling and/or detecting nucleic acid, appropriate buffers for amplification or hybridization reactions, and/or instructions for carrying out the present method. Optionally, the reaction mixtures include a nucleic acid sample from a human.

VIII. CONTROLS FOR VALIDATING LOI MEASUREMENTS

25 [0175] An assay that determines the imprinting status of *IGF2* in a clinical sample involves a determination of the ratio of the amount of expression from one allele of the gene and the amount of expression of the other allele, and a comparison of the ratio to a cutoff value associated with loss of imprinting of the gene, and or associated with a clinical factor such as the presence of cancer, the risk of cancer or the selection of a treatment regime for
30 the patient.

[0176] *IGF2* imprinting status measurements are subjected to many process factors that have the potential to introduce either random or systematic error in the assay measurement and therefore have the potential to lower the accuracy of measurement results. For example, imprinting status assays typically require multiple steps. These steps can include
5 the isolation of RNA from the sample, the reverse transcription of RNA into 1st strand cDNA, the second strand synthesis of 1st strand cDNA into 2nd strand cDNA, the amplification of cDNA into amplified cDNA, and the SNP-based quantification of the amplified cDNA copies arising from each transcribed allele of the gene in the sample.

[0177] In the clinical testing environment, from time to time, different reagent lots,
10 different equipment, different laboratory personnel, and even different standard operating procedures might be used to measure the same clinical sample multiple times, or optionally to measure different clinical samples. An assay which measures more than one heterozygous SNP may contain components that differ for each measured SNP. For example, different RT primers may be used to reverse transcribe different sequence regions
15 of the transcript, or different PCR primers may be used to amplify cDNA of different sequence regions, or different detection probes used to detect the polymorphic options of the different SNPs of the panel.

[0178] If any step or any assay component in a given imprinting status measurement leads to an allele-specific amplification bias, or optionally, to an allele-specific detection bias,
20 then such step or component will effect the measured ratio of alleles and introduce error in the resulting imprinting status ratio. Therefore is it useful to develop controls that can be used to measure the variation of the steps and components of any given imprinting status measurement, and that allow for the correction of these measurements resulting in improved measurement results.

[0179] A preferred source of controls for the assays measuring the optimized panels of SNPs described herein would be DNA or RNA isolated from a single pair of individuals, where one individual is homozygous for one allele of every SNP in a given panel, and the another individual is homozygous for the other allele of every SNP in the panel. However, due to the combined heterozygosity frequencies of the SNPs of the optimized panels in the
25 general population, the likelihood of finding such a pair of individuals is extremely low.

[0180] An optional source of controls for the assays measuring the optimized panels of SNPs described herein is DNA and/or RNA derived from a set of multiple pairs of

individuals; where in each pair of individuals, one individual is homozygous for one allele of a given SNP (e.g., is homozygous for the G allele at a G/A SNP nucleotide position) and the another individual is homozygous for the other allele of the same SNP (e.g., is homozygous for the A allele at the same G/A SNP nucleotide position); and where the set of multiple pairs of individuals represent the different allelic options of all of the SNPs in an optimized panel. By identifying such a set of pairs of individuals, representative sources of DNA or RNA useful for controlling each SNP could be established. However, the use of multiple pairs of controls, where each pair represents one or a few SNPs, would necessitate the generation and use of multiple control curves, and this in turn would greatly increase assay complexity, assay cost, and the cumulative error of the controls thereby eroding the power of a inter assay comparison of ASE ratios determined between multiple heterozygous SNPs within the same clinical sample.

[0181] To address these problems, one aspect of the invention provides synthetic control nucleic acid sequences for *IGF2* LOI assays and methods of using the controls. The control nucleic acids of the invention (also referred to herein as “LOI control pairs”) are pairs of polynucleotides that represent alleles and the alternative alleles of least two *IGF2* SNPs. Thus, one member of the pair comprises at least two *IGF2* SNPs, e.g., at least two of the exon 9 *IGF2* SNPs set forth in SEQ ID NOs. 1-16, or the complement thereof. The nucleotide complementary to one of the SNP alleles (a first SNP) is present on one of the members of the pair; a nucleotide complementary to an alternative allele of the first SNP is present on the second member of the pair. Similarly, for the second *IGF2* SNP for the control, one member of the pair comprises a nucleotide complementary to one of the alleles of the second SNP and the other member of the pair comprises a nucleotide complementary to an alternative allele of the second SNP. In the following description of the control pair of nucleic acids, references to reference SEQ ID NOs also refer to the complementary sequence of the SEQ ID NOs, even though it may not be explicitly stated.

[0182] A “LOI control pair” of the invention is “substantially free” of cellular nucleic acids; thus, the nucleic acids are substantially free of genomic DNA, RNA, and the like from a human or a host cell, e.g., a bacterial host cell. For example, the control pair may be obtained using an *in vitro* transcription reaction. By being substantially free of cellular nucleic acids, the LOI control pair can be stored in mixtures at high concentrations and in the presence of nucleic acid stabilizers, so as to remain un-degraded for long periods of

time, and can be diluted to working volumes at the time imprinting assays are run on clinical samples to serve as a control.

[0183] The control polynucleotide pair may represent any number of SNPs, e.g., the control pair may have 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16, or more, *IGF2* SNPs, where one member of the pair has a nucleotide for one of the SNP alleles for each of the different SNPs and the second member of the pair has a nucleotide for an alternative allele for each of those SNPs. In some embodiments, one member of the pair may have minor allele nucleotides for 2 or more, e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16, of the SNPs. For example, for a LOI control nucleic acid pair for ten of the SNPs shown in SEQ ID NOs 1-16, one member of the pair may have the nucleotides for a minor allele for all ten SNPs and the other member of the pair may have nucleotides for all of the major alleles of the ten SNPs. Alternatively, for example, one member of the pair may have the nucleotide for a minor allele for two of the ten SNPs with the other eight SNP nucleotides being for the major allele; and the other member of the pair has the nucleotides for the major alleles of the two SNPs and the minor alleles for the other eight SNPs.

[0184] In some embodiments, the polynucleotides that make up the control LOI pair are anywhere from 40 nucleotides to about 3600 or 4000 nucleotides, or 4500, 5000, or 6,000 nucleotides, in length. In some embodiments, the control LOI pair is from 40, 50, 60, 70, or 80 nucleotides in length to 100, 200, 300, 400, 600, 800, 1000, 1500, 2000, 2500, or 3000 nucleotides in length. The members of the pair may be of the same length or different lengths.

[0185] The control pair polynucleotides can comprise any SNP present in an *IGF2* transcript, including SNPs present in exon 9, exon 8, and exon 7. In some embodiments, the LOI pair comprises exon 9 SNPs.

[0186] In some embodiments, an LOI control polynucleotide member of the nucleic acid pair has a 3' nucleic acid sequence adjacent to the first SNP (referred to herein as "3' adjacent sequence") that is substantially identical to at least 15 contiguous nucleotides, typically at least 20, 25, or 50 contiguous nucleotides, to the corresponding region of an *IGF2* transcript, e.g., SEQ ID NO 17 or SEQ ID NO:18; and has a 3' adjacent sequence for the second SNP that is substantially identical to at least 15 contiguous nucleotides, typically at least 20, 25, or 50, contiguous nucleotides, of the corresponding region of an *IGF2* transcript, e.g., SEQ ID NO 17 or SEQ ID NO:18. In some embodiments, at least 8

contiguous nucleotides, or at least 10, 12, 15, 20, or 25 contiguous nucleotides, of the 3' nucleic acid sequence adjacent to the first SNP is identical to the corresponding region of an *IGF2* transcript, *e.g.*, SEQ ID NO:17 or SEQ ID NO:18; and at least at least 8 contiguous nucleotides, or at least 10, 12, 15, 20, or 25 contiguous nucleotides, of the 3' nucleic acid sequence adjacent to the second SNP is identical to the corresponding region of SEQ ID NO:17 or SEQ ID NO:18. In the context of this invention as it relates to the description of the control pair of synthetic nucleic acids, "3' nucleic acid sequence adjacent to a SNP" refers to the nucleic acid sequence immediately 3' of the SNP position, including the nucleotide 3' to the SNP site.

[0187] In some embodiments, an LOI control polynucleotide member of the nucleic acid pair has a 3' nucleic acid sequence adjacent to the first SNP that is substantially identical to at least 15 contiguous nucleotides, typically at least 20, 25, or 50 contiguous nucleotides, to the corresponding region of an *IGF2* nucleic acid sequence that comprises exon 9 polymorphic sites, *e.g.*, SEQ ID NO:21 or SEQ ID NO:23; and has a 3' adjacent sequence for the second SNP that is substantially identical to at least 15 contiguous nucleotides, typically at least 20, 25, or 50, contiguous nucleotides, of the corresponding region of an *IGF2* nucleic acid sequence *e.g.*, SEQ ID NO:21 or SEQ ID NO:23. In some embodiments, at least 8 contiguous nucleotides, or at least 10, 12, 15, 20, or 25 contiguous nucleotides, of the 3' nucleic acid sequence adjacent to the first SNP is identical to the corresponding region of an *IGF2* sequence *e.g.*, SEQ ID NO:21 or SEQ ID NO:23; and at least at least 8 contiguous nucleotides, or at least 10, 12, 15, 20, or 25 contiguous nucleotides, of the 3' nucleic acid sequence adjacent to the second SNP is identical to the corresponding region of SEQ ID NO:21 or SEQ ID NO:23.

[0188] The terms "identical" or "100% identity," in the context of two or more nucleic acids refer to two or more sequences or subsequences that are the same sequences. Two sequences are "substantially identical" or a certain percent identity if two sequences have a specified percentage of amino acid residues or nucleotides that are the same (*i.e.*, 70% identity, optionally 75%, 80%, 85%, 90%, or 95% identity, over a specified region, or, when not specified, over the entire sequence), when compared and aligned for maximum correspondence over a comparison window, or designated region as measured using known sequence comparison algorithms, *e.g.*, BLAST using the default parameters, or by manual alignment and visual inspection.

[0189] In some embodiments, at least one of the SNPs included in the control pair is selected from the group consisting of the SNPs as shown in SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and 16. In typical embodiments, at least two of the SNPs shown in SEQ ID NOs. 1-16 are include in the control nucleic acid pair. Often, at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or all 16 of the SNPs shown in SEQ ID NOs. 1-16 are included in the control LOI nucleic acid pair. In some embodiments, at least one of the SNPs in the control is selected from SEQ ID NO:1, 2, 3, 4, 5, or 6. In some embodiments, the control LOI nucleic acid pair comprises the SNPs shown in SEQ ID NOs: 1, 5, 8, 9, 10, 11, 14, 15, and 16; SEQ ID NOs. 1, 5, 8, 9, 10, 11, 12, 14, 15, and 16; or SEQ ID NOs. 1, 2, 4, 5, 8, 9, 10, 12, 13, 14, 15, and 16.

[0190] In some embodiments, the first member of a control pair of nucleic acids of the invention that has at least two *IGF2* SNPs comprises a polynucleotide having at least 8 contiguous nucleotides, or at least 10, 12, 15, 20, 25, or 30 contiguous nucleotides, including the SNP site, of one allele of a SNP shown in SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16, or the complement thereof; and the second *IGF2* SNP site present on the first member of the control polynucleotide has at least 8 contiguous nucleotides, or at least 10, 12, 15, 20, 25, or 30 contiguous nucleotides, including the SNP site, of one allele of a different SNP shown in SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16, or the complement thereof. The second member of the control pair has the same polynucleotide sequence as the first member of the pair, however, the nucleotides present at the polymorphic positions correspond to alternative alleles of the two SNPS.

[0191] In some embodiments, the one member of a control pair of nucleic acids of the invention has at least 70% identity, typically at least 80% identity, at least 90% identity, or at least 95%, 96%, 97%, 98%, 99%, or 100% identity, to SEQ ID NO: 21 or SEQ ID NO:23 and includes the SNPs shown in SEQ ID NOs. 1-16. In some embodiments, the second member of a control pair of nucleic acids of the invention has at least 70% identity, typically at least 80% identity, at least 90% identity, or at least 95%, 96%, 97%, 98%, 99%, or 100% identity, to SEQ ID NO 21 or SEQ ID NO:23 and includes alternative alleles of the SNPs shown in SEQ ID NOs. 1-16.

[0192] In some embodiments, the first member of a control pair of nucleic acids of the invention that has at least two *IGF2* SNPs comprises a polynucleotide that has at least 8

contiguous nucleotides, or at least 10, 12, 15, 20, 25, 30, 35, 40, 50, or 100 contiguous nucleotides, including at least one SNP site, of SEQ ID NO:21 or SEQ ID NO:23.

[0193] In some embodiments, the polynucleotides comprised by the LOI control pair have substantially the same sequence as SEQ ID NO:20, or the complement thereof, however, comprises less than 500 nucleotides of the CA-rich polymorphic region. The CA-rich polymorphic region of SEQ ID NO:20 occurs between positions 1115 and 1692 of SEQ ID NO:20 and is immediately flanked by positions 1168 and 1169 of the nucleotide sequence set forth in SEQ ID NO:21. The CA-rich region of SEQ ID NO:20 is provided in SEQ ID NO:22. Thus, in some embodiments, the first and second polynucleotides of the control pair comprise substantially the same sequence as SEQ ID NO:20, but comprises less than 500 nucleotides of SEQ ID NO:22. In some embodiments, the LOI control polynucleotides may contain additional sequences to facilitate specific amplification. For example, where the control comprises *IGF2* exon 9 SNPs, additional sequences from the 3' end of *IGF2* exon 8 may be incorporated into the 5' sequence of a control polynucleotide.

[0194] The control nucleic acid may be RNA or DNA or other base pairing nucleic acid. In some embodiments, the polynucleotides corresponding to the members of the pair are operably linked to an RNA polymerase promoter, e.g., a T7 promoter, so that RNA transcripts can be made from the polynucleotide to provide an RNA control. In some embodiments, the polynucleotides may be linked to promoters on separate vectors such that one vector encodes one member of the control pair and a separate vector encodes the other member of the pair. Control nucleic acid pairs may be obtained using methods well known in the art. For example, in some embodiments, e.g., for pairs where each member is less than 100 nucleotides in length, the polynucleotides may be synthesized chemically. In typical embodiments, the control polynucleotides may be obtained using amplification reactions.

[0195] In some embodiments, the members of the LOI control pair are separated. In the context of this invention, "separated" means that the two members of a pair are not present in the same mixture or solution. In some embodiments, the members of the pair are present in a mix together.

[0196] In a further aspect, the invention provides a mixture comprising an LOI control pair. In some embodiments, the members of the pair are present in equimolar amounts. In some embodiments, the members of the pair are present in a molar ratio, e.g., of 1:2, 1:4,

1:8, and the like. In some embodiments, the invention provides a plurality of mixtures, where each mixture contains a different predetermined amount of pair members. For example, the invention also provides a plurality of mixtures where the mixtures have the individual members of the pair present at 10:1, 8:1, 6:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:6,
5 1:8 and 1:10.

[0197] In some embodiments, the mixture may comprise a second LOI control pair of isolated nucleic acids, substantially free of cellular nucleic acids, wherein both members of the second pair comprise at least one *IGF2* SNP sequence where the *IGF2* SNP sequence(s) in the second pair is different from the *IGF2* SNPs in the first pair. Thus, LOI at various
10 *IGF2* SNPs, e.g., the SNPs shown in SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16, can be evaluated using one control pair of polynucleotides where each polynucleotide has all 16 SNPs, or can be evaluated using multiple control pairs of nucleic acids, e.g., 2 pairs, 3 pairs, 4 pairs, 5 pairs, 6 pairs, 7 pairs, or 8 pairs, or more.

[0198] The invention additionally provides a kit comprising LOI control pairs of nucleic
15 acids as described herein. The control nucleic acids may be provided in the kit in a mixture. Alternatively, the kit may be provided with the two members of the control pair in separate containers. In some embodiments, a kit of the invention comprises one or more transcription vectors that comprise polynucleotides encoding the members of the pair.

[0199] In some embodiments, a kit of the invention also comprises a second pair of *IGF2*
20 LOI control nucleic acids wherein both members of the second pair comprise at least one *IGF2* SNP sequence and wherein the at least one *IGF2* SNP sequence in the second pair is different from the *IGF2* SNPs in the first pair. In some embodiments the second pair of control nucleic acids is in a separate container from the first pair of nucleic acids.

[0200] A kit of the invention that comprises a control pair of *IGF2* nucleic acids may
25 further comprise any of the reagents, including primers and probes, described in the KIT section.

[0201] The invention also provides methods of using the control pair of nucleic acids in an *IGF2* LOI assay as a control to validate assay conditions. A method of the invention typically comprises quantifying the maternal and paternal copies of *IGF2* genomic DNA or
30 cellular RNA as described herein using oligonucleotides that distinguish between one SNP allele and a second SNP allele; quantifying the SNP; using a control pair of oligonucleotides where the members of the pair are present in a known ratio and quantifying the ratio of the

two members of the control pair that is actually detected in the assay and comparing this ratio to the ratio of maternal and paternal copies quantified in the patient sample. This provides a means of validating the genotyping or imprinting status assay conditions and further quantifying the actual amounts of the maternal vs. paternal IGF2 genomic DNA or
5 RNA in the patient sample

IX. MANAGEMENT OF CANCER

[0202] LOI of *IGF2* is associated with, for example, the presence of cancer and may be associated with a predisposition of cancer as well as predicting the efficacy of treatment of cancer using various drugs. *See, e.g.*, WO2004/003003; Kaneda *et al. Proc. Natl. Acad. Sci. USA* 104(52):20926-20931 (2007). Accordingly, detection of LOI in *IGF2* as described herein can be used in the diagnosis, prognosis, classification, prediction of cancer risk, detection of recurrence of cancer, and the selection of a treatment for a number of types of cancers. A cancer at any stage of progression can be detected, such as primary, metastatic, and recurrent cancers. Information regarding numerous types of cancer can be found, *e.g.*,
15 from the American Cancer Society (available on the worldwide web at cancer.org), or from, *e.g.*, *Harrison's Principles of Internal Medicine*, Kaspar, *et al.*, eds., 16th Edition, 2005, McGraw-Hill, Inc. Exemplary cancers that can be detected include bladder, breast, cervical, choriocarcinoma, colorectal neoplasia (colorectal adenoma or colorectal cancer), esophageal, gastric adenocarcinoma, glioma, hepatocellular, acute myeloid leukemia,
20 chronic myelogenous leukemia, lung, medulloblastoma, prostate, mesothelioma, ovarian, renal cell carcinoma, testicular germ cell, and uterine cancer.

[0203] The present invention provides methods for determining whether or not a mammal (e.g., a human) has cancer, whether or not a biological sample taken from a mammal contains cancerous cells, estimating the risk or likelihood of a mammal developing cancer,
25 classifying cancer types and stages, monitoring the efficacy of anti-cancer treatment, or selecting the appropriate anti-cancer treatment in a mammal with cancer.

[0204] In some embodiments, the biological sample comprises a tissue sample from a tissue suspected of containing cancerous cells. For example, in an individual suspected of having cancer, breast tissue, lymph tissue, lung tissue, brain tissue, or blood can be
30 evaluated. Alternatively, lung, renal, liver, ovarian, head and neck, thyroid, bladder, cervical, colon, endometrial, esophageal, prostate, or skin tissue can be evaluated. The tissue or cells can be obtained by any method known in the art including, *e.g.*, by surgery,

biopsy, phlebotomy, swab, nipple discharge, stool, etc. In other embodiments, a tissue sample known to contain cancerous cells, *e.g.*, from a tumor, will be analyzed for LOI status to determine information about the cancer, *e.g.*, the efficacy of certain treatments, the survival expectancy of the individual, *etc.* In some embodiments, the methods will be used
5 in conjunction with additional diagnostic methods, *e.g.*, detection of other cancer biomarkers, *etc.*

[0205] The methods of the invention can be used to evaluate individuals known or suspected to have cancer or as a routine clinical test, *i.e.*, in an individual not necessarily suspected to have cancer. Further diagnostic assays can be performed to confirm the status
10 of cancer in the individual.

[0206] Further, the present methods may be used to assess the efficacy of a course of treatment. For example, the efficacy of an anti-cancer treatment can be assessed by monitoring LOI over time in a mammal having cancer. For example, a reduction or absence of LOI in *IGF2* in a biological sample taken from a mammal following a treatment,
15 compared to a level in a sample taken from the mammal before, or earlier in, the treatment, may indicate efficacious treatment. Further, an individual can be screened for LOI of *IGF2* prior to selection of an appropriate drug for either cancer prevention or cancer treatment. For example, once LOI is detected, the patient is likely a good candidate for an IGF1R inhibitor, which can either be taken as a preventative therapy if the patient is found to be
20 cancer free and is believed to be at an increased risk of developing cancer in the future, or can be taken as a chemotherapy if the patient is found to have cancer in order to treat existing disease. *See, e.g.*, Kaneda *et al.*, *supra*.

[0207] In some embodiments, the methods comprise recording a diagnosis, prognosis, risk assessment or classification, based on the LOI status determined from an individual.
25 Any type of recordation is contemplated, including electronic recordation, *e.g.*, by a computer.

X. COMPUTER-BASED METHODS

[0208] The calculations for the methods described herein can involve computer-based
30 calculations and tools. For example, LOI can be determined using the data generated as described herein. For example, inputs relating to the presence, absence or quantity of each allele of a SNP, optionally also including genotype information about an individual, can be

used in isolation, or in comparison to similar measurements made of a control pair of nucleic acids to generate a predicted LOI. The tools are advantageously provided in the form of computer programs that are executable by a general purpose computer system (referred to herein as a "host computer") of conventional design. The host computer may be
5 configured with many different hardware components and can be made in many dimensions and styles (e.g., desktop PC, laptop, tablet PC, handheld computer, server, workstation, mainframe). Standard components, such as monitors, keyboards, disk drives, CD and/or DVD drives, and the like, may be included. Where the host computer is attached to a network, the connections may be provided via any suitable transport media (e.g., wired,
10 optical, and/or wireless media) and any suitable communication protocol (e.g., TCP/IP); the host computer may include suitable networking hardware (e.g., modem, Ethernet card, WiFi card). The host computer may implement any of a variety of operating systems, including UNIX, Linux, Microsoft Windows, MacOS, or any other operating system.

[0209] Computer code for implementing aspects of the present invention may be written
15 in a variety of languages, including PERL, C, C++, Java, JavaScript, VBScript, AWK, or any other scripting or programming language that can be executed on the host computer or that can be compiled to execute on the host computer. Code may also be written or distributed in low level languages such as assembler languages or machine languages.

[0210] The host computer system advantageously provides an interface via which the user
20 controls operation of the tools. In the examples described herein, software tools are implemented as scripts (e.g., using PERL), execution of which can be initiated by a user from a standard command line interface of an operating system such as Linux or UNIX. Those skilled in the art will appreciate that commands can be adapted to the operating system as appropriate. In other embodiments, a graphical user interface may be provided,
25 allowing the user to control operations using a pointing device. Thus, the present invention is not limited to any particular user interface.

[0211] Scripts or programs incorporating various features of the present invention may be encoded on various computer readable media for storage and/or transmission. Examples of suitable media include magnetic disk or tape, optical storage media such as compact disk
30 (CD) or DVD (digital versatile disk), flash memory, and carrier signals adapted for transmission via wired, optical, and/or wireless networks conforming to a variety of protocols, including the Internet.

EXAMPLES

[0212] The following examples are offered to illustrate, but not to limit the claimed invention.

5 **Example 1. Discovery and independent validation of SNPs within exon 9 of the *IGF2* gene.**

[0213] A collection of a limited number of SNPs within exon 9 of the *IGF2* gene has previously been reported. To identify previously uncharacterized SNPs, 12 PCR amplicons
10 were designed to tile the entirety of *IGF2* exon 9. Each was used to amplify a PCR amplicon from genomic DNA derived from a panel of 571 individuals, including 433 samples that are part of the International HapMap Project collection. The 571 individual panel included a subpanel of 207 Caucasian individuals (96 from Coriell Human Variation Panel including unrelated healthy Caucasian individuals who were Utah residents with
15 ancestry from northern and western Europe, and 111 individuals from whom blood samples were commercially obtained). This subpanel is hereafter referred to as the Caucasian panel and is denoted as (CAU). The 571 individual panel also included a subpanel 96 unrelated healthy individuals with African ancestry in the southwestern United States (from Coriell Human Variation Panel HD100A). This subpanel is hereafter referred to as the African
20 American panel and is denoted as (AA). The 571 individual panel also included a subpanel of 96 unrelated individuals of Mexican descent (from Coriell Human Variation Panel HD100MEX). Each individual in this subpanel was from the Mexican-American Community of Los Angeles, each having either three or four grandparents born in Mexico). This subpanel is hereafter referred to as the Mexican descent panel and is denoted as
25 (MEX). The 571 individual panel also included a subpanel of 88 unrelated Japanese individuals from Tokyo, Japan (International Hapmap Project collection HAPMAPPT02 and HAPMAPPT05). This subpanel is hereafter referred to as the Japanese panel and is denoted as (JPN). The 571 individual panel also included a subpanel of 84 unrelated Han Chinese individuals from Beijing, China (International Hapmap Project collection
30 HAPMAPPT02 and HAPMAPPT05). This subpanel is hereafter referred to as the Chinese panel and is denoted as (CHI). Amplicons generated from each of the 571 individuals were sequenced in both directions. Sequences were assembled and aligned, and SNPs were identified by an automated polyphred and polyscan analysis pipeline, and were confirmed

by human review. We previously reported the confirmation of 65 previously identified SNPs and identification of 47 previously unpublished putative SNPs in *IGF2* exon 9 (PCT/US2008/072356).

[0214] To further confirm SNPs and obtain precise frequencies of heterozygosity for
5 selected SNPs, primer extension-based genotyping assays were designed for SNPs that were determined by DNA sequencing to be heterozygous in greater than 1% of individuals within any ethnic population. Various PCR amplicons were designed to include one or more SNP nucleotides to be analyzed. These were used to amplify PCR products from the appropriate subpanels of individual genomic DNA samples. For single nucleotide primer extension
10 assays, a primer was designed so that the 3' terminal nucleotide of the primer anneals to the PCR template strand immediately 3' to each SNP nucleotide to be analyzed. Single nucleotide primer extension reactions were performed using differentially fluorescently labeled dideoxynucleotide triphosphates (ddNTPs). Extended primers were resolved on an ABI 3730XL instrument, raw fluorescent intensity data was transferred to a receiving
15 computer, and genotypes were determined on the receiving computer by GeneMapper software.

[0215] As described in detail in Example 3, the observed genotypes within each human subpanel of samples were analyzed in combination to identify a panel of SNPs that together provided the maximum informativity across each of five individual populations and across
20 all five human populations considered as a single population. For example, if the combination of two or SNPs provides an increase in informativity relative to a smaller combination of SNPs, these SNPs are not in complete linkage disequilibrium with each other and can therefore be effectively combined to allow for an improved informativity for determining the imprinting status of *IGF2*. This analysis revealed a panel of 16 SNPs that
25 provided maximal informativity across all populations. This panel includes 6 previously unpublished SNPs. Table 1 lists the genomic coordinates (NCBI build 36), single nucleotide sequence variants, and surrounding nucleotide sequences of these previously unpublished SNPs. In addition, the panel includes 10 previously published SNPs. Table 2 lists the genomic coordinates (NCBI build 36), single nucleotide sequence variants, NCBI
30 dbSNP reference identifier and surrounding nucleotide sequences of these previously identified SNPs. As described in the Examples below, combinations of previously published and previously unpublished SNPs allow for an increase in overall informativity, which increases the number of patients who can successfully be monitored for loss of

imprinting of *IGF2* relative to combinations of previously published SNPs alone, especially where the patient population includes African-Americans or others of black African descent.

5 [0216] The observed frequencies of heterozygosity for each SNP (including both previously unpublished and previously identified SNPs) in the panel of all individuals genotyped for that SNP (overall), as well as in the African American (AA), Caucasian (CAU), Chinese (CHI), Japanese (JPN) and Mexican descent (MEX) panels separately are listed in Table 3.

10 **Example 2. Use of any one or more SNPs for improved detection of LOI of the *IGF2* gene**

[0217] As described above, the detection of LOI of the *IGF2* gene is based on the independent comparison of the amount of expression derived from each of the two copies of the *IGF2* gene isolated from a biological sample from a given individual. The *IGF2* gene is normally maternally imprinted, (*i.e.* the copy inherited from an individual's mother is normally transcriptionally repressed), while the paternally inherited copy of the gene is normally expressed. LOI occurs when the *IGF2* maternal imprint is relaxed, resulting in similar expression levels of both the paternally and maternally inherited copies of the gene. One method of measuring the imprinting status of *IGF2* in a sample is to first isolate genomic DNA from a biological sample and then determine the genotype(s) of one or more polymorphic sites in the transcribed region of the *IGF2* gene. Second, allele-specific expression of *IGF2* is then measured by utilizing one or more heterozygous nucleotides in RNA that is extracted from the same biological sample, or from a different biological sample from the same individual. Expression from each of the two copies of the *IGF2* gene may be independently measured with an assay(s) that is quantitative, and that can sufficiently discriminate between the two alleles of one or more heterozygous SNPs within the sample. Third, a ratio of the amount of expression from one allele to the amount of expression of the other allele is computed, is optionally compared to a control value and optionally adjusted, and compared to a threshold value, thereby determining the imprinting status of the *IGF2* gene in the sample.

30 [0218] One specific intended approach is described here as an example of the utility of using any one or more of the previously unpublished SNPs reported in the present application for determining the imprinting status of *IGF2* in a patient sample. It is apparent to those skilled in the art that multiple approaches for detection and quantification of SNPs

exist, and any of these may be utilized for both the genotyping of genomic DNA from a biological sample for a particular SNP and the quantification of relative levels of each sequence variant present in expressed mRNA of a biological sample. A basic strategy is outlined in Figure 2. This strategy involves isolating both genomic DNA and total RNA (or polyadenylated RNA) from the same biological sample or matched pairs of biological samples taken from the same individual (for example, peripheral blood, peripheral blood mononuclear cells, colonic mucosa sample, stool sample, etc.). The genomic DNA sample is then genotyped with assays detecting the alleles of one or more SNPs. This step determines what SNPs, if any, may be utilized for analysis of allele-specific expression of the *IGF2* gene in the matched RNA sample. If the individual is homozygous for all SNPs evaluated by an assay, the individual is not informative for those SNPs and can not be measured for LOI of *IGF2* using SNP assays. If the individual is heterozygous (informative) for one or more SNPs, cDNA is amplified from the relevant region of the *IGF2* transcript using standard reverse transcriptase/PCR (RT-PCR) methods. Expression from each of the two copies of the *IGF2* gene is independently measured using the generated cDNA with an assay that is quantitative, and that can sufficiently discriminate between the two alleles. Computation of the ratio of the amount of expression of one allele relative to the amount of expression of the other allele, and comparison of this ratio to a threshold value determines the imprinting status of the *IGF2* gene. If multiple heterozygous SNPs exist for a given sample, assays that discriminate each of the SNPs may be used simultaneously. This allows redundant measurements of allele-specific expression within a sample, and comparison of these measurements may be used to determine a new value representing the average or mode or median value, and to determine an intra-assay coefficient of variance. While a range of threshold values can be used (such as the quantified proportion of the lesser abundant allele being greater than or equal 10%, 15%, 20%, 25% or 30% the quantified proportion of the more abundant allele), typically, a sample is classically determined to display LOI of *IGF2* if the quantified proportion of the lesser abundant allele is greater than or equal to 33.3% the quantified proportion of the more abundant allele.

[0219] One method for genotyping an individual for a given SNP is accomplished by designing an oligonucleotide primer that is complementary to the sequence of the *IGF2* gene and that has a 3' terminal nucleotide that is complementary to the *IGF2* template nucleotide one base 3' to the template polymorphic nucleotide. Assays may be designed to

genotype any one or more of the SNPs listed in Tables 1 and 2. The oligonucleotide primer is combined with and hybridized to the PCR amplified DNA product from the genomic DNA sample in a mixture including all ddNTPs (ddATP, ddCTP, ddGTP, ddTTP (or ddUTP)), each tagged with a different fluorescent moiety, is added. For example, if a G/A polymorphism is to be genotyped (and the G/A nucleotide is on the template strand of the genomic DNA sample), the oligonucleotide primer is designed to hybridize to the complementary template with its 3' terminal nucleotide hybridized to the complementary template nucleotide one base 3' to the template G/A position. Single nucleotide primer extension is catalyzed by a DNA polymerase in the presence of the differentially fluorescently labeled ddNTPs such that oligonucleotides that extend by incorporation of ddCTP (representing the G allele) or by incorporation of ddTTP (representing the A allele) are differentially fluorescently labeled at their 3' termini. Extended oligonucleotides are then resolved by capillary electrophoresis and analyzed in the presence of a fifth-fluorescent dye-labeled size standard. Peaks representing specific single nucleotide primer extension products are detected and quantified to determine the genotype for the given DNA sample. Multiple SNPs may be genotyped in one reaction by multiplexing with oligonucleotides of different lengths designed to terminate just 3' to different polymorphic sites. Different genotypes are obtained based on i) resolution of different length extended oligonucleotides and ii) the specific fluorescent tagged ddNTP incorporated during single nucleotide extension.

[0220] One method for determining the imprinting status of *IGF2* involves an analogous single nucleotide primer extension approach that is designed to discriminate different alleles of a particular SNP. Assays may be designed to utilize any one or more of the SNPs listed in Tables 1 and 2. If a given SNP is determined to be heterozygous in a genomic DNA sample, first strand cDNA is amplified from the matched RNA sample by a reverse transcriptase (RT) using random hexamer or decamer primers, oligodT primers complementary to polyA tails of mRNA or a primer complementary to a specific region of the *IGF2* transcript. Oligonucleotide primers complementary to sequences flanking the SNP site are subsequently used to PCR amplify a cDNA product including the polymorphic site. Alternatively, nested PCR approaches may be used to generate cDNA products. Alternatively, approaches including generation of antisense RNA from cDNA by linear *in vitro* transcription, followed by a second reverse transcription reaction using random hexamer or decamer primers or *IGF2* transcript-specific primer and subsequent PCR

amplification may be used to generate cDNA products. These RT-PCR products are then assayed for the specific sequence variants of the polymorphic site using the same single nucleotide primer extension assay(s) described above. Peaks representing specific single nucleotide primer extension products are detected and quantified. The ratio of the

5 quantified amount of one allele to the other allele is determined. This ratio can be compared to, and potentially adjusted by, similar ratios determined by a control curve. LOI is detected if the quantified proportion of the PCR product representing the lesser abundant allele is greater than or equal to 33.3% the quantified proportion of the PCR product representing the more abundant allele. As described above, multiple heterozygous SNPs may be used to

10 measure LOI in a common reaction by multiplexing with oligonucleotides of different lengths designed to terminate just 3' to different polymorphic sites or with oligonucleotides that incorporate different labeled or mass modified ddNTPs into the extended primer.

[0221] It is possible for an individual that is determined to display normal imprinting of *IGF2* to express both copies of the *IGF2* gene, provided that expression of the lesser

15 abundantly expressed copy of the *IGF2* gene is below a particular threshold level relative to the more abundantly expressed copy of the *IGF2* gene. In this case, a quantitative assay that is capable of detecting the low level of *IGF2* gene expression from the imprinted copy of the gene can be used to determine both the genotype of an individual for any of the SNPs and the *IGF2* imprinting status of the individual by performing the assay only on RNA or

20 cDNA amplified from RNA (*i.e.* excluding the step of determining the genotype of the individual by performing the assay on PCR products amplified from genomic DNA). For example, consider that normal expression from the imprinted maternal copy of the *IGF2* gene is 1/1000 the level of expression of the paternal copy of the *IGF2* gene. A quantitative assay capable of detection of, for example, 1 maternally expressed copy in the presence of

25 10,000 paternally expressed copies of the *IGF2* gene could be used to determine both the genotype of an individual at any of the SNPs and the imprinting status of *IGF2*, provided that the individual is heterozygous for at least one of the assayed SNPs. Detection of expression of the *IGF2* gene including different alleles of a particular SNP would indicate that the individual is heterozygous for that particular SNP. The quantified relative level of

30 expression of the two alleles would then be compared to determine the imprinting status of *IGF2*. The individual would be determined to display LOI of *IGF2* if the quantified proportion of the lesser abundant allele is greater than or equal to a threshold percentage of the quantified proportion of the more abundant allele.

Example 3. Demonstration of use of SNP combinations for improved detection of LOI of the *IGF2* gene

[0222] The application of one particular SNP to detection of LOI of *IGF2* allows only those individuals who are heterozygous (*i.e.* informative) for that one SNP to be analyzed.

5 For example, Table 3 indicates that the most informative SNP across the entire cohort of individuals is the SNP represented by SEQ ID NO: 8 (45.6% of individuals were informative for this SNP). However, the application of combinations of individual SNPs which are not in linkage disequilibrium would result in a higher rate of informativity of the combination relative to a single SNP alone. To identify combinations of SNPs that improve
10 informativity for detection of LOI of *IGF2*, the combination of SNPs that together provides the maximal informativity within each ethnic population was identified. Only samples that were successfully genotyped for all 16 SNPs listed in Tables 1 and 2 were included in the analysis. 74 of 96 African American panel samples, 150 of 207 Caucasian panel samples, 69 of 96 Mexican descent panel samples, 79 of 88 Japanese panel samples and 71 of 84
15 Chinese panel samples were successfully genotyped for all 16 SNPs. As shown in Fig. 3, combinations of SNPs dramatically increase informativity relative to that of any one particular SNP, demonstrating the lack of complete linkage disequilibrium among SNPs listed in Tables 1 and 2. This finding is surprising given the close proximity of each of the 16 SNPs to one another, and multiple published reports suggest that the region is comprised
20 of a few linkage blocks and generally displays linkage disequilibrium. Furthermore, a large percentage of individuals analyzed were informative for 2 or more SNPs among the SNP combination panels (indicated by black and gray bars in Fig. 3. The combinations of SNPs for each ethnic population included SNPs represented by SEQ ID NOs: 1, 2, 3, 4, 12, 13, 15 and 16 for the African American sample panel; SEQ ID NOs: 5, 8, 9, 10, 12, 15 and 16 for
25 the Caucasian sample panel; SEQ ID NOs: 1, 7, 9, 10, 11, 12, 14, 15 and 16 for the Mexican descent sample panel; SEQ ID NOs: 10, 12, 14 and 16 for the Japanese sample panel; and SEQ ID NOs: 6, 8, 12 and 16 for the Chinese sample panel.

[0223] To identify combinations of SNPs that provide optimal informativity across general populations, the overall informativity for all possible combinations of SNPs

30 including at least one SNP listed in Table 1 across all samples genotyped for each of the 16 SNPs listed in Tables 1 and 2 was calculated. For each panel of a particular number of SNPs, multiple combinations are capable of providing similar informativity. For example, 4 different combinations of 15 SNPs provide 80.59% informativity across all samples; 5

different combinations of 14 SNPs provide 80.36% informativity, 10 different combinations of 13 SNPs provide 79.91% to 80.14% informativity, and so on. For each panel of a particular number of SNPs, the specific SNPs that were present in each possible optimal panel were identified, and the informativity for each of these combinations across all samples was calculated. The combined informativity for panels of 16, 12, 10, 9 and 4 SNPs common to optimal combination panels (Panels A, B, C, D and E, respectively) is listed in Table 4 and graphed in Figure 4. Although the entire panel of 16 SNPs (Panel A) provides the highest informativity overall and for each ethnic group specifically, sub-panels provide similar observed informativity. The SEQ ID NOs representing SNPs included in each of these panels are provided in Table 5. As shown in Figure 4, the observed informativity of a panel of 10 SNPs (Panel C) is only slightly lower than the combination of 16 SNPs (Panel A). The optimal informativity across all samples for a panel including the 10 previously known SNPs (Table 2) is 76.98%, indicating that the previously unpublished SNPs reported in the present application offer improvements in informativity.

15 **Example 4. Demonstration of use of SNPs to determine LOI status of *IGF2*.**

[0224] The SNP corresponding to SEQ ID NO: 8 (rs680) falls within the target recognition sequences of two restriction enzymes, *Apa I* and *Ava II*. These two enzymes cleave in an allele-specific manner. *Apa I* recognizes and cleaves the sequence when the “G” allele is present, and *Ava II* recognizes and cleaves the sequence when the “A” allele is present. To independently assess genotypes within a selected panel of individuals, a PCR amplicon including the position of SEQ ID NO: 8 was amplified from a genomic DNA sample derived from each individual. Amplicons were digested with *Apa I* or *Ava II* or a combination of both enzymes. Digestion by *Apa I* only indicates that the individual is homozygous for the G allele, digestion by *Ava II* only indicates that the individual is homozygous for the A allele, and digestion by both enzymes indicates that the individual is heterozygous for the SNP. An example of the data output for each possible genotype of SEQ ID NO: 8 is shown in Figure 5.

[0225] The same basic assay strategy can be utilized to detect LOI of *IGF2*, provided the individual being tested is heterozygous for SEQ ID NO: 8. An example is shown in Figure 6. Total RNA was extracted from whole blood from three individuals heterozygous for SEQ ID NO: 8. Two individuals were previously shown to be LOI for *IGF2* and the third was previously shown to display normal imprinting of *IGF2*. The region including SEQ ID

NO: 8 was RT-PCR amplified from each sample. Reactions lacking reverse transcriptase were performed in parallel to confirm that there was no amplification from genomic DNA. RT-PCR amplicons were then digested with *Apa I* or *Ava II* or a combination of both enzymes, as described above. Digested products were resolved on an Agilent Bioanalyzer, and concentrations of cut and uncut fragments were determined. The quantity of fragments cut by *Apa I* represents the proportion of cDNA amplified from the “G” allele. The quantity of fragments cut by *Ava II* represents the proportion of cDNA amplified from the “A” allele. Therefore, the ratio of *Apa I* cut fragments to *Ava II* cut fragments indicates the relative ratio of expression of the two alleles in the original RNA sample. As shown in Figure 6, Sample 2 expresses exclusively the “A” allele and therefore displays normal imprinting of *IGF2*. Sample 1 expresses both alleles (*i.e.* display LOI *IGF2*), with a G:A ratio of 0.53 and therefore displays loss of imprinting of *IGF2*. Sample 3 expresses detectable levels of both alleles, with a G:A ratio of 0.27. As described above, previous studies have used a threshold of 33.3% expression from the lesser abundant allele relative to the more abundant allele as the definition for LOI of *IGF2*. Therefore, using a restriction enzyme based method for determining LOI of *IGF2* status, Sample 3 reports a ratio of alleles close to the typical 33.3% threshold for determining LOI of *IGF2* and could be considered to represent a borderline call for LOI status. One limitation of a restriction enzyme-based approach for determining LOI of *IGF2* status is that, during PCR amplification of cDNA, amplified strands including one allele of a heterozygous SNP can hybridize with amplified complementary strands including the complement of the second allele. This results in a heteroduplexed molecule with mis-matched bases at the SNP position. These molecules are not recognized and digested by either of the two restriction enzymes, resulting in uncut DNA. As a result, the calculated ratio of alleles may not be absolutely precise. As describe below, the use of methods that do not involve restriction enzyme digestion can overcome the issues introduced by PCR product heteroduplex formation.

[0226] Other SNPs that can be useful for detecting LOI of *IGF2* do not fall within restriction enzyme recognition sequences. Therefore, the ability to monitor LOI in a given individual is improved by developing allele-specific gene expression assays that do not require restriction enzyme digestion. As a demonstration, we developed a primer extension based assay for SEQ ID NO: 8. Figure 7 diagrams the use of a primer extension assay for genotyping SEQ ID NO: 8. The region (SEQ ID NO:25) including the SNP of interest is PCR amplified using genomic DNA obtained from the individual to be genotyped. A

primer (SEQ ID NO:24) is added to the purified PCR product that anneals with its 3' terminal nucleotide complimentary to the template nucleotide 1 base to the 3' side of the polymorphic nucleotide to be genotyped. Single nucleotide primer extension is carried out using a thermostable DNA polymerase and differentially fluorescently labeled ddNTPs. In the example diagrammed in Figure 7, either dR110 labeled ddGTP or dR6G labeled ddATP is added to the 3' end of the primer (SEQ ID NOs: 25 and 26). These labeled polynucleotides are then resolved and quantified by capillary gel electrophoresis and fluorescent imaging. The peak areas representative of each possible incorporated nucleotide are calculated (*i.e.* using an ABI 3730XL Gene Analyzer with Gene Mapper software). Peak areas are compared to determine the genotype of the individual at that SNP position.

[0227] The three individuals that were assayed for LOI of *IGF2* by the restriction enzyme based assay (Figure 6) were genotyped for SEQ ID NO: 8 using the primer extension assay (Figure 8). As expected, peaks representing both alleles of the SNP were detected, confirming that the three individuals are heterozygous for SEQ ID NO: 8.

[0228] To measure allele-specific expression of *IGF2* in the same three individuals, the region including SEQ ID NO: 8 was RT-PCR amplified from a total RNA sample derived from each individual. Reactions lacking reverse transcriptase were performed in parallel to confirm that there was no amplification from genomic DNA. The cDNA products obtained were purified and analyzed with the single nucleotide primer extension assay as diagrammed in Figure 7. Peak areas representing each of the two possible alleles were calculated. To correct for differences in dye intensities, these values were normalized based on comparisons of peak areas calculated using predetermined 1:1 ratios of each allele (*i.e.* 1:1 ratio of DNA amplicons derived from individuals that are homozygous for each of the two alleles). The resulting chromatograms and calculated allele ratios are shown in Figure 9. In agreement with the results shown in Figure 6, Samples 1 and 3 were determined to show LOI of *IGF2*, and Sample 2 was determined to show normal imprinting of *IGF2*. It is obvious that the same type of single nucleotide primer extension assay that utilizes any SNP within the transcribed region of *IGF2* could be used to monitor allele-specific expression of *IGF2* (see Figures 10 and 11).

[0229] To demonstrate the use of additional SNPs for measuring allele-specific expression of *IGF2*, single nucleotide primer extension assays were designed based on 12 additional SNPs (SEQ ID NOs: 2, 3, 4, 5, 6, 7, 9, 10, 11, 14, 15 and 16). For each of the 13

SNPs (including SEQ ID NO: 8), PCR products were separately amplified from genomic DNA samples derived from two individuals; one homozygous for one allele of the SNP and the other homozygous for the other allele of the SNP. The PCR products were purified and quantified. For each of the 13 SNPs, two PCR products (one amplified from the DNA sample homozygous for one allele and the other amplified from the DNA sample homozygous for the other allele) were combined in the following ratios of allele 1 to allele 2; 1:10, 1:6, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1, 6:1, and 10:1. For each of the nine SNPs, the single nucleotide primer extension assay was performed in triplicate on each dilution point. Peak areas representing each of the two possible alleles were calculated. To correct for differences in dye intensities, these values were normalized based on comparisons of peak areas calculated using predetermined 1:1 ratios of each allele. The analytical quantitative linearity of each assay is shown in Figure 10 and Figure 11. The R^2 and slope for each assay is shown in Table 6.

[0230] Single nucleotide primer extension assays may be used in a multiplexed format so that a combination of SNPs is genotyped (or alternatively, so that a combination of SNPs is used to measure allelic expression in RNA or cDNA), in a single assay. Each SNP that is found to be informative in a given individual can then be used to determine imprinting status of *IGF2* of that individual. Assays can be combined into a multiplexed assay panel by using primers that migrate differentially during capillary electrophoresis or that have unique masses and can be differentially quantified by mass spectrometry, for example.

Figure 12A shows the result of a multiplexed genotyping assay performed on genomic DNA which was extracted from a blood sample from one individual. The assay determines the genotypes and determines imprinting status at SNP positions represented by SEQ ID NOs: 1, 2, 3, 7, 8, 10, 11, 12, 15 and 16. Single nucleotide primer extension assays may be designed to determine the single nucleotide sequence on either of the two strands (or of the two or more allelic options) at the SNP position. It is noted that the nucleotides indicated in Figure 12A and 12B and Table 7 are complimentary to the sequences indicated in Table 1 and Table 2 for the SNPs represented by SEQ ID NOs: 2, 3, 7 and 11 because the primer extension assay monitors the opposite strand as that represented in Table 1 and Table 2. As shown in Figure 12A and in Table 7, Sample A is homozygous at the SNPs represented by SEQ ID NOs: 1, 2, 7, 8, 10, 15 and 16. However, the same sample is heterozygous (and therefore, informative) at the SNPs represented by SEQ ID NOs: 3, 11 and 12. It should be noted that while all three heterozygous SNPs were used in the present example, any one of

these three heterozygous SNPs, or any combination of two of these SNPs, can now be used to determine the imprinting status of *IGF2* in this individual. Figure 12B shows the result of the same multiplexed assay panel when used to detect allele-specific expression of *IGF2* in cDNA generated from total RNA derived from the same blood sample. As shown in

5 Figure 12A and in Table 7, Sample A displays normally imprinted expression of *IGF2*. That is, expression is derived from a single copy of the *IGF2* gene. The expressed allele includes a T at the SNP position represented by SEQ ID NO: 3, a G at the SNP position represented by SEQ ID NO: 11 and a C at the SNP position represented by SEQ ID NO: 12. The copy of the *IGF2* gene containing a G at the SNP position represented by SEQ ID NO: 3, an A at the SNP position represented by SEQ ID NO: 11 and a T at the SNP position represented by SEQ ID NO: 12 is not detected. Table 7 displays the results of the same multiplexed assay performed on a second sample (Sample B). This sample is heterozygous (and therefore, informative) at the SNP represented by SEQ ID NO: 16. Sample B displays normally imprinted expression of *IGF2*. The expressed allele includes a G at the SNP position represented by SEQ ID NO: 16. The copy of the *IGF2* gene containing the A allele is not detected.

[0231] The same two samples shown in Figure 12 (Sample A and Sample B) were analyzed using single-plex assays for SNPs represented by SEQ ID NOs: 4, 5, 6, 9, 13 and 14 to determine the genotypes at these SNP positions and to determine imprinting status based on these SNPs (Table 7). Sample A is homozygous at the SNP positions represented by SEQ ID NOs: 4, 5, 6, 9, 13 and 14. Sample B is homozygous at the SNP positions represented by SEQ ID NOs: 4, 6, 9, 13 and 14. However, Sample B is heterozygous (informative) at the SNP position represented by SEQ ID NO: 5. Analysis of allele-specific expression of *IGF2* detected both the G and A alleles of SEQ ID NO:5 (Table 7).

25 [0232] Table 8 lists the values obtained for each peak detected in the experiment described above (Sample A and Sample B, analyzed for all 16 SNPs). Following capillary electrophoresis of single nucleotide primer extension reactions and measurement of fluorescent intensities using an ABI 3730XL Genetic Analyzer, peak areas were calculated by a computer program (GeneMapper). Values were received at host computer. Peak area values represented the presence or absence of each polymorphic option at each of the 16 SNP positions derived from the assay of PCR products amplified from genomic DNA (Genomic DNA Peak Area 1 and Genomic DNA Peak Area 2 in Table 8). A computer program correlated the presence or absence of detected peak areas to a determination of

genotype at each SNP position. For example, Sample A is homozygous (T/T) at the SNP position represented by SEQ ID NO: 1 because a peak was detected for the T allele (Peak Area 1), but not the G allele (Peak Area 2). Furthermore, Sample A is heterozygous (C/T) at the SNP position represented by SEQ ID NO: 12 because a peak was detected for the C allele (Peak Area 1 = 54813) and for the T allele (Peak Area 2 = 163646). Genotypes at each SNP position and in both samples were similarly determined. A computer implemented method was used to output these results, as shown in Table 7.

[0233] To calculate ratios representing the abundance of detected alleles, it is necessary to normalize for differences in fluorescent tag intensities among different labeled ddNTPs used for the single nucleotide primer extension reaction. For a given SNP position, the ratio of the presence of two alleles in genomic DNA extracted from an diploid individual that is heterozygous for that SNP is 1:1. Therefore, a computer implemented method was used to normalize for differences in fluorescent intensities. For example, the calculated peak area for the G allele of the SNP represented by SEQ ID NO: 5 in Sample B (16043) was divided by the calculated peak area for the A allele of the SNP represented by SEQ ID NO: 5 in Sample B (12107) to obtain Allele 1:Allele 2 ratio of 1.3251. A Normalization Factor (Table 8) was calculated so that the ratio of the two alleles is readjusted to account for dye effects to 1.0 ($1/1.3251 = 0.7547$). Normalization factors may also be determined using standard mixtures.

[0234] To determine a value representing the imprinting status of *IGF2*, peak area values represented the presence or absence of each polymorphic option at each of the 16 SNP positions derived from the assay of PCR products amplified from cDNA (RNA Peak Area 1 and RNA Peak Area 2 in Table 8). Values were received at host computer, and a computer implemented method was used to compare peak areas detected for each possible allele. For example, Sample A is determined to be informative for the SNPs represented by SEQ ID NOs: 3, 11 and 12. The individual is determined to display normal imprinting of *IGF2* because, at each of the three SNP positions, a peak area for only one of the two possible alleles was detected. Sample B is determined to be informative for the SNPs represented by SEQ ID NOs: 5 and 16. A peak area for only one of the two possible alleles was detected for the SNP represented by SEQ ID NO: 12. However, a peak area for both of the two possible alleles was detected for the SNP represented by SEQ ID NO: 5 (RNA Peak Area 1 = 6283 and RNA Peak Area 2 = 14115 in Table 8). A computer implemented method was used to calculate a normalized ratio of Allele 1 to Allele 2 ((RNA Peak Area 1 (6283)/RNA

Peak Area 2 (14115)) * Normalization Factor (0.7541) = Normalized Ratio (0.3359)). The individual is determined to display borderline imprinting status of *IGF2* because one informative SNP reported detection of only one of two possible alleles (SEQ ID NO: 12) and a different SNP reported detection of both alleles at a ratio very close to the threshold
 5 for determining imprinting vs. loss of imprinting. A computer implemented method was used to output these results, as shown in Table 8.

[0235] As described above, the analysis of more than one heterozygous SNP in a given individual (compound heterozygotes) provides a method for determining multiple independent measurements of imprinting status for an individual, thereby allowing
 10 calculations of additional values including, but not limited to, i) the average value of calculated peak areas, genotype peak area ratios, normalization factors, allele-specific expression peak area ratios and normalized allele-specific expression ratios, ii) the standard deviation between calculated peak areas, genotype peak area ratios, normalization factors, allele-specific expression peak area ratios and normalized allele-specific expression ratios,
 15 iii) the mode of calculated peak areas, genotype peak area ratios, normalization factors, allele-specific expression peak area ratios and normalized allele-specific expression ratios, and iv) coefficients of variation for calculated peak areas, genotype peak area ratios, normalization factors, allele-specific expression peak area ratios and normalized allele-specific expression ratios. Applying these methods can allow for a more precise single
 20 determination of imprinting status for a given individual. For example, consider an individual that is heterozygous for three SNPs (SNP1, SNP2, SNP3) in a panel, and analysis of imprinting status resulted in the detection of peaks representing both alleles of each SNP. If the calculated Peak Area 1 (allele 1) was 153330 (SNP1), 136263 (SNP2) and 147544 (SNP3), and the calculated Peak Area 2 (allele 2) was 124589 (SNP1), 132581 (SNP2) and
 25 126598 (SNP3). If the normalization factor for these Peak Areas is 0.778 (SNP1), 0.897 (SNP2) and 1.258 (SNP3), then the normalized ratios are 0.9575 (SNP1), 0.9219 (SNP2) and 1.4661 (SNP3). The average allele-specific expression ratio is 1.115, the median allele-specific expression ratio is 0.9574, the standard deviation among the allele-specific expression ratios is 0.3045, and the coefficient of variation between the allele-specific
 30 expression ratios is 0.273. It is noted that multiple different algorithms of comparing values obtained from assaying compound heterozygous SNPs may be used to calculate a precise value correlating with the imprinting status of *IGF2*.

Example 5. Development of a pair of synthetic nucleic acids, useful for controlling genotype and allele specific expression assays measuring SNPs within exon 9 of the IGF2 gene.

5 [0236] A pair of control synthetic nucleic acids were designed, which were engineered to provide a vastly improved control for genotyping and imprinting assays for *IGF2*. Four objectives influenced the design.

10 [0237] First, the two nucleic acid members of the pair (“Synth1”; SEQ ID NO:21), and (“Synth 2”; SEQ ID NO:23) were designed to contain a portion of the 3’ end of the sequence of *IGF2* exon 8 and a majority of the sequence of IGF2 exon 9 (a CA repeat-rich region which occurs naturally in exon 9 of human *IGF2* was omitted from the control sequence). The 3’ end of exon 8 and a majority of the sequence of exon 9 of *IGF2* were included in the design of the controls to allow polynucleotides used in genotyping and imprinting assays for *IGF2* (including reverse transcriptase primers, PCR primers, and SNP primers or probes that are designed to anneal specifically to the transcribed portion of IGF2 in clinical samples) to anneal to the nucleic acids members of the control and to *IGF2* transcripts from clinical samples with equal efficiency. Additionally, the CA repeat-rich region was omitted from the design of the control nucleic acid pair due to the fact that such a semi-repetitive region can be difficult to synthesize *in vitro*, may be unstable when cloned into bacteria, and may introduce difficulties for PCR amplification in the subsequent use of the control.

20 [0238] Second, the nucleic acid members of the pair (Synth1 and Synth2) were designed to be identical in their sequence, with the exception of the polymorphic option designed in each control member at each of the 16 SNP positions. Synth1 was designed to contain one polymorphic option of each of the 16 SNPs, while Synth2 was designed to contain the other polymorphic option of each of the 16 SNPs. For purposes of this example in developing the control, the nucleic acid members of the pair were designed to be identical in all base positions except for the 16 SNP positions to avoid potential inadvertent introduction of a sequence specific amplification or detection bias of one member of the control pair relative to the other, or between a member of the control pair and an assay measurement of a clinical sample.

30 [0239] Third, the sequence of the 3’ end of *IGF2* exon 8 followed by the sequence at the 5’ end of *IGF2* exon 9, (i.e., containing the exon 8-9 splice junction), was included in the

design of the 5' end of each of SYNTH1 and SYNTH2 (Figure 13 A). The use of polynucleotides that overlap exon splice junctions in imprinting assays measuring clinical samples may significantly reduce the possibility that the imprinting assay will inadvertently amplify contaminating genomic DNA in the RNA extracted from patient samples during the RT-PCR amplification step. By including the 3' region of exon 8, by omitting the intron between exon 8 and 9, and by including the 5' region of exon 9 in the design of the 5' end of the sequence of Synth1 and Synth2, any exon 8-9 spanning polynucleotides used in an *IGF2* imprinting assay will likely anneal as efficiently to the pair of nucleic acids in the control as they will to *IGF2* transcripts in from clinical samples.

[0240] Fourth, a T7 promoter sequence was included 5' to the beginning exon 8 sequence to allow for in vitro transcription of RNA including the engineered exon8-9 sequences, and sequences including Not I restriction enzyme sites for cloning were included on each end of the Synth1 and Synth2 sequences (Figure 13 B) to allow for convenient insertion into plasmid vectors.

[0241] Once the synthesis of the nucleic acid pair was complete, the design of Synth1 and Synth2 was confirmed by DNA sequence analysis. The DNA sequence of Synth1 is listed as SEQ ID NO:21. The sequence of and Synth2 is listed as SEQ ID 20. The location of the 16 SNP positions and the polymorphic option present in each of Synth1 and Synth2 is provided in Table 9, and the SNP positions for each of the 16 SNPs designed into Synth1 and Synth2 are listed as SEQ ID NOs:1-16. The complete sequence of *IGF2* exon 9 is provided as SEQ ID NO:20, a sequence which corresponds exactly to Ensemble exon entry ENSE00001488587 (Human GRCh37, February 2009). The CA-rich semi-repetitive and length-polymorphic region, which was omitted from the synthesized control nucleic acids as described above, is provided in SEQ ID NO:22, and is located between positions 1115 and 1692 of SEQ ID NO:20, the native sequence of *IGF2* exon 9. The omitted CA repeat-rich region is immediately flanked by positions 1168 and 1169 of SEQ ID NO:21 and SEQ ID NO:23. This omitted sequence region does not include any of the 16 SNP positions listed in SEQ ID 1-16. The exon 8 derived sequence is located between positions 34 and 54 of SEQ IDs NOs. 21 and 23. The T7 promoter sequences is located between positions 11 and 30 of SEQ IDs 21 and 23.

[0242] Once Synth1 and Synth2 were confirmed by DNA sequencing, the fragments were separately digested with Not I and ligated into the Not I cloning site of the pEZ vector,

producing two independent plasmids; pEZ-Synth1 and pEZ-Synth2. These plasmids were individually transformed into the DH5 α *E. coli* strain.

[0243] One embodiment of the invention uses the nucleic acid members of the control in mixtures of Synth1 and Synth2 in known quantitative ratios and using these mixtures as
5 template in an assay designed to monitor allele-specific expression of *IGF2*. Therefore, we designed a strategy to confirm that the quantification of the control molecules is accurate so that assay results from clinical samples of unknown imprinting status can be compared to accurate standard control results. The strategy for the assay designed to monitor allele-specific expression of *IGF2*, and the use of the control nucleic acids in this assay, is
10 diagrammed in Figure 13. Figure 13 A shows a diagram of the *IGF2* gene. Various potential promoters for *IGF2* are indicated by arrows labeled Promoter 1, P0, P2, P3 or P4. Potential transcribed exons are indicated by block arrows connected by a hashed line that represents intronic sequence regions. Untranslated exonic sequence regions are indicated by filled block arrows, and translated exonic sequence regions are indicated by open block
15 arrows. The scale bar at the top of Figure 13 A is shown in 1000 base pair (Kb) increments. An expanded view of the Synth1 (or Synth2) nucleic acid region is shown in Figure 13 B. The scale bar is shown in 500 base pair increments. The Synth1 (or Synth2) nucleic acid sequence includes the 3'-most 21 base pairs of exon 8 followed immediately by the sequence of exon 9 (i.e. the intronic sequence between exons 8 and 9 are omitted, as
20 diagrammed in Figure 13 A). The 5' and 3' ends of Synth1 (or Synth2) include Not I restriction enzyme recognition sequences that were included to allow ligation of the sequences into a transcription vector. The CA repeat-rich sequence region present in *IGF2* exon 9 was omitted from the Synth1 (or Synth2) sequence, as indicated in Figure 13 B.

[0244] To generate cDNA from endogenous *IGF2* mRNA or from *in vitro* transcribed
25 RNA derived from pEZ-Synth1 or pEZ-Synth2 plasmids, four primers are used to generate first strand cDNA by reverse transcriptase. These reactions may be performed as four separate reactions for each primer, or optionally, as one multiplexed reaction including all four primers. The annealing sites of these four primers within the Synth1 (or Synth2) region (or optionally, within the *IGF2* mRNA region) are indicated by arrow heads in
30 Figure 13 B (RT primers). The first strand cDNA molecules generated by this RT reaction are indicated by hashed lines in Figure 13 C.

[0245] Following reverse transcription, the first strand cDNAs are used as template for first round PCR amplification of four independent amplicons. The annealing sites of the four primer pairs relative to the generated first strand cDNA are indicated by arrow heads in Figure 13 D. Solid lines connecting the primer pairs represent the PCR amplicon produced in each first round PCR amplification reaction. These reactions may be performed as four separate reactions for each primer pair, or optionally, as one multiplexed reaction including all four primer pairs. Note that the primer indicated by the open box in Figure 13 D includes the exon 8-9 splice junction spanning sequence.

[0246] Next, the amplicons produced in the first round PCR amplification are used as template for amplification of four independent nested amplicons. The annealing sites of the four primer pairs relative to the generated first strand cDNA are indicated by arrow heads in Figure 13 E. Solid lines connecting the primer pairs represent the PCR amplicon produced in each second round PCR amplification reaction. These reactions may be performed as four separate reactions for each primer pair, or optionally, as one multiplexed reaction including all four primer pairs.

[0247] Each of the four amplicons generated by the second round PCR reaction includes one or more of the SNP positions represented by SEQ ID NOs: 1-16. The position of each SNP is indicated by a diamond in Figure 13 F. The amplicons generated by this PCR reaction can be used to quantify the amount of each polymorphic option of each SNP position present. For an RNA sample derived from an individual that is heterozygous for one or more SNPs, quantifying the amount of a generated amplicon including one polymorphic option of the SNP relative to the amount of a generated amplicon including the other polymorphic option of the SNP allows the determination of the amount of expression from one allele of *IGF2* relative to the amount of expression from the other allele of *IGF2* within the sample derived from that individual.

[0248] To confirm the precision of the quantification achieved with the controls, the nucleotide at each SNP position represented by SEQ ID NOs: 1-16 in pEZ-Synth1 and pEZ-Synth2 was measured using a multiplex single-nucleotide primer extension assay. Sixteen primers were designed that hybridized such that the 3' end of each primer annealed one base position to the 5' side of each SNP position. Single nucleotide primer extension reactions were performed in the presence of differentially fluorescently labeled ddNTPs (for example, see

<https://products.appliedbiosystems.com/ab/en/US/adirect/ab?cmd=catNavigate2&catID=600762&tab=DetailInfo>; or *Biotechniques*. 2001 Dec;31(6):1374-80). Resolution of single nucleotide extended primers was performed by capillary electrophoresis (ABI 3730XL), and specific peak areas were calculated using ABI GeneMapper software. Results are shown in Table 10.

[0249] These results confirmed that the SNP-based single nucleotide primer extension assay recapitulated the genotype calls generated by DNA sequencing for each SNP position in each control nucleic acid. Furthermore, these results demonstrated that the control nucleic acids may be used as positive controls for any type of genotyping assay that determines the nucleotide present at these 16 SNP positions. For example, pEZ-Synth1 (or molecules derived from pEZ-Synth1, such as by restriction enzyme digestion or by PCR amplification) can serve as a positive control for genotyping assay results that are to be expected for an individual homozygous for any of the alleles included in the Synth1 construct. Likewise, pEZ-Synth2 (or molecules derived from pEZ-Synth2, such as by restriction enzyme digestion or by PCR amplification) can serve as a positive control for genotyping assay results that are to be expected for an individual homozygous for any of the alleles included in the Synth2 construct. Finally, a mixture containing equal amounts of pEZ-Synth1 and pEZ-Synth2 (or equal amounts of molecules derived from pEZ-Synth1 and pEZ-Synth2, can serve as a positive control for genotyping assay results for an individual heterozygous for any of the 16 SNPs.

Example 6. Use of DNA controls to determine the quantitative linearity of an assay monitoring relative abundance of different alleles.

[0250] The plasmids pEZ-Synth1 and pEZ-Synth2 were quantified by Nanodrop, and the concentration of each purified plasmid was normalized to 1 ng/μL. Mixtures of pEZ-Synth1 and pEZ-Synth2 were made in the following ratios: 8:1, 6:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:6 and 1:8 (Synth1:Synth2). Four non-overlapping PCR amplicons were designed to amplify the transcribed regions of *IGF2* exon 9 including the 16 SNP nucleotides, as shown in Figure 13 E. For each ratio point, 1 ng of the plasmid mixture was used as template for PCR amplification of the four amplicons. Amplicons derived from the Synth1/Synth2 ratio mixtures were individually purified on PCR purification spin columns (Qiagen), and used as template for the multiplexed single-nucleotide primer extension assay described in Example 5. Assays were performed in triplicate, and average peak areas for

each peak were calculated. Results are shown in Figure 14. The known input ratio of Synth1:Synth2 template was plotted on the x-axis. For each SNP-based single nucleotide primer extension assay within the multiplexed assay, the average measured ratio of peak areas representing the Synth 1 allele: the Synth2 allele was plotted on the y-axis. Error bars indicate plus and minus one standard deviation across the triplicated measurements. All average data point values were multiplied by a common normalization factor that adjusts the measured value for the known 1:1 input data point to equal exactly 1.0. Data were plotted in log scale to evenly visualize all data points across the ratio series. Data derived from one SNP-based assay utilizing one SNP position within each of the four amplicons are shown. These include the assays utilizing the SNPs represented by SEQ ID NO: 7 within Amplicon 1 (Figure 14 A), SEQ ID NO: 5 within Amplicon 2 (Figure 14 B), SEQ ID NO: 1 within Amplicon 3 (Figure 14 C) and SEQ ID NO: 13 within Amplicon 4 (Figure 14 D).

[0251] These data demonstrate that the assay was quantitative and reproducible in this range, and that the pair of control nucleic acid mixtures provided in a single dilution series, a standard curve dataset sufficient to control for all of the assay components required to detect all 16 SNPs. The present example thus demonstrates how the assay measurements of the standard curve of mixtures can be run along with clinical samples such that assay measurements of samples of unknown allele ratios may be extrapolated against this curve to determine the relative abundance of molecules containing the two alleles.

Example7. Use of RNA controls to determine the quantitative linearity of an assay monitoring the relative abundance of different alleles.

[0252] Because both control nucleic acids include a T7 promoter upstream of the IGF2 exon 8-9 junction sequence region, RNA molecules analogous to *IGF2* mRNA may be generated by *in vitro* transcription (IVT). Each of the control nucleic acids were excised from pEZ-Synth1 or pEZ-Synth2 by Not I digestion and used as templates in IVT reactions using T7 RNA polymerase. The resulting RNA was then treated with DNase to remove residual plasmid DNA template. IVT RNAs were quantified by Nanodrop.

[0253] Next, RNA control mixtures were constructed comprising background RNA, which mimicked the RNA complexity of clinical samples, added to known mixtures of IVT RNA derived from Synth1 and Synth2. In principle, a series of RNA control mixtures for an imprinting assay will generally have the following properties: i) resemble the transcriptome complexity of a typical test sample, ii) contain a known ratio of the quantities

of the two nucleic acids of the control, and iii) will be constructed such that the ratio of the quantity of IVT control RNA (i.e., the sum of all Synth1 and Synth2 IVT RNA molecules in this example) relative to the quantity of total RNA of the control (i.e., the total quantity of the background RNA added to the Synth1 and Synth2 IVT RNA mixtures) is similar to the ratio of the quantity of native *IGF2* mRNA typically present in a clinical sample relative to the total quantity of RNA that is typically present in a clinical sample.

[0254] To accurately model the potential sources of variability in an assay designed to monitor LOI in a biological sample using known quantities of input control RNA, the amount of *IGF2* mRNA that would be expected to be present in a given biological sample was first determined. To accomplish this, a series of RNA template mixtures were generated. In order for the RNA mixture to reflect the transcriptome complexity of a biological sample, a series of known quantities of IVT RNA generated from Synth2 was spiked into aliquots of 500ng of yeast total RNA. This amount of yeast total RNA was used because the typical total RNA input amount for the LOI assay is 500 ng. Yeast total RNA was used as an RNA source lacking *IGF2* mRNA to mimic the complexity of RNAs present in the blood RNA sample, yet ensure that RT-PCR amplification would be derived from the spiked-in control RNA rather than from the background RNA source. The series of RNA template mixtures included spiked-in IVT RNA in the quantity of 120 ng, 12 ng, 1.2 ng, 120 pg, 12 pg, 1.2 pg, 120 fg, 12 fg or 1.2 fg (i.e., nine independent mixtures were made, each with one of these amounts of input IVT RNA).

[0255] Alternatively, Synth1 and/or Synth2 IVT RNA can be added to other complex RNA sources that are similar in complexity to the RNA source in the clinical samples with unknown imprinting status, and that substantially lack *IGF2* mRNA. Examples of alternative background RNA sources, which are useful in combination with Synth1 and/or Synth2 IVT RNA as a control for imprinting assays of human samples include i) RNA derived from eukaryotic cells or cell lines lacking *IGF2* expression (e.g., *IGF2*-knock out mouse cells), ii) RNA derived from eukaryotic cells or cell lines that are lacking an *IGF2* homologous gene or have sufficient sequence divergence from the human *IGF2* sequence such that the polynucleotides of the *IGF2* genotyping and imprinting assays do not anneal to the transcripts of the eukaryotic cell *IGF2* homolog, iii) RNA derived from human cells lacking *IGF2* expression (e.g., ovarian teratoma cells in which both copies of *IGF2* are maternally imprinted and are confirmed to be transcriptionally silent), iv) RNA derived

from genetically modified human cells lacking *IGF2* expression, or v) RNA extractions of human cells where once-present *IGF2* mRNA has been removed.

[0256] Next, four qRT-PCR assays were designed that utilized the four PCR primer pairs indicated in Figure 13 E. Each of the nine RNA mixtures (each including 500ng of yeast
5 total RNA and one of the nine quantities of spiked-in IVT control RNA) was used as template for RT-PCR as diagrammed in Figure 13. A control lacking reverse transcriptase was performed for each template mixture to ensure that downstream amplification was derived from cDNA rather than potential contaminating DNA. The second-round PCR reactions were performed in reaction buffer including SYBR Green, and C_t values were
10 determined. Reactions were performed in duplicate and C_t values were averaged. These data were used to construct a standard curve of C_t values across a wide range of known input control IVT RNA quantities.

[0257] Next, the same qRT-PCR assays were performed on total RNA extracted from four blood samples derived from four different individuals. In each reaction, 500ng of total
15 RNA was used as template for RT-PCR as diagrammed in Figure 13. A control lacking reverse transcriptase was performed for each template mixture to ensure that downstream amplification was derived from cDNA rather than potential contaminating genomic DNA. The second round PCR reactions were performed in reaction buffer including SYBR Green, and C_t values were determined. Reactions were performed in duplicate and C_t values were
20 averaged.

[0258] The C_t values obtained for each of the four PCR amplicons derived from blood RNA were extrapolated relative to the standard curve of C_t values derived from the series of IVT RNA/yeast RNA mixtures. The average C_t value of the four blood samples was similar to the C_t value that was obtained from 84 pg of Synth1, Synth2, or a mixture of Synth1 and
25 Synth2. Therefore, the amount of total IVT control RNA (*i.e.*, the amount of IVT control RNA derived from Synth1 plus the amount of IVT control RNA derived from Synth2) to be used in control curve experiments, was set at 120 pg, an amount ~50% greater than the average amount in 500ng of blood RNA. This amount (*i.e.*, 120 pg) of control IVT RNA was selected so that i) it would slightly exceed the typical amount of *IGF2* mRNA that is
30 expected to be present in a 500 ng sample of total RNA isolated from a whole blood sample, and ii) it would provide consistent RT-PCR amplification success when used in multiple control RNA mixture experiments.

[0259] To determine the quantitative linearity of all steps of the assay to monitor allele-specific expression of IGF2, IVT RNA derived from Synth1 was mixed with IVT RNA derived from Synth2 in ratios including 10:1, 8:1, 6:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:6, 1:8, and 1:10 (Synth1:Synth2). A total of 120 pg of each Synth1:Synth2 IVT RNA mixture (i.e., the amount of IVT control RNA derived from Synth1 plus the amount of IVT control RNA derived from Synth2 equaled 120 pg) was spiked into 500 ng of yeast RNA (i.e., thirteen mixtures were produced, each containing 500 ng of yeast RNA plus 120 ng of one of the thirteen Synth1:Synth2 ratios described above). This RNA mixture was used as template for the RT-PCR reactions described in Figure 13. For each ratio point, a control reaction lacking RT was performed to ensure that amplification was derived from the IVT RNA rather than any residual contaminating DNA. Following first-strand cDNA synthesis, 1 μ L of each RT+ or RT- reaction was used as template for nested PCR amplification of the four amplicons diagrammed in Figure 13 E. An aliquot of each PCR reaction was analyzed on an agarose gel to confirm that no amplification was present in reactions derived from the RT- control reaction. Amplicons derived from the Synth1:Synth2 ratio mixtures were individually purified on PCR purification spin columns (Qiagen), and used as template for the multiplexed single-nucleotide primer extension assay described in Example 5. Assays were performed in triplicate (specifically, each reaction triplicate included one RT reaction, three independent first round PCR reactions per amplicon, three independent second round PCR reactions per amplicon and three independent multiplexed primer extension assay reactions), and average peak area ratios for each primer extension assay were calculated. The resulting data are plotted in Figure 15.

[0260] In Figure 15, the known input ratio of Synth1:Synth2 IVT RNA template was plotted on the x-axis. For each SNP-based single nucleotide primer extension assay within the multiplexed assay, the average measured ratio of peak area representing the Synth 1 allele and the Synth2 allele was plotted on the y-axis. In the plot, error bars indicate plus and minus one standard deviation across the triplicated measurements. All average data point values were multiplied by a common normalization factor that adjusts the measured value for the known 1:1 input data point to equal exactly 1.0. Data were plotted in log scale to evenly visualize all data points across the ratio series. Data derived from one SNP-based assay utilizing one SNP position within each of the four amplicons are shown. These include the assays utilizing the SNPs represented by SEQ ID NO: 7 within Amplicon 1

(Figure 15 A), SEQ ID NO: 5 within Amplicon 2 (Figure 15 B), SEQ ID NO: 1 within Amplicon 3 (Figure 15 C) and SEQ ID NO: 13 within Amplicon 4 (Figure 15 D).

[0261] These data demonstrated that the imprinting assay is quantitative and reproducible in this range, and that the pair of control nucleic acid mixtures in the form of IVT RNA
5 derived from Synth1 and Synth2 provided, in a single dilution series, a standard curve dataset for all 16 SNPs. The allele-specific expression measurements of this series of mixtures can be run along with imprinting assay measurements of clinical samples such that measurements of samples of unknown allele ratios may be extrapolated against a standard
10 curve generated from the series of control mixtures to determine the relative abundance of molecules containing the two alleles.

[0262] Additionally, these data demonstrate the use of control RNA mixtures to indicate deviations of assay results from expected results, as well as to point out what components of the assay are responsible for this variation. For example, quantified allele ratios obtained from one SNP located on three of the four first round and second round amplicons (Amp1,
15 Amp2 and Amp3 – see amplicon locations in Figure 13 E) demonstrated a tight correlation with the expected input allele ratios (Figure 15 A, B and C). Furthermore, allele ratios obtained from a second SNP located on the same amplicon reported a very similar tight correlation between measured and input allele ratios (compare Figure 15 B depicting the curve of a first SNP on Amp1 and Figure 15 E depicting the curve of a second SNP also on
20 Amp1). These data confirmed that the control RNA ratio mixtures were accurate and that all steps and all assay components in the assays involving amplicons 1, 2 and 3 (including RT, PCR and single nucleotide primer extension reactions) reported accurate quantitative measurements. However, the quantified allele ratios obtained from one SNP located on the first round and second round amplicon Amp4 (see location in Figure 13 E) demonstrated a
25 significant deviation between input and measured allele ratios (note the deviations from the line for the data points in the lower left quadrants of Figure 15 D and F). Figure 15 D plots the allelic ratios obtained from a first SNP within amplicon 4 represented by SEQ ID NO: 13, while Figure 15 F plots the allelic ratios obtained from a second SNP within Amp4, represented by SEQ ID NO: 14. For a given datapoint in each plot, the standard deviations
30 across triplicated measurements are small, indicating that the deviations were not primarily due to variation in the first round PCR, second round PCR and the primer extension reaction component of the assay, since the triplicate measurements were independent replicates of these three steps. Furthermore, the direction and magnitude that each data point for each

input ratio deviated from the expected line in the two plots (D and F) is remarkably similar between data derived from the two independent SNP positions within the same amplicon. Based on a comparison to the control curve, it can be determined that these results indicate that the variability occurred upstream of the triplicated primer extension reactions, the triplicated 2nd round PCR amplification, and the triplicated 1st round PCR amplification. Furthermore, since three of four amplicons reported expected results, the variability did not occur in the IVT reaction or in the preparation of IVT RNA mixtures. The results are instead consistent with the variability being introduced at the non-replicated RT step, specifically the reverse transcription of first strand cDNA using the RT primer required to RT-PCR amplify Amp4 (the right-most RT primer diagrammed in Figure 13 B). In contrast to this source of variability, consider the data point for the 2:1 Synth1:Synth2 mixture in Figure 15 D. In this case, substantial variability is seen in the triplicated allele ratio measurements (reflected by the large standard deviation). In this case, the source of variability likely occurred at one or more of the triplicated reactions (1st round PCR, 2nd round PCR, primer extension reaction or peak detection and area calculation).

Example 8. Use of RNA controls to determine relative abundance of allele-specific gene expression in blood samples.

[0263] Genomic DNAs extracted from two whole blood samples (A and B) were genotyped using the single-nucleotide primer extension assay described in Example 5. Sample A was heterozygous (and, therefore, informative) for SNPs represented by SEQ ID NOs: 3, 11 and 12. Sample B was heterozygous (and, therefore, informative) for SNPs represented by SEQ IDs: 5 and 16 (Table 11).

[0264] Total RNA was extracted from the same two blood samples (A and B). For each, 500 ng of RNA was used as template for first-strand cDNA synthesis as described in Example 7. A control reaction lacking reverse transcriptase was performed to ensure that downstream amplification was derived from cDNA rather than potential contaminating genomic DNA. Following first-strand cDNA synthesis, 1 μ L of each RT+ or RT- reaction was used as template for nested PCR amplification of the four amplicons, as described in Example 7 and diagrammed in Figure 13. An aliquot of each PCR reaction was analyzed on an agarose gel to confirm that no amplification was present in reactions derived from the RT- control reaction. Amplicons were individually purified on PCR purification spin columns (Qiagen), and used as template for the multiplexed single-nucleotide primer

extension assay described in Example 5. The resulting raw peak areas and raw peak area ratios are provided in Table 11.

[0265] Because Sample A was heterozygous at the SNP positions represented by SEQ ID NOs: 3, 11 and 12, these three specific SNP-based assays were informative for measuring
5 LOI of *IGF2* (Table 11). In the cDNAs tested for Sample A, the single nucleotide primer extension assay for SEQ ID NO: 3 detected a peak only for the C allele (no peak was detected for the A allele). In the cDNAs tested for Sample A, the single nucleotide primer extension assay for SEQ ID NO: 11 detected a peak only for the G allele (no peak was detected for the A allele). In the cDNAs tested for Sample A, the single nucleotide primer
10 extension assay for SEQ ID NO: 12 detected a peak only for the C allele (no peak was detected for the T allele). Therefore, this sample was determined to exhibit normal imprinting of *IGF2*. That is, only one of the two alleles of the *IGF2* gene was expressed. This allele includes the nucleotides C, G and C at the SNP positions represented by SEQ ID NO: 3, 11 and 12, respectively. The other allele (including the nucleotides A, A and T at
15 the SNP positions represented by SEQ ID NO: 3, 11 and 12, respectively) was imprinted and no expression was detected.

[0266] Sample B was heterozygous at the SNP positions represented by SEQ ID NOs: 5 and 16 (Table 11). For the cDNAs tested for Sample B, the single nucleotide primer extension assay for SEQ ID NO: 16 detected a peak only for the A allele (no peak was
20 detected for the G allele). However, the single nucleotide primer extension assay for SEQ ID NO: 5 detected peaks above background for both alleles (G and A, respectively). Note that these nucleotides represent the complementary strand relative to the sequence indicated in SEQ ID NO: 5. The ratio of Peak Area 1:Peak Area 2 was 0.445. In some reports, loss of imprinting of *IGF2* is considered to be present if the ratio of the two detected alleles is
25 between 1:3 and 3:1 (*i.e.*, ratios between 0.333 and 3.0). This raw result for Sample B would seem to indicate that SNP assays for SEQ ID NO: 5 and SEQ ID NO: 16 reported different LOI results (*i.e.* SEQ ID NO: 16 reported normal imprinting and SEQ ID NO: 5 reported LOI). However, the ratio of 0.445 was not corrected by extrapolating against the standard control series of known input RNA allele ratios shown in Figure 15 B. The linear
30 equation for this control data series is $y = 0.8717x + 0.2032$. The measure ratio, y , is 0.445. Therefore, by using this value to solve for the input ratio, x , the corrected value was determined to be 0.278. Therefore, by the definition of LOI as described above (0.333 – 3.0), this assay indicated that Sample B does not display LOI of *IGF2*.

[0267] It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes.

Table 1. Previously Unpublished Single Nucleotide Polymorphisms in *IGF2* exon 9.

SEQ ID NO:	Genomic Position*	Alleles	Sequence
1	2108417	[T/G]	TTCCCCCTCTTTGTTTCTTGGGGCA[T/G]TTTTCCTTTTCTTTTCTTTTGT
2	2110187	[C/T/G/A]	GGACCCAGAAATCACAGGTGGGCA[C/T/G/A]GTCGCTGCTACCGCCATCTCCCTTC
3	2109220	[A/C]	GCGCACACACGCACACCCCCACA[A/C]AATTGGATGAAACAATAAGCATAT
4	2108843	[T/C]	CATTCCCGATACACCTTACTTACTG[T/C]GTGTTGGCCAGCCAGAGTGAGGAA
5	2108835	[C/T]	ATACACCTTACTTACTGTGTGTTGG[C/T]CCAGCCAGAGTGAGGAAGGAGTTTG
6	2107668	[G/A]	ATGCCATAGCAGCCACCACCGCGG[C/G/A]CCTAGGGCTGCGGCAAGGACTCGGC

* Coordinates relative to NCBI Build 36, Chr:11

Table 2. Previously Identified Single Nucleotide Polymorphisms in *IGF2* exon 9.

SEQ ID NO:	Genomic Position*	dbSNP ID	Alleles	Sequence
7	2110764	rs2230949	[C/T]	AAACTGCCGCAAGTCTGCAGCCCGG[C/T]GCCACCATCCTGCAGCCTCCTCCTG
8	2110210	rs680	[G/A]	CTGAACCAGCAAGAGAAAGAGG[G/A]CCCCAGAAATCACAGGTGGGCACGT
9	2109215	rs1065687	[G/A]	CACACACGCACACCCCCACAAAT[G/A]GATGAAACAATAAGCATATCTAAG
10	2109117	rs3168310	[C/G]	CCAATGTTTTCATGGTCTGAGCCCC[C/G]CTCCTGTTCCCATCTCCACTGCCCC
11	2108682	rs57156844	[C/T]	ACATTTCTTGGGGGTCCCAGGAGA[C/T]GGGCAAGATGATCCCTAGGTGTGC
12	2108628	rs3802971	[C/T]	AGTCCTCGGGGGCCGTGCACTGATG[C/T]GGGGAGTGTGGGAAGTCTGGCGGTT
13	2107971	rs11825733	[G/A]	AGGCTGGCCGGAGGGGAAGGGGCTA[G/A]CAGGTGTGTAAACAGAGGGTTCCAT
14	2107471	rs11564732	[G/A]	AGTCGCAGAGGGTCCCTCGGCAAGC[G/A]CCCTGTGAGTGGGCCATTTCGGAACA
15	2107273	rs7873	[A/G]	GTGTTCCCGGGGGCACTTGCCGACC[A/G]GCCCCCTTGCGTCCCCCAGGTTTGCAG
16	2107020	rs2585	[G/A]	TGCGGCCCGTGTGTGACTCAACTCA[G/A]CTCCTTTAACGCTAATATTTCGGGC

* Coordinates relative to NCBI Build 36,

Chr:11

Table 3. Observed Heterozygosity of Transcribed *IGF2* SNPs in Human Populations

SEQ ID NO:	Genomic Position*	Overall			AA		CAU		MEX		JPN		CHI	
		% het	het of total	% het	% het	het of total	% het	het of total	% het	het of total	% het	het of total	% het	het of total
1	2108417	16.1%	36 of 223	16.2%	12 of 74	18.8%	15 of 80	13.0%	9 of 69	---	---	---	---	---
2	2110187	31.1%	23 of 74	31.1%	23 of 74	---	---	---	---	---	---	---	---	---
3	2109220	24.3%	18 of 74	24.3%	18 of 74	---	---	---	---	---	---	---	---	---
4	2108843	6.8%	5 of 74	6.8%	5 of 74	---	---	---	---	---	---	---	---	---
5	2108835	14.0%	21 of 150	---	---	14.0%	21 of 150	---	---	---	---	---	---	---
6	2107668	6.7%	10 of 150	---	---	---	---	---	---	---	2.5%	2 of 79	11.3%	8 of 71
7	2110764	11.9%	35 of 293	14.9%	11 of 74	10.7%	16 of 150	11.6%	8 of 69	---	---	---	---	---
8	2110210	45.6%	202 of 443	18.9%	14 of 74	54.7%	82 of 150	31.9%	22 of 69	57.0%	45 of 79	54.9%	39 of 71	---
9	2109215	9.1%	20 of 219	---	---	12.7%	19 of 150	1.4%	1 of 69	---	---	---	---	---
10	2109117	35.0%	155 of 443	28.4%	21 of 74	36.7%	55 of 150	33.3%	23 of 69	30.4%	24 of 79	45.1%	32 of 71	---
11	2108682	20.3%	29 of 143	37.8%	28 of 74	---	---	1.4%	1 of 69	---	---	---	---	---
12	2108628	15.3%	68 of 443	9.5%	7 of 74	10.7%	16 of 150	13.0%	9 of 69	21.5%	17 of 79	26.8%	19 of 71	---
13	2107971	14.9%	11 of 74	14.9%	11 of 74	---	---	---	---	---	---	---	---	---
14	2107471	7.0%	21 of 298	---	---	0.7%	1 of 150	20.3%	14 of 69	7.6%	6 of 79	---	---	---
15	2107273	20.5%	60 of 293	35.1%	26 of 74	16.0%	24 of 150	14.5%	10 of 69	---	---	---	---	---
16	2107020	45.1%	200 of 443	21.6%	16 of 74	41.3%	62 of 150	37.7%	26 of 69	63.3%	50 of 79	64.8%	46 of 71	---

Table 4. Observed Heterozygosity for Combinations of Transcribed *IGF2* SNPs in Human Populations

Human Group	# Het	# Total	Panel A	Panel B	Panel C	Panel D	Panel E
Overall	358	443	80.81%	78.56%	78.56%	75.17%	61.17%
Chinese	52	71	73.24%	71.83%	71.83%	69.01%	70.42%
Japanese	59	79	74.68%	74.68%	74.68%	72.15%	73.42%
Mexican	51	69	73.91%	71.01%	72.46%	68.12%	60.87%
African American	68	74	91.89%	82.43%	81.08%	78.38%	31.08%
Caucasian	128	150	85.33%	85.33%	85.33%	81.33%	65.33%

Table 5. Seq ID NOs for SNP combinations described in Table 4.

Panel:	Panel A	Panel B	Panel C	Panel D	Panel E
	1	1	1	1	8
	2	2	5	5	11
	3	4	8	8	14
	4	5	9	9	16
	5	8	10	10	
	6	9	11	11	
	7	10	12	14	
	8	12	14	15	
	9	13	15	16	
	10	14	16		
	11	15			
	12	16			
	13				
	14				
	15				
	16				
Total # SNPs:	16	12	10	9	4

Table 6. Linearity of assays measuring allele-specific ratios of 13 independent SNPs

SEQ ID	R²	slope
2	0.9986	0.8256
3	0.9817	0.5946
4	0.9995	0.8973
5	0.9963	0.8351
6	0.9757	0.6219
7	0.9949	0.7825
8	0.9915	0.8494
9	0.9949	0.8297
10	0.9964	0.814
11	0.9988	0.8681
14	0.9987	0.835
15	0.9953	0.818
16	0.9984	0.8531

Table 7. Results of Multiplexed Assay for *IGF2* Genotype and Imprinting Status.

Sample	SEQ ID NO:	Genomic DNA*		Total RNA [†]		Genotype [‡]	Expression ^a
		Allele 1	Allele 2	Allele 1	Allele 2		
A	1	T		T		hom	n/a
A	2	G		G		hom	n/a
A	3	G	T		T	informative	imprinted
A	4	T		T		hom	n/a
A	5	G		G		hom	n/a
A	6	G		G		hom	n/a
A	7	G		G		hom	n/a
A	8	G		G		hom	n/a
A	9	G		G		hom	n/a
A	10	C		C		hom	n/a
A	11	G	A	G		informative	imprinted
A	12	C	T	C		informative	imprinted
A	13	G		G		hom	n/a
A	14	G		G		hom	n/a
A	15	A		A		hom	n/a
A	16	G		G		hom	n/a
B	1	T		T		hom	n/a
B	2		T		T	hom	n/a
B	3	G		G		hom	n/a
B	4	T		T		hom	n/a
B	5	G	A	G	A	informative	borderline
B	6	G		G		hom	n/a
B	7	G		G		hom	n/a
B	8	G		G		hom	n/a
B	9	G		G		hom	n/a
B	10	C		C		hom	n/a
B	11	G		G		hom	n/a
B	12	C		C		hom	n/a
B	13	G		G		hom	n/a
B	14	G		G		hom	n/a
B	15	A		A		hom	n/a
B	16	G	A	G		informative	imprinted

*Genotypes at each of the ten assayed SNPs.

[†]Alleles detected in expressed *IGF2* transcripts.[‡]Indicates homozygous (hom) or heterozygous and informative (informative) at each SNP.^aImprinted: monoallelic expression of *IGF2*; n/a: result not applicable due to homozygosity at the particular SNP.

Table 8. Comparisons of Peak Areas for *IGF2* Genotype and Imprinting Status Analysis.

Sample	SEQ ID NO:	Genomic DNA*				Total RNA†		
		Peak area 1	Peak Area 2	Allele 1: Allele 2 ^a	Normalization Factor ^b	Peak Area 1	Peak Area 2	Allele 1: Allele 2 ^c
A	1	58328	0	-		78730	0	-
A	2	153330	0	-		126343	0	-
A	3	67871	30193	2.2479	0.4449	0	36005	-
A	4	5030	0	-		3669	0	-
A	5	40432	0	-		28478	0	-
A	6	25890	0	-		9038	0	-
A	7	134730	0	-		120747	0	-
A	8	88657	0	-		77231	0	-
A	9	22926	0	-		39965	0	-
A	10	79426	0	-		48415	0	-
A	11	97000	106229	0.9131	1.0951	103671	0	-
A	12	54813	163646	0.3349	2.9855	59419	0	-
A	13	40100	0	-		33286	0	-
A	14	10205	0	-		6230	0	-
A	15	96528	0	-		49735	0	-
A	16	136263	0	-		138675	0	-
B	1	60360	0	-		71841	0	-
B	2	0	124496	-		0	79158	-
B	3	37814	0	-		35854	0	-
B	4	3850	0	-		4377	0	-
B	5	16043	12107	1.3251	0.7547	6283	14115	0.3359
B	6	19750	0	-		8647	0	-
B	7	95420	0	-		96206	0	-
B	8	61002	0	-		38661	0	-
B	9	29844	0	-		54430	0	-
B	10	50863	0	-		48856	0	-
B	11	109546	0	-		112126	0	-
B	12	60364	0	-		61683	0	-
B	13	39767	0	-		38418	0	-
B	14	14754	0	-		9525	0	-
B	15	110227	0	-		55892	0	-
B	16	63791	58086	1.0982	0.9106	108307	0	-

*Data for Genotype assays.

†Data for Allele-Specific Expression Analysis.

^aCalculated ratio of genotyping Peak Area 1/Genotyping Peak Area 2^bNormalization to account for dye intensity differences (1/(Genotyping Peak Area 1/Genotyping Peak Area 2))^cNormalized calculated ratio for expression Peak Area 1/expression Peak Area 2 ((Expression Peak Area 1/Expression Peak Area 2)*Normalization Factor)

Table 9. SNP positions and genotypes in Synth1 and Synth2

SEQ ID NO:	Genomic Position ^a	Synth1 or Synth2 Position ^b	Possible Alleles	Synth1 Allele	Synth2 Allele	Sequence
1	2108417	2089	[T/G]	T	G	TTCCCCCTCTTTGTTTCTTGGGGCA[T/G]TTTCCCTTTTTTTTTTTTGT
2	2110187	897	[C/T]	C	T	GGACCCACAGAAATCACAGGTGGGCA[C/T/G/A]GTCGCTGCTACCGCCATCTCCCTTC
3	2109220	1286	[A/C]	A	C	GCGCACACACACGACACACCCCCACA[A/C]AATTGGATGAAACAATAAGCATAT
4	2108843	1663	[T/C]	T	C	CATTCCCGATACACCTTACTTACTGT[C/G]GTGTGGCCAGCCAGAGTGAGGAA
5	2108835	1671	[C/T]	C	T	ATACACCTTACTTACTGTGTGTGGG[C/T]CCAGCCAGAGTGAGGAGGATTG
6	2107668	2838	[G/A]	G	A	ATGCCATAGCAGCCACACCGCGG[C/G/A]CCTAGGGCTGCGGAGGACTCGGC
7	2110764	320	[C/T]	C	T	AAACTGCCGCAAGTCTGACGCCGG[C/T]GCCACCATCCTGCAGCCTCCTCTG
8	2110210	874	[G/A]	A	G	CTGAACACAGCAAAGAGAAAGAGG[G/A]CCGCCAGAAATCACAGGTGGGACGT
9	2109215	1291	[G/A]	G	A	CACACACGCACACCCCCACAAAAT[G/A]GATGAAACAATAAGCATATCTAAG
10	2109117	1389	[C/G]	G	C	CCAATGTTTTTCATGGTCTGAGCCCC[C/G]CTCCTGTTCCTCACTCCACTGCCCC
11	2108682	1824	[C/T]	G ^c	A ^c	ACATTTCTTGGGGGTCCCCAGGAGA[C/T]GGGCAAGATGATCCCTAGGTGTC
12	2108628	1878	[C/T]	C	T	AGTCCTCGGGGGCGTGCACTGATG[C/T]GGGAGTGTGGGAAAGTCTGGCGGT
13	2107971	2535	[G/A]	G	A	AGGCTGGCCGGAAGGGGAAGGGGCTA[G/A]CAGGTGTGTAAACAGAGGTTCCAT
14	2107471	3035	[G/A]	G	A	AGTCGCAGAGGGTCCCTCGGCAAGC[G/A]CCCTGTGAGTGGGCCATTCCGGAACA
15	2107273	3233	[A/G]	A	G	GTGTTCCTCGGGGGCACTTGCCGACC[A/G]GCCCTTGCCTCCCGAGGTTTGCAG
16	2107020	3486	[G/A]	A	G	TGCGGCCCCGTGTTTGACTCAACTCA[G/A]CTCCTTAAACGCTAATATTCCGGC

^a Coordinates relative to NCBI Build 36, Chr:11

^b Coordinates relative to SEQ ID: 18 and SEQ ID: 20

^c Sequence provided in "Sequence" and "Possible Alleles" columns correspond to the opposite strand relative to that shown in "Synth1 Allele" and "Synth2 Allele" columns.

Table 10. SNP-based primer extension assay confirmation of SNP alleles of Synth1 and Synth2

Synth Control ^a	SEQ ID of SNP	Genomic Position ^b	Designed Allele	Detected Allele 1	Detected Allele 2	Peak Area Allele 1	Peak Area Allele 2	Genotype Call
1	1	2108417	T	T	-	67148	0	T
1	2	2110187	C	G*	-	63747	0	G*
1	3	2109220	A	A	-	150505	0	A
1	4	2108843	T	T	-	57166	0	T
1	5	2108835	C	G*	-	34768	0	G*
1	6	2107668	G	G	-	17764	0	G
1	7	2110764	C	G*	-	57660	0	G*
1	8	2110210	A	A	-	165497	0	A
1	9	2109215	G	C*	-	102012	0	C*
1	10	2109117	G	G	-	174460	0	G
1	11	2108682	G c	G c	-	54188	0	G
1	12	2108628	C	C	-	101444	0	C
1	13	2107971	G	G	-	31305	0	G
1	14	2107471	G	C*	-	42605	0	C*
1	15	2107273	A	A	-	68516	0	A
1	16	2107020	A	A	-	76774	0	A
2	1	2108417	G	-	G	0	86007	G
2	2	2110187	T	-	A*	0	87563	A*
2	3	2109220	C	-	C	0	80903	C
2	4	2108843	C	-	C	0	45169	C
2	5	2108835	T	-	A*	0	46015	A*
2	6	2107668	A	-	A	0	33683	A
2	7	2110764	T	-	A*	0	72463	A*
2	8	2110210	G	-	G	0	93147	G
2	9	2109215	A	-	T*	0	92444	T*
2	10	2109117	C	-	C	0	98591	C
2	11	2108682	A c	-	A c	0	115660	A*
2	12	2108628	T	-	T	0	98328	T
2	13	2107971	A	-	A	0	50002	A
2	14	2107471	A	-	T*	0	63342	T*
2	15	2107273	G	A	G	10393	27474	G
2	16	2107020	G	-	G	0	45753	G

^a Indicates genotyping reaction for either Synth 1 (1) or Synth 2 (2)^b Genomic position of SNP relative to NCBI Build 36, Chr:11^c Synth1 and Synth2 allele designation reflects the opposite strand relative to the sequence shown in SEQ ID NO: 11

* Genotyping assay reports the opposite strand relative to the sequence shown in the SEQ ID sequence

Table 11. Comparisons of Peak Areas for IGF2 Genotype and Imprinting Status Analysis.

Sample	SEQ ID NO:	Genomic DNA ^a			Total RNA ^b			
		Peak area 1	Peak Area 2	Genotype	Peak Area 1	Peak Area 2	Allele 1: Allele 2	Corrected Ratio ^c
A	1	58328	0	-	78730	0	-	-
A	2	153330	0	-	126343	0	-	-
A	3	67871	30193	het	0	36005	-	-
A	4	5030	0	-	3669	0	-	-
A	5	40432	0	-	28478	0	-	-
A	6	25890	0	-	9038	0	-	-
A	7	134730	0	-	120747	0	-	-
A	8	88657	0	-	77231	0	-	-
A	9	22926	0	-	39965	0	-	-
A	10	79426	0	-	48415	0	-	-
A	11	97000	106229	het	103671	0	-	-
A	12	54813	163646	het	59419	0	-	-
A	13	40100	0	-	33286	0	-	-
A	14	10205	0	-	6230	0	-	-
A	15	96528	0	-	49735	0	-	-
A	16	136263	0	-	138675	0	-	-
B	1	60360	0	-	71841	0	-	-
B	2	0	124496	-	0	79158	-	-
B	3	37814	0	-	35854	0	-	-
B	4	3850	0	-	4377	0	-	-
B	5	16043	12107	het	6283	14115	0.445	0.000
B	6	19750	0	-	8647	0	-	-
B	7	95420	0	-	96206	0	-	-
B	8	61002	0	-	38661	0	-	-
B	9	29844	0	-	54430	0	-	-
B	10	50863	0	-	48856	0	-	-
B	11	109546	0	-	112126	0	-	-
B	12	60364	0	-	61683	0	-	-
B	13	39767	0	-	38418	0	-	-
B	14	14754	0	-	9525	0	-	-
B	15	110227	0	-	55892	0	-	-
B	16	63791	58086	het	108307	0	-	-

^a Data for Genotype assays.^b Data for Allele-Specific Expression Analysis.^c Ratio corrected by extrapolating ratio value from the RNA control standard curve shown in Figure X+3

SEQUENCE TABLE

5	SEQ ID NO:1 TTCCCCCTCTTTGTTTCTTGGGGCA[T/G]TTTTCCTTTTTTTTTTTTTTTTGTGTT
	SEQ ID NO:2 GGACCCCAGAAATCACAGGTGGGCA[C/T/G/A]GTCGCTGCTACCGCCATCTCCCTTC
10	SEQ ID NO:3 GCGCACACACACGCACACCCCCACA[A/C]AATTGGATGAAAACAATAAGCATAT
15	SEQ ID NO:4 CATTCCCGATACACCTTACTTACTG[T/C]GTGTTGGCCCAGCCAGAGTGAGGAA
	SEQ ID NO:5 ATACACCTTACTTACTGTGTGTTGG[C/T]CCAGCCAGAGTGAGGAAGGAGTTTG
20	SEQ ID NO:6 ATGCCATAGCAGCCACCACCGCGGC[G/A]CCTAGGGCTGCGGCAGGGACTCGGC
	SEQ ID NO:7 AAAGTCCGCAAGTCTGCAGCCCGG[C/T]GCCACCATCCTGCAGCCTCCTCCTG
25	SEQ ID NO:8 CTGAACCAGCAAAGAGAGAAAAGAAGG[G/A]CCCCAGAAATCACAGGTGGGCACGT
30	SEQ ID NO:9 CACACACGCACACCCCCACAAAATT[G/A]GATGAAAACAATAAGCATATCTAAG
	SEQ ID NO:10 CCAATGTTTTTCATGGTCTGAGCCCC[C/G]CTCCTGTTCCCATCTCCACTGCCCC
35	SEQ ID NO:11 ACATTTCTTGGGGGGGTCCCCAGGAGA[C/T]GGGCAAAGATGATCCCTAGGTGTGC
40	SEQ ID NO:12 AGTCCTCGGGGGCCGTGCACTGATG[C/T]GGGGAGTGTGGGAAGTCTGGCGGTT
45	SEQ ID NO:13 AGGCTGGCCGGAGGGGAAGGGGCTA[G/A]CAGGTGTGTAAACAGAGGGTTCCA
	SEQ ID NO:14 AGTCGCAGAGGGTCCCTCGGCAAGC[G/A]CCCTGTGAGTGGGCCATTCGGAACA
50	SEQ ID NO:15 GTGTTCCCGGGGGGCACTTGCCGACC[A/G]GCCCCCTTGCGTCCCCAGGTTTGCAG

SEQ ID NO:16

TGCGGCCCGTGTTTGACTCAACTCA[G/A]CTCCTTTAACGCTAATATTTCCGGC

5 SEQ ID NO:17

NM_000612

1 cgccctgtccc cctccccgagg cccggggtcgc cgacggcaga gggctccgtc
 ggcccaaacc
 61 gagctgggag cccgcgggtcc ggggtgcagcc tccactccgc cccccagtca
 10 cccgctcccc
 121 cggccccctgc acgtggcgcc cttccctccg cttctctgtg ctccccgcgc
 cctctctggc
 181 gtctggcccc ggcccccgct ctttctcccc caaccttccc ttcgctccct
 cccgtcccc
 241 ccagctccta gcctccgact ccctcccccc ctccagcccc cctctctgcc
 15 ttcgcccgaac
 301 caaagtggat taattacacg ctttctgttt ctctccgtgc tgttctctcc
 cgctgtgcgc
 361 ctgccccgct ctgctgtgcc tctctcccc tcgcccctctc ttcggcccc
 20 ccttttcacg
 421 ttcactctgt ctctccact atctctgccc ccctctatcc ttgatacaac
 agctgacctc
 481 atttccccgat accttttccc ccccgaaaag tacaacatct ggcccccccc
 agcccgaaga
 541 cagccccgtcc tccctggaca atcagacgaa ttctcccccc cccccaaaa
 25 aaaagccatc
 601 cccccgctct gccccgtgc acattcggcc cccgcgactc ggccagagcg
 gcgctggcag
 661 aggagtgtcc ggcaggaggg ccaacgcccc ctgttcgggt tgcgacacgc
 30 agcaggaggg
 721 tgggcggcag cgtcgccggc ttccagacac caatgggaat cccaatgggg
 aagtcgatgc
 781 tgggtgcttct caccttcttg gccttcgcct cgtgctgcat tgcgtcttac
 cgccccagtg
 841 agaccctgtg cggcggggag ctgggtggaca ccctccagtt cgtctgtggg
 35 gaccgcgggt
 901 tctacttcag caggccccga agccgtgtga gccgtcgcag ccgtggcatc
 gttgaggagt
 961 gctgtttccg cagctgtgac ctggccctcc tggagacgta ctgtgctacc
 40 ccgccaagt
 1021 ccgagaggga cgtgtcgacc cctccgaccg tgcttccgga caacttcccc
 agataccccg
 1081 tgggcaagtt cttccaatat gacacctgga agcagtccac ccagcgctg
 cgcagggggc
 1141 tgcttgcct cctgcgtgcc cgcgggggtc acgtgctcgc caaggagctc
 45 gaggcgttca
 1201 gggaggccaa acgtcaccgt cccctgattg ctctaccac ccaagacccc
 gccacgggg
 1261 gcgccccccc agagatggcc agcaatcgga agtgagcaaa actgcccga
 50 gtctgcagcc
 1321 cggcgccacc atcctgcagc ctctcctga ccacggacgt ttccatcagg
 ttccatcccc
 1381 aaaatctctc ggttccacgt cccctgggg cttctcctga cccagtcccc
 gtgccccgc
 1441 tccccgaaac aggctactct cctcgcccc ctccatcggg ctgaggaagc
 55 acagcagcat
 1501 cttcaaakat gtacaaaatc gattggcttt aaacaccctt cacataccct
 cccccaaat
 1561 tatccccaat tatccccaca cataaaaaat caaaacatta aactaaccct
 60 cttccccccc

1621 cccacaca accctcttaa aactaattgg ctttttagaa acaccccaca
 aaagctcaga
 1681 aattggcttt aaaaaaaca accaccaaaa aaaatcaatt ggctaaaaaa
 aaaaagtatt
 5 1741 aaaaacgaat tggctgagaa acaattggca aaataaagga atttggcact
 ccccaccccc
 1801 ctctttctct tctcccttgg actttgagtc aaattggcct ggacttgagt
 ccctgaacca
 1861 gcaaagagaa aagaaggacc ccagaaatca caggtgggca cgtcgctgct
 10 accgccatct
 1921 cccttctcac ggaatttttc agggtaaact ggccatccga aaatagcaac
 aaccagact
 1981 ggctcctcac tcccttttcc atcactaaaa atcacagagc agtcagaggg
 acccagtaag
 15 2041 accaaaggag gggaggacag agcatgaaaa ccaaaatcca tgcaaataaa
 atgtaattgg
 2101 cagaccctc acccccaaat cttacatctc aattcccatc ctaaaaagca
 ctcatacttt
 2161 atgcatcccc gcagctacac acacacaaca cacagcacac gcatgaacac
 20 agcacacaca
 2221 cgagcacagc acacacacaa acgcacagca cacacagcac acagatgagc
 acacagcaca
 2281 cacacaaacg cacagcacac acacgcacac acatgcacac acagcacaca
 aacgcacggc
 25 2341 acacacacgc acacacatgc acacacagca cacacacaaa cgcacagcac
 acacaaacgc
 2401 acagcacaca cgcacacaca gcacacacac gagcacacag cacacaaacg
 cacagcacac
 2461 gcacacacat gcacacacag cacacacact agcacacagc acacacacaa
 30 agacacagca
 2521 cacacatgca cacacagcac acacacgcga acacagcaca cacgaacaca
 gcacacacag
 2581 cacacacaca aacacagcac acacatgcac acagcacacg cacacacagc
 acacacatga
 35 2641 acacagcaca cagcacacac atgcacacac agcacacacg catgcacagc
 acacatgaac
 2701 acagcacaca cacaacacaca cagcacacac atgcacacac agcacacaca
 ctcacatgca
 2761 gcacatacat gaacacagct cacagcacac aaacacgcag cacacacgtt
 40 gcacacgcaa
 2821 gcacccacct gcacacacac atgcgcacac acacgcacac cccacacaaa
 ttggatgaaa
 2881 acaataagca tatctaagca actacgatat ctgtatggat caggccaaag
 tcccgtctag
 45 2941 attctccaat gttttcatgg tctgagcccc gctcctgttc ccatctccac
 tgccctcgg
 3001 ccctgtctgt gccctgcctc tcagaggagg gggctcagat ggtgcggcct
 gagtgtgcgg
 3061 ccggcggcat ttgggataca cccgtagggg gggcgggggtg tgtcccaggc
 50 ctaattccat
 3121 ctttccacca tgacagagat gcccttgtga ggctggcctc cttggcgcct
 gtccccacgg
 3181 cccccgcagc gtgagccacg atgctcccca taccacaccc attcccagata
 caccttactt
 55 3241 actgtgtgtt ggcccagcca gagtgaggaa ggagtttggc cacattggag
 atggcggttag
 3301 ctgagcagac atgccccac gagtagcctg actccctggg gtgctcctgg
 aaggaagatc
 3361 ttggggaccc cccacccgga gcacacctag ggatcatctt tgcccgtctc
 60 ctggggaccc

3421 cccaagaaat gtggagtcct cggggggccgt gcactgatgc ggggagtgtg
 ggaagtcttg
 3481 cggttggagg ggtgggtggg gggcagtggg ggctgggcgg ggggagttct
 ggggtaggaa
 5 3541 gtggtcccgg gagatthttg atggaaaagt caggaggatt gacagcagac
 ttgcagaatt
 3601 acatagagaa attaggaacc cccaaatttc atgtcaattg atctattccc
 cctctttgtt
 3661 tcttggggca tttttccttt tttttttttt tttgtttttt ttttaccctt
 10 ccttagcttt
 3721 atgcgctcag aaaccaaatt aaaccccccc cccatgtaac agggggggcag
 tgacaaaagc
 3781 aagaacgcac gaagccagcc tggagaccac cacgtcctgc cccccgcat
 ttatcgccct
 15 3841 gattggattt tgtttttcat ctgtccctgt tgcttgggtt gagttgaggg
 tggagcctcc
 3901 tggggggcac tggccactga gcccccttg agaagtcaga ggggagtgga
 gaaggccact
 3961 gtccggcctg gcttctgggg acagtggctg gtccccagaa gtccctgaggg
 20 cggagggggg
 4021 gggtgggcag ggtctcctca ggtgtcagga ggggtgctcg agggcacagg
 agggggctcc
 4081 tggctggcct gaggctggcc ggaggggaag gggctagcag gtgtgtaaac
 agagggttcc
 25 4141 atcaggctgg ggcagggtgg ccgccttccg cacacttgag gaaccctccc
 ctctccctcg
 4201 gtgacatctt gcccggccct cagcacctg ccttgtctcc aggaggtccg
 aagctctgtg
 4261 ggacctcttg ggggcaaggt ggggtgaggg cggggagtag ggaggtcagg
 30 cgggtctgag
 4321 cccacagagc aggagagctg ccaggctctg ccatcgacca gggtgcttgg
 gccccggagc
 4381 ccacgggtct ggtgatgcca tagcagccac caccgcggcg cctagggctg
 cggcagggac
 35 4441 tcggcctctg ggaggtttac ctgcggccca cttgtgcccc cagctcagcc
 cccctgcagc
 4501 cagcccgact agcagtctag aggcctgagg cttctgggtc ctggtgacgg
 ggctggcatg
 4561 accccggggg tcgtccatgc cagtccgcct cagtgcgaga gggtcctctg
 40 gcaagcgccc
 4621 tgtgagtggg ccattcggaa cattggacag aagcccaaag agccaaattg
 tcacaattgt
 4681 ggaaccacaca ttggcctgag atccaaaacg cttcgaggca ccccaaatta
 cctgcccatt
 45 4741 cgtcaggaca cccaccacc cagtgttata ttctgcctcg ccggagtggg
 tgttcccggg
 4801 ggcacttgcc gaccagcccc ttgcgtcccc aggtttgcag ctctccctg
 ggccactaac
 4861 catcctggcc cgggctgcct gtctgacctc cgtgcctagt cgtggctctc
 50 catcttgtct
 4921 cctccccgtg tccccaatgt cttcagtggg gggccccctc ttgggtcccc
 tcctctgcca
 4981 tcacctgaag acccccacgc caaacactga atgtcacctg tgccctgccg
 ctcggtccac
 55 5041 cttgcggccc gtgtttgact caactcaact cctttaacgc taatatttcc
 ggcaaaatcc
 5101 catgcttggg ttttgtcttt aaccttgtaa cgcttgcaat cccaataaag
 cattaaaagt
 5161 catgaaaaaa aaaaaaaaaa aa

60

SEQ ID NO:18

ENST00000300632

CCGCTAATGTACCATGCCCTGGTGCTGGAAAGTGCCTGAGCCAGCTGCCCCAGCGGCCTC
 AGCACTACCAAGTTGGCACAAAGCTCCCCAAATTCGGAGGGGCTCAGGGAAACGAGTGGA
 GGGGATGAGGAGGTGAGGGGTAAACCCATCATTTTCAGTTGGCATTTGAGCAGGTGCCATG
 5 CTCAGCGGAGATGAGGCTCTCCCATCTGTAGGGGCCGTATTAACATGCACACTCTAAAAG
 TGCCTTCGTTTCTCCAGCCTCAGCTTTGTCCCTCTCCTCCTCCACGTCAACCTGGCCAG
 AGGGTCTGGACGCCACAGCCAGGGCACCCCTGCTTTGGTGCTGACTGCTAATATTGGCC
 AGGCCGGCGGATCATCGTCCAGGCAGTTTCGGCAGAGAGCCTTGGGCACCAGTGACTCCC
 CGGTCTCTTTATCCACTGTCCAGGAGCTGCGGGGACTGCGCAGGGACTAGAGTACAGGG
 10 GCCGAAGAGTCACCACCGAGCTTGTGTGGGAGGAGGTGGATTCCAGCCCCCAGCCCCAGG
 GCTCTGAATCGCTGCCAGCTCAGCCCCCTGCCAGCCTGCCCCACAGCCTGAGCCCCAGC
 AGGCCAGAGAGCCCAGTCCTGAGGTGAGCTGCTGTGGCCTGTGGCCCAGGCGACCCAGC
 GCTCCCAGAACTGAGGCTGGCAGCCAGCCCCAGCCTCAGCCCCAACTGCGAGGCAGAGAG
 ACACCAATGGGAATCCCAATGGGGAAGTCGATGCTGGTGCTTCTCACCTTCTTGGCCTTC
 15 GCCTCGTGCTGCATTGCTGCTTACCGCCCCAGTGAGACCCTGTGCGGCGGGGAGCTGGTG
 GACACCCTCCAGTTCGTCTGTGGGGACCGCGGCTTCTACTTCAGCAGGCCCCGCAAGCCGT
 GTGAGCCGTGCGCAGCCGTGGCATCGTTGAGGAGTGCTGTTTCCGCAGCTGTGACCTGGCC
 CTCCTGGAGACGTACTGTGCTACCCCCGCCAAGTCCGAGAGGGACGTGTGACCCCTCCG
 ACCGTGCTTCCGGACAACTTCCCCAGATACCCCGTGGGCAAGTTCTTCCAATATGACACC
 20 TGGAAGCAGTCCACCCAGCGCCTGCGCAGGGGCCTGCCTGCCCTCCTGCGTGCCCGCCGG
 GGTACGTGCTCGCCAAGGAGCTCGAGGCGTTCAGGGAGGCCAAACGTACCGTCCCCTG
 ATTGCTCTACCCACCCAAGACCCCGCCACGGGGGCGCCCCCCCCAGAGATGGCCAGCAAT
 CGGAAGTGAGCAAACTGCCGCAAGTCTGCAGCCCGGCGCCACCATCCTGCAGCCTCCTC
 CTGACCACGGACGTTTCCATCAGGTTCCATCCCGAAAATCTCTCGGTTCCACGTCCCCCT
 25 GGGGCTTCTCCTGACCCAGTCCCCGTGCCCGCCTCCCCGAAACAGGCTACTCTCCTCGG
 CCCCCTCCATCGGGCTGAGGAAGCACAGCAGCATCTTCAAACATGTACAAAATCGATTGG
 CTTTAAACACCCTTCACATACCCTCCCCCAAATTATCCCCAATTATCCCCACACATAAA
 AAATCAAAACATTAAACTAACCCCTTCCCCCCCCCCCCACAACAACCTCTTAAACTAA
 TTGGCTTTTTTAGAAACACCCACAAAAGCTCAGAAATTGGCTTTAAAAAAAACAACCACC
 30 AAAAAAATCAATTGGCTAAAAAAAAGTATTAAAAACGAATTGGCTGAGAAACAATT
 GGCAAAATAAAGGAATTTGGCACTCCCCACCCCTCTTTCTCTTCTCCCTTGGACTIONT
 AGTCAAATTGGCCTGGACTTGAGTCCCTGAACCAGCAAAGAGAAAAGAAGGACCCAGAA
 ATCACAGGTGGGCACGTGCTGCTACCGCCATCTCCCTTCTCACGGGAATTTTCAGGGTA
 AACTGGCCATCCGAAAATAGCAACAACCCAGACTGGCTCCTCACTCCCTTTTCCATCACT
 35 AAAAATCACAGAGCAGTCAGAGGGACCCAGTAAGACCAAAGGAGGGGAGGACAGAGCATG
 AAAACCAAATCCATGCAAATGAAATGTAATTGGCAGCAGCCCTCACCCCCAAATCTTACA
 TCTCAATTCCCATCCTAAAAAGCACTCATACTTTATGCATCCCCGAGCTACACACACAC
 AACACACAGCACACGCATGAACACAGCACACACACAGGACACAGCACACACAAACGCAC
 AGCACACACAGCACACAGATGAGCACACAGCACACACACAAACGCACAGCACACACACGC
 40 ACACACATGCACACACAGCACACAAACGCACGGCACACACACGCACACACATGCACACAC
 AGCACACACACAAACGCACAGCACACACAAACGCACAGCACACACGCACACACAGCACAC
 ACACGAGCACACAGCACACAAACGCACAGCACACAGCACACACATGCACACACAGCACACA
 CACTAGCACACAGCACACACACAAAGACACAGCACACACATGCACACACAGCACACACAC
 GCGAACACAGCACACACGAACACAGCACACACAGCACACACACAAACACAGCACACACAT
 45 GCACACAGCACACGCACACACAGCACACACATGAACACAGCACACAGCACACACATGCAC
 ACACAGCACACACGCATGCACAGCACACATGAACACAGCACACACACAAACACACAGCAC
 ACACATGCACACACAGCACACACACTCATGCGCAGCACATACATGAACACAGCTCACAGC
 ACACAAACACGCAGCACACACGTTGCACACGCAAGCACCCACCTGCACACACACATGCGC
 ACACACACGCACACCCCCACAAAATTGGATGAAAACAATAAGCATATCTAAGCAACTACG
 50 ATATCTGTATGGATCAGGCCAAAGTCCCGCTAAGATTCTCCAATGTTTTTCATGGTCTGAG
 CCCCCTCCTGTTCCCATCTCCACTGCCCTCGGCCCTGTCTGTGCCCTGCCTCTCAGAG
 GAGGGGGCTCAGATGGTGCGGCCTGAGTGTGCGGCCGGCGGCATTTGGGATACACCCGTA
 GGGTGGGCGGGGTGTGTCCCAGGCCTAATTCCATCTTTCCACCATGACAGAGATGCCCTT
 GTGAGGCTGGCCTCCTTGGCGCCTGTCCCCACGGCCCCCGCAGCGTGAGCCACGATGCTC
 55 CCCATACCCACCCATTCCCGATACACCTTACTTACTGTGTGTTGGCCCAGCCAGAGTGA
 GGAAGGAGTTTGGCCACATTGGAGATGGCGGTAGCTGAGCAGACATGCCCCACGAGTAG
 CCTGACTCCCTGGTGTGCTCCTGGAAGGAAGATCTTGGGGACCCCCCACCGGAGCACAC
 CTAGGGATCATCTTTGCCCGTCTCCTGGGGACCCCCCAAGAAATGTGGAGTCTCGGGGG
 CCGTGCACTGATGCGGGGAGTGTGGGAAGTCTGGCGGTTGGAGGGGTGGGTGGGGGGCAG
 60 TGGGGGCTGGGCGGGGGGAGTTCTGGGGTAGGAAGTGGTCCCGGGAGATTTTGGATGGAA
 AAGTCAGGAGGATTGACAGCAGACTTGCAGAATTACATAGAGAAATTAGGAACCCCCAAA

TTTCATGTCAATTGATCTATTCCCCCTCTTTGTTTCTTGGGGCATTTTTCTTTTTTTTTT
 TTTTTTTGTTTTTTTTTTTACCCCTCCTTAGCTTTATGCGCTCAGAAACCAAATTAAACCC
 CCCCCCATGTAAACAGGGGGGAGTGACAAAAGCAAGAACGCACGAAGCCAGCCTGGAGA
 CCACCACGTCCTGCCCCCGCCATTTATCGCCCTGATTGGATTTTGTTCATCTGTCC
 5 CTGTTGCTTGGGTTGAGTTGAGGGTGGAGCCTCCTGGGGGGCACTGGCCACTGAGCCCCC
 TTGGAGAAAGTCAGAGGGGAGTGGAGAAGGCCACTGTCCGGCCTGGCTTCTGGGGACAGTG
 GCTGGTCCCCAGAAGTCCTGAGGGCGGAGGGGGGGGTTGGGCAGGGTCTCCTCAGGTGTC
 AGGAGGGTGCTCGGAGGCCACAGGAGGGGGCTCCTGGCTGGCCTGAGGCTGGCCGGAGGG
 GAAGGGGCTAGCAGGTGTGTAAACAGAGGGTTCCATCAGGCTGGGGCAGGGTGGCCGCCT
 10 TCCGCACACTTGAGGAACCTCCCCTCTCCCTCGGTGACATCTTGCCCGCCCCCTCAGCAC
 CCTGCCTTGTCTCCAGGAGGTCCGAAGCTCTGTGGGACCTCTTGGGGGCAAGGTGGGGTG
 AGGCCGGGGAGTAGGGAGGTGAGGCGGGTCTGAGCCACAGAGCAGGAGAGCTGCCAGGT
 CTGCCCATCGACCAGGTGCTTGGGCCCCGGAGCCACGGGTCTGGTGATGCCATAGCAG
 CCACCACCGCGGCGCCTAGGGCTGCGGCAGGGACTCGGCCTCTGGGAGGTTTACCTCGCC
 15 CCCACTTGTGCCCCCAGCTCAGCCCCCTGCACGCAGCCCGACTAGCAGTCTAGAGGCCT
 GAGGCTTCTGGGTCTTGGTGACGGGGCTGGCATGACCCCGGGGGTGTCCATGCCAGTCC
 GCCTCAGTCGCAGAGGGTCCCTCGGCAAGCGCCCTGTGAGTGGGCCATTTCGGAACATTGG
 ACAGAAGCCCAAAGAGCCAAATTGTACAAATTGTGGAACCCACATTGGCCTGAGATCCAA
 AACGCTTCGAGGCACCCCAAATTACCTGCCCATTCGTGAGGACACCCACCCACCCAGTGT
 20 TATATTCTGCCTCGCCGGAGTGGGTGTTCCCGGGGGCACTTGCCGACCAGCCCCCTTGCCT
 CCCCAGGTTTGCAGCTCTCCCCTGGGCCACTAACCATCCTGGCCCGGGCTGCCTGTCTGA
 CCTCCGTGCCTAGTCGTGGCTCTCCATCTTGTCTCCTCCCCGTGTCCCCAATGTCTTCAG
 TGGGGGGCCCCCTCTTGGGTCCCCCTCCTCTGCCATCACCTGAAGACCCCCACGCCAAACA
 CTGAATGTCACCTGTGCCTGCGCCTCGGTCCACCTTGCGGCCCGTGTCTTGAATCAACTC
 25 AACTCCTTTAACGCTAATATTTCCGGCAAATCCCATGCTTGGGTTTTGTCTTTAACCTT
 GTAACGCTTGCAATCCCAATAAAGCATTAAGTCAATGA

SEQ ID NO:19

30 ENSG00000167244

TCTTTGCCTCTTCCTGAGTCTTTGCTAGCTTGGGGAAGAGGTTAGAAATTTCCAGTG
 TGATTTAGTCCAATCTGGTGGATGCTTCTATATGAACCTCAGCCAGCTGCTGTCAG
 35 CTTTGAGTCTGTGCTTTAATTAGAAAGGCTGCGAACCTGTCCAATCGCCCAATCCAG
 AAATGCCTGCAAGTGCCCCCTGCAGCAGTGTCTATTAGAGCTTAGTACCACACAGGGA
 GTGTCTGAGGTCAGATCAGACGTGACCAGTGAAGTGAAAAACCCCCAGCTGAGTAC
 CTTGCTCATGGAAGATGGAAGGACATAACTGCACAGTACATAACTGTACCGGGAGCA
 CCTAAAATCCAATTTTTCTGCTGATTCTTGAACCTGCTTTGTCCCCCTTATTCCCC
 40 CCCCCCGCCATTTTACCAGTGCCACGTCCACCAACATTCCAGGGTGTCAAGTAAC
 TGCCAAGTGTCACTCTAAGTAAAGCTACACCCACTCCCCACCACCTCCACATAGCCC
 CCACCTCCTAGCTGGCAGGGAGCTTCTGGCTTATGCCCACGCCACAGGCGCCTTTC
 TGCCAGGTGAGGGGTGGGCCAAACCTCCACCCGCTAATGTACCATGCCCTGGTGCTG
 GAAAGTGCCTGAGCCAGCTGCCCCAGCGGCCTCAGCACTACCAAGTTGGCACAAGC
 45 TCCCCAAATTCGGAGGGGCTCAGGGAAACGAGTGGAGGGGATGAGGAGGTGAGGGGT
 AAACCCATCATTTTCAAGTTGGCATTTGAGCAGGTGCCATGCTCAGCGGAGATGAGGCT
 CTCCCATCTGTAGGGGCCGTATTAACATGCACACTCTAAAAG
 TGCCCTTCGTTTCTCCAGCCTCAGCTTTGTCCCTCTCCTCCTCCACGTCAACCTGGCCAG
 AGGGTCTGGACGCCACAGCCAGGGCACCCCTGCTTTGGTGGTGACTGCTAATATTGGCC
 50 AGGCCGGCGGATCATCGTCCAGGCAGTTTCGGCAGAGAGCCTTGGGCACCAGTGACTCCC
 CGGTCTCTTTATCCACTGTCCAGGAGCTGCGGGGACTGCGCAGGGACTAGAGTACAGGT
 AACTGGGCTCCCATCCCTTGAGTGTGAGAGAAAAGCTGCACCTTTAAGTGTTTCAAGCGTGG
 GTGGGCCGGGAGCTTGGGGCAGCTGCCAGGATCCTGGTTTCTGAAGGAGGGGAAGAACTT
 CTGCTGCTGGAGGGTGCAGGGAAGCCTCCTGAGAGCAGCCTCAACTTCAGGGATGGGGTG
 55 TGCAGGAAAGGCCATTGTGAGAGGGTTCTCCTTTAGGGCTGCACAAAGCCACTGAGGCT
 TTTGCAAGGAAAATAGGTTTTCCTTGACTAATTCACCAAGCAAAATGGGAGGGGTAGGGG
 AGGAGGGCTAGGCCGCTCTTCCCAGCGGGAACACACAGCTGTCTTCACAAGTGTGAAAGG
 AAGAGTCTTTCTGTGTGAAAAGTTTCTCCCGTTGCATCCCCCATCCCATTTCCAGAGAC
 AAACAGGAGACTTTGCAGAGGAGCCAGGGGCCGAGATTCTGGCGCAGAGATTTTATTTA
 60 TACATATATACACCATTTTACAGGTAAAGCTTCCTTCCCTCCTGCCTCCCTATGCCTCCT

GACCACCAGCAAGAAATTGGACAGGAGACTGAGGAGAAATGCCGGGAGAGGCAACAACCG
 CCCTCCATGTCCCCCTAGGTTTAGCTTCTCTCCTCCTGATGGCGCACCTGGTCCCCCTT
 GCTGCTCTCCCAGCCTCCCTGGCACAGAGAGGCGCCCTGGGGCCAAGGCAGTTTCCCTGG
 GAATGCTCATTTCATGCATGAAGTTTTTCTCTGTTGCACCCTGGACCCAGACTCCTCGATC
 5 CACCCAGGGTGGTGTCTGTGGGGAGGGGGTTTCAATTTCCCCAGGAAGCACAGCCACGCCGT
 CCCTCACTGGCCTCGTCAAGCAGAGCTGTGTGTCCAGTGGCTTTTGCTGGGGCCCCCTCC
 TTATCTCCTTCCAAGGTGGGGGTGTTTGGAGGTGGAGGAGGCTTTCATATTCCGTGCCAT
 GACCCCTCAAGGCGGGCCATTTCGTGTGCACCCTCCACCCCAAGTGCCAGGCAGAAGCCCA
 TCCTCACCCAGGAACAGGGCAGCCTGTCCAACAGAAGGGTCTCGGCCTCTCCATCAGCAC
 10 CGGGAAGCCCTTTCTAGGCAAACCTTCTCACCACCTTCTTCCCTCCCTTATACTTTGAAAGA
 GGGAGCTCTAGGCAGGGGAGGGGCTAGAGGGGGAAGCCGCTGCCAGATCCTGACAAGGT
 GACCTGAAGGAACCCGGGGAGGGGGATGGGACAGGGCTCAGGCTTGGGGTGTATGGGGAG
 GGGGGCTTTGCTTTTAAAAGAGGTTCATCTCAGCAATATCTTTTGTTTTCCCCAGGGGC
 CGAAGAGTCACCACCGAGCTTGTGTGGGAGGAGGTGGATTCCAGCCCCAGCCCCAGGGC
 15 TCTGAATCGCTGCCAGCTCAGCCCCCTGCCAGCCTGCCCCACAGCCTGAGCCCCAGCAG
 GCCAGAGAGCCCAGTCTTGAGGTGAGCTGCTGTGGCCTGTGGCCAGGGCGACCCAGCGC
 TCCCAGAACTGAGGCTGGCAGCCAGCCCCAGCCTCAGCCCCAACTGCGAGGCAGAGAGGT
 GAGTGTCTCAGGCACCCTGAGGCCTGGCAGAGAGGGCCACAGGCTCTGCGCGGGAGTCTT
 CGAACTGGGATCTCCCCCTTCTGCAAGCAGCTTTGGCTCAGAGAGGCTGGCGTGGATTCA
 20 GTCACACAGCTGGGATCTGGAGTTCCGTGGTTGGCTCCAGGTGCTTCCGTCTAGGGGCCA
 GAGCAGGTGTGGGCAGAGCAGGTTCCCCCGCAGTCTCCACGGCACCGAGGTCTTGGCAGGG
 GAGCTCCTGGGAGACGAAAGAGGGCAAAGAAGGGGAGAGGGGCAGGGAGAGAGCGGGCAG
 CCAAAGGGGAGAAGATGGGGGGCAGAAAGTGGGTAGAGAGGGAAAAAGGGAAAAATATCAT
 TGGGGAAGAACCTAAAAACCCAAGGAAAGCTGGGCTCTGCTGGGGGCTGTGAGACCCCCG
 25 GGTCTCCCCGCCCCAGGCTGCTGGCCATGGGGTCTTGCACCAATGGCCTGACCTTTCTG
 TCGGTCTGTATTTATCAAAGTGGGTGACAGTCTCAGGCCTCCTGGCTGTTTCAAGATTGAG
 GTAATAACCAGAGGCCTTCTGAGCAAAGGGCCTAAGGGGCTCCGGCGTCAGGATCCCATT
 GTGGTCAGGAGCCTGCGGGGCTTCCCGTGTGCAAGAGGGGTGAAAGGTGGCTAGAAAGGC
 CCAGCCAGTGGCCTCTGCCTCAGCCAGAGGGAGCTCTGTAGTGGGGGCAGCACCCATTCA
 30 CTGGTCAGGCACTGGGGTGACAGGGGAGGCTCCAGGACTTGGGGAGCGTTGGAGCTGGAG
 GCACATGGATTGGAGTCCCTGTACCTGCCCCACGACAGGGCCTGCAGGGAGGGATCCAGC
 AGGTGACTCTTCAGGCTGATTTGCCCATCCAGATAGAAGCCGGGAGTGTTCTTTCAAAG
 GTGTCTTTACCTTAGACACTCAATAAAATGGTAACACAGTGGCGCCGCCTCAGTCCTTTG
 GAGTGTGCACCGTCTGAACCCCTCTCCAGGGCCCTCTCCAAGCACCCCAACCTGGACC
 35 CATATCCCCACGTACTTTTGGCTTTGGGCAGATTGAGCAGCCTTGGGGTGGTCTGTGCT
 GTCTGGTGTGGAGGGTTGCAGTTCGGGTCTTAGTCTTACTTCCCAGGCCGGCCGGGCTG
 ACGCCAGCGAGTGTGTCTTCCCCAGCGAGGGGAGTGAGCGCAAGGTCAGCGCCTCGTCT
 GCGGCGCCCTGCAGGGGGTGACGGAGGGGGCGCTCTGAGGACCCTTGGAGAAAGGAGCTGG
 GTTTGTAAAATGCTGGGCTTGGTCCCACGGACGGCGGAGCGGTGAGCTCAGAGCCAGAGC
 40 TGGGGAGGAAATGGGAATGAGAAAGGCCCACTTCAGGGCTGGTGAGCGAGGGGATGGGGA
 GCAGCCACAGGCCGAGGCTGGGGCATGGGCCAGGCTCCATGGGGTGAGTCTGAGTCCTTG
 AGGGGATGTTTCATCCTCTGTGGAATGTGGGTTTGCCAGTGGAGAGGAGACCAGCGTTGCC
 CTGGTGAGGTGCTGGTTTCAAGGCTGGGGGGCGGACGCTGCTTGGGGCTAAAGTTCTTGCC
 GGCCAAGCTCTGGGTGGGAGGAGACCCTGGCCCCCTCCCAACACCCTTGGACTGCTGGCG
 45 GGACCCTTCTTACCTCCGGGGGCTGGAAGTAGTGGGGGAGGAGCCAGTCTTGAGGAAGAA
 CCCCAGATGCTGGTCTTGACTAGAGGGGAGCCGGTGTGCTTTTCGAGCCTCAGGGTGACCC
 GCGTCTGCCCCAGCCTCCAGCCTGCCCTGGTCACTTCTGACTAAATAAGGAGAGCACTCA
 GCAGGCAGCCCCACGAGGGAGGGGGAACATGTGTGCACCCCCACTCCCCACCTGCTCCT
 CCCTCCCTACAGGGCCACTACACCCTGCTGTGGGCACCCCAAGGTGACCCTCAGCCTTCT
 50 TCCTACCTTAAAAAGTCCAGGCATGCATTTTCAAGCATGAGCGGTGGCCCCCTGGGGGAA
 GGCACCTCGGCAGGGCAGAACAAAGGGAAGGGACCCCCAAACAGGTCACTGGTGTAATTG
 TCCCCAGCACCCCCAAAGAGGAGGAGAACCACAACTCGGAACTGGGGCTCACCCCCGAT
 GCCCAACCTGTCCCCAGCCTGGGAAGCAGGCGTGGAGGAGAAGGTGGGGGGAGCCTAGAG
 CTGGCCCTGGGGGCCCTGGTTTTGTCCATGACGGGAGCCTCGGCAACCTAGTCCGCTCTC
 55 CCGGGGACCAGGTTTGCAGACAGGCACCTTTCAAATGCTCCTCACCCCCAAATTTACAAG
 TCACCCTGCAGAGGAAAACATCAACACAGCCAGGGGTTCTCTGCTGGAGGCTCCCCCTTC
 TATAGGCACAGCCGGAGAGGCCAGAGAGCTGGGGACACGGGGAGGCTGCAGAAGGCTGGT
 GGGAAAGGGGGCAGTGATGGGTGGGGAGAGATGGGCCAGATGTTCTTGGAATGGGACATG
 GGGGTGATTGATGCAGACAGAAATTTGAAGGGGACATTTCCACGTGTCTTGTCTGTGGG
 60 TGGAAAATGGGCTGTTTTTTCATGGTGGGGGGCGGGTTCTCCCTGTCTTGCCAAGCTAATGT
 GAAAGAGATGCCTCATCCTGCCAGCTCCCCACACCTGTCCAAGGCCATTAACCTTCTGCC

106

CATTGTTCCCGGCTCGCCGGCCACCCACTGCAGCTTCCCCAACCCCGCGCACAGCGGGCA
 CTGGTTTCGGGCCTCTCTGTCTCCTACGAAGTCCCCAGAGCAACTCGGATTTGGGAAATT
 TCTCTCTAGCGTTGCCCAAACACACTTGGGTGCGCCGCGCGCCCTCAGGACGTGGACAGG
 GAGGGCTTCCCCGTGTCCAGGAAAGCGACCGGGCATTGCCCCCAGTCTCCCCCAAATTTG
 5 GGCATTGTCCCCGGGTCTTCCAACGGACTGGGCGTTGCTCCCGGACACTGAGGACTGGCC
 CCGGGGTCTCGCTCACCTTCAGCAGCGTCCACCGCCTGCCACAGAGCGTTCGATCGCTCG
 CTGCCTGAGCTCCTGGTGCGCCCGCGGACGCGAGCCTCCAGCTTCGCGGTGAGCTCCCCGC
 CGCGCCGATCCCCTCCGCCTCTGCGCCCTGACCGGCTCTCGGCCCGCATCTGCTGCTGT
 CCGCCCGGTGCTGGCGCTCGTCTCCGGCTGCCGCCGGGAGGCGGCGTGGGGCGCGGGA
 10 CACGGCTGCGGACTTGCGGCTGGCGGCTGCGCTCGCTCCTGCTGGGCGCCCCGAAATCCG
 CGCCACTTTTCTTTGCTCATTGCAAAGATCTCATTTGTGGGAAAGCGGCTGGAGGGTCC
 CAAAGTGGGGCGGGCAGGGGGCTGGGGCGAGGGACGCGGAGGAGAGGCGCTCCCGCCGGG
 CGGTAAAGTGCTCTAGCCCGCGGGCCTAGGACTCCGCCGGGAGGCGCGCGCGGAGCGCG
 GGCGAAGTGATTGATGGCGGAGCGAGGGGGGCGAGGGGGGCGAGGGGGCGCGAGATTCC
 15 GCCGGCGGCCCCCTTCCCCCTTGGCTAGGCTTAGGCGGCGGGGGGCTGGCGGGGTGCGGGAT
 TTTGTGCGTGGTTTTTTGACTTGGTAAAAATCACAGTGCTTTCTTACATCGTTCAAACCTCT
 CCAGGAGATGGTTTCCCCAGACCCCCAAATTATCGTGGTGGCCCCCGAGACCGAACTCGC
 GTCTATGCAAGTCCAACGCACTGAGGACGGGGTAACCATTATCCAGATATTTTGGGTGGG
 CCGCAAAGGCGAGCTACTTAGACGCAACCCCGGTGAGCTCGGCCATGCAGGTAGGATTTGA
 20 GCTGTGTTTCCCGCCCTGATCCTCTCTCCTCTGGCGGCCGAGCCTCCGTAGGCTCCAAG
 CCTGGCCCAGATTCCGCCCGGCGCAGCCGGCCTTCCGCGCGTCCCGCACCTGGCGGGGGC
 TCCGGGGCTCCGGCGCGGCACCGGGGGGCGCTCGGGATCTGGCTGAGGCTCCAAGCGCCG
 CGTGGCCCGCTCCTCCTGCTGGGGCAGGTGGCGGCTGCGCGCCCCCGCCGAGCCAGGGG
 CCCCCTCAGCCGCAACAACAGCAAGGACCCCCGACTCAGCCCCAAGCCACCTGCATCT
 25 GCACTCAGACGGGGCGCACCCGCAAGTGCAGCCTCCTGGTGGGGCGCTGGGAGCCCGCCTG
 CCCCTGCCTGCCCGGAGACCCAGCTCACGAGCACAGGCCGCCCGGGCACCCAGAAACC
 CGGGATGGGGCCCCCTGAATTCTCTAGAACGGGCATTACGATGGCCTTGGCGCTCTGCGG
 CTCCCTGCCCCCACCCAGCCTCGCCCCCGCGCACCCCCAGCCCTGCGACCGCCGCCC
 CCCCCCGGGGCCCCAGGGCCCCCAGCCCGCACCCCCCGCCCCGCTCTTGGCTCGGGTTG
 30 CGGGGGCGGGCCGGGGGCGGGGCGAGGGCTCCGCGGGCGCCATTGGCGCGGGCGCGAGG
 CCAGCGAGGCCCCGCGCGGGGCCCTGGGCCGCGGGCTGGCGCGACTATAAGAGCCGGGCGTG
 GCGGCCCGCAGTTTCGCTGCTCTCCGGCGGAGCTGCGTGAGGCCCGGCGGGCCCCGGCCC
 CCCCCTTCCGGCCGCCCCCGCCTCCTGGCCACGCTGCCCCGCGCTCTGCCACCGAGCGC
 CTCCATCGGGCAAGGCGGCCCCGCGTCCAGCGCCCGCTGCCTCGCTGCTGACTCCCGT
 35 CCCGGGCGCCGTCCGCGGGGTGCGGCTCCGCCGGGCTGCGGATTCCCCGCGCCTCCTC
 TTCATCTACCTCAACTCCCCCATCCCCGCTTCGCCCGAGGAGGCGGTTCCCCCGCAGG
 CAGTCCGGCTCGCAGGCCGCGGGCGTTGTACCCCCCCCCCGCGCTCCCCCTCCAGCCCTC
 CCCCCGGCGCGCAGCCTCGGGCCGCTCCCTTTCCGCGCTGCGTCCCGGAGCGGCCCCGG
 TGCCGCCACCGCCTGTCCCCCTCCCGAGGCCCGGGCTCGCGACGGCAGAGGGCTCCGTG
 40 GCCCAAACCGAGCTGGGCGCCCGCGGTCCGGGTGCAGCCTCCACTCCGCCCCCAGTCAC
 CGCCTCCCCCGGCCCTCGACGTGGCGCCCTTCCCTCCGCTTCTCTGTGCTCCCCGCGCC
 CCTCTTGGCGTCTGGCCCCGGCCCCCGCTCTTTCTCCCGCAACCTTCCCTTCGCTCCCTC
 CCGTCCCCCCCCAGCTCCTAGCCTCCGACTCCCTCCCCCCCCCTCACGCCCCGCTCTCGCCT
 TCGCCGAACCAAAGTGGAATTAATTACAGCTTTTCTGTTTCTCTCCGTGCTGTTCTCTCCC
 45 GCTGTGCGCCTGCCCGCCTCTCGCTGTCTCTCTCCCCCTCGCCCTCTCTTCGGCCCCC
 CCTTTCAGTTCACTCTGTCTCTCCCACTATCTCTGCCCCCTCTATCCTTGATACAACA
 GCTGACCTCATTTCCCGATACCTTTTCCCCCCCCGAAAGTACAACATCTGGCCCCGCCCA
 GCCCGAAGACAGCCCGTCTCCTCCCTGGACAATCAGACGAATTCTCCCCCCCCCCCCAAAAA
 50 AAAGCCATCCCCCGCTCTGCCCCGTGCGACATTCCGCCCCCCGCGACTCGGCCAGAGCGG
 CGCTGGCAGAGGAGTGTCCGGCAGGAGGGCCAACGCCCGCTGTTCCGGTTTGCGACACGCA
 GCAGGGAGGTGGGCGGCAGCGTCGCCGGCTTCCAGGTAAAGCGGCGTGTGCGGGCCGGGCC
 GGGGCCGGGGCTGGGGCGGCGGGGCTTGCGCCGGACGCCCGGCCCTTCTCCTCCGCCCGCT
 CCCGGCCCCGGGGCCTGCGGGGCTCGGCGGGGCGGCTGAGCCCCGGGGGGGAGGAGGAGGAG
 GAGGAGGAGGACGGACGGCTGCGGGTCCCGTTCCCTGCGCGGAGCCCCGCGCTCACCTG
 55 GCGGCGGAGCTGGGGGTGGGGTGGGGGCGTCGGGAAGGGCCGAGGGAGGTGTGAGGTGTC
 TGCAGGGGCGACTTCCCGGTGCGTCTGTGGGTGCAGGGGGTGCCGCCTCACATGTGTGAT
 TCGTGCCTTGCGGGCCCTGGCCTCCGGGGTGCTGGGTAAAGAGGAGGGGCGCGGAGCCGC
 AGAAGCCCACCTGGTATGTTGACGCGGTGCCAGCGAGACCGCGAGAGGAAGACGGGGGT
 GGGCGGGGCCAGGATGGAGAGGGGCCGAGTTGGCAGGAGTCATGGCAGACGCCACATTG
 60 CGACATCTCCCCACACCCCTCTGGCTCTGTCCGCAACATTTCCAAACAGGAGTCCCGG
 GAGAGGGGGAGAGGGGCTGCTGGTCTGAGGCTAAGAAGGGCAGAGCCTTCGACCCGGAGA

GAGGCCGCGGCCCTGCCCAGTGGGCAGCGTGGAAGTTTCCATACAAGGAGGTGGGAAGG
 AGACCCCCCCCCCTTCACTGCCCTGTGCAGAGATGAGCCGGGGGTGCAGGATGGGAGCC
 CATGGCACTTCGCTACGGGATGGTCCAGGGCTCCCGGTTGGGGGTGCAGGAGAGAAGAGA
 CTGGCTGGGAGGAGGGAGAGGGCGGGAGCAAAGGCGCGGGGAGTGGTCAGCAGGGAGAG
 5 GGGTGGGGGGTAGGGTGGAGCCCGGGCTGGGAGGAGTCGGCTCACACATAAAAGCTGAGG
 CACTGACCAGCCTGCAAAGTGGACATTAGCTTCTCCTGTGAAAGAGACTTCCAGCTTCCT
 CCTCCTCCTCTTCTCCTCCTCCTCCTGCCCCAGCGAGCCTTCTGCTGAGCTGTAGGTAA
 CCAGGGCTGTGGAGTGAGGACCCCCGCTGCCATCCCACTCCAGCCTGAGGCAGGGCAGCA
 10 GGGGGCACGGCCACGCCTGGGCCTCGGGCCCTGCAGCCGCCAGCCCGCTGCCTCTCGGA
 CAGCACCCCCCTCCCCTCTTTTCTCCTCTGCCCTGCCCCACCTGGTCTCTGCTCCCTCAC
 CTGCTCCTTCCCCTTCTGTTCCCTTCCCTTCGGCCCCCTCCTTGCCCAGCTCAGGACTTTT
 CCTGGGCCCTCACCTGCTCCGCACCGCTGCATGCTTCTGCTCCTGCTTTCTGCCGGTCCC
 CTGACCCGGACCTCCAAGTTCAGAGTGGTGGGGCTTGTTCGGAAGCGCGGGCAGGGCTA
 15 GAGTGGCCAGCTGGCGGAGTGTGCTCTTAGAATTTGGAAGGGGGTGGCAGAGGGGGCGGT
 GAGAGGACTGGCCAGGGTCCAGTCAAGGAGATGACCAAGGAGGCTTTCAGATCCTCGGCG
 CAGCTGCCCACTAGTCTTTAGAGAGGGCATGCAAAGTTGTGCTTCTGTCCCACTGCCTGC
 TCAGTCGCTCACATAATTTATTGCATCAAAAACCTCCCCTGGGTCTGCGGAGCGAAGGCTG
 GGGCTGCCCGCCTGGAGGGTTCACCTTCTGCAGGGGCAGGGCCAACTTGCTGTGGTGGC
 20 TCCCGGCCTCCCACCCCCGAGTGGGTAAACCCGGCCCTGTGGCCCTGCAGCCTGTGGAGG
 GGGTGTGTCCTAAGACTGGCCTCCCCTTCCAGATTGTAGTCTGGGGAACCTGGTGTGCGA
 CTTCCCAGGTGGCCTGAGCTGGTCTCTCCAGCTCCCACGGGGAGAGTTTGGTAGCGCAA
 TAGGGAGATGTTCTGGAGGCCCTGGCCTTACTGGTTTCGATTTGAGGCCTGGAAAGGAGG
 CTCTGGGCGTGTGTGTGTGTGTTTGGGGGTACCCAAGGCAGACTGGAGTTGGAGAACTGG
 25 GTGACTGGGAAAACAAGGTTTCTAGAGCATGGGTGGCGTGGTTGTGTTAACCATTGGAGT
 CCTTGACCCAGGCCTGGCTCAGCTGCAGACTGGAAAGGTGGAAAAGCCAGGGGGAGGGGC
 GGGGCTGGCCAGCAGGACTGGCCTGCTGCTTTGAGGGCGATGGTCCTCCTGGACCCCC
 CTGCTCAGCTGGGGGTTGTGGGGAGGAAGGGACTGGTCCTCCTGGATGCACATGCTCTGT
 AGGGGTGGGGCTGTCTGCCATCTTGGCTGGCGCTGGAGGCCTGAGAAGTGGCGATGTGAC
 30 GCTGGGCTGGCCCTGCCCCCATGGTGTCTAGGACGGAGGCCAGGTCGGGTGTCCAGCCT
 GGGCCCCTGCAGCTGTGGATGCCGCTGAGCTCCTGCAATAATGACCGTGGAGATGGTCAC
 CCCTCGTGTAATAATTACTAGTGCTTCTTGCAAATGGAAGGAAGTGGGCCTTTTCTGTGTG
 CTTCTGGACGCTTCATTCTGCACATGGCCCTGCGCCCTCACCTCGGCATTATGACCTGTG
 TGTACTTTTGTAAATAAAATAATGTTTATAGGAAAGCCGTGCTTTCAATTTTCAACTGA
 35 ATTTGTAGGTTGGCAAATTTGGTTTGGGAGGGGCACCTCTGGCCTGGGGCTTGGCCTGGC
 TGCCCCGCTCACGCCACTTCTCTCCCGCCCCCAGACACCAATGGGAATCCCAATGGGGAA
 GTCGATGCTGGTGTCTTCTACCTTCTTGGCCTTCGCCTCGTGCTGCATTGCTGCTTACCG
 CCCCAGTGAGACCCTGTGCGGCGGGGAGCTGGTGGACACCCTCCAGTTCTGTCTGTGGGA
 CCGCGGCTTCTACTTCAGTAAGTAGCTGGGAGGGGCTTCCCTCAGACCTGGTCAGGCCCT
 40 AGAGTGACCGGTGAGGACGCCCAACCTCAAGCCAGGGGAGCACACTCCTAGGTGAGCAGC
 CCAGCCGCTTGCTCTGAGACTTTGACCTTCCCGCCGCGTTTCTGAGCACGTGCGGTGTCC
 CAGGGCATCCACACCAGCTGCCTTTCCCATCACACGCCTCCTTCGAAGGGTGGGCCAGAG
 GTGCCCCCTAGACGTGAGGGGCACTCACAGGGGTCTCCCTGGGCATCAGAATTTCTGTTG
 GGGGCCGTGAGGCTCCTGCTCCTGAGGCACCGCACGCCTAGTGACGGCTTCCAGGCTCTG
 45 GAGGAAGAGCCTGCCTTTCTTCTGACCTTTTGGACATTCTGACAAGGGACGTGCGTTC
 GGTGAATGATCAGAATTAAATCAATAAAGTGATTTATATAATTAATAAATCAATAAGACAA
 GTGCAGTTGGTGGGTGGCAGGGGTGAGCGGTGCATGCGCCTCCTTGGGCCCCAAGGCTGC
 CGTGGGGGGTGGCCACCTGCTGACCTCAAGGACGCTTCAGCCTTTCTCATGTTTCTCTC
 TTGGTTCTCCAGCCTGGGGGCTGGCAGGTGGGTGCATGGCCATTGTCTTGAGACCCCA
 50 CCCCAGATAGGGGGGCTGGGTGGATGCAGAGGCAGGCATGGTGCCTGGGCATGCCTGAT
 GGGGCAGGGGAGGGGCCGCTCCTTACTGGCAGAGGCCGCACGGCTTATCCACCTGACAC
 TCACCACGTGACATCTTTACCACCACTGCTTACTCACGCTGTGAAATGGGCTCACAGGAT
 GCAAATGCACTTCAAAGCTTCTCTCTGAAAAGTTCCTGCTGCTTGACTCTGGAAGCCCCT
 GCCCGCCCTGGCCTCTCCTGTGCCCTCTCTCTTGCCTGCCCCATTGGGGGTAGGAAGTG
 55 GCACTGCAGGGCCTGGTGCCAGCCAGTCCTTGCCAGGGGAGAAGCTTCCCTGCACCAGGC
 TTTCTGAGAGGAGGGGAGGGCCAAGCCCCCACTTGGGGGACCCCCGTGATGGGGCTCCT
 GCTCCCTCCTCCGGCTGATGGCACCTGCCCTTTGGCACCCCAAGGTGGAGCCCCCAGCGA
 CCTTCCCCTTCCAGCTGAGCATTGCTGTGGGGGAGAGGGGGAAGACGGGAGGAAAGAAGG
 60 GAGTGGTTCCATCACGCCTCCTCACTCCTCTCCTCCCGTCTTCTCCTCTCCTGCCCTTGT
 CTCCCTGTCTCAGCAGCTCCAGGGGTGGTGTGGGGCCCTCCAGCCTCCTAGGTGGTGCCA
 GGCCAGAGTCCAAGCTCAGGGACAGCAGTCCCTCCTGTGGGGGCCCTGAACTGGGCTCA
 CATCCCACACATTTTCAAACCACTCCCATTTGTGAGCCTTTGGTCCTGGTGGTGTCCCTC

TGGTTGTGGGACCAAGAGCTTGTGCCCATTTTTTCATCTGAGGAAGGAGGCAGCAGAGGCC
 ACGGGCTGGTCTGGGTCCCCTCACCTCCCCTCTCACCTCTCTTCTTCTGGGACGCCTC
 TGCCTGCCAGCTCTCACTTCCCTCCCCTGACCCGAGGGTGGCTGCGTCCTTCCAGGGCC
 TGGCCTGAGGGCAGGGGTGGTTTGTCTCCCCCTTACGCTCCGGGGGCTGGGGTCAGTGCG
 5 GTGCTAACACGGCTCTCTCTGTGCTGTGGGACTTCCAGGCAGGCCCCGCAAGCCGTGTGAG
 CCGTCGCAGCCGTGGCATCGTTGAGGAGTGCTGTTTCCGCAGCTGTGACCTGGCCCTCCT
 GGAGACGTACTGTGCTACCCCCGCCAAGTCCGAGAGGGACGTGTGACCCCTCCGACCGT
 GCTTCCGGTGAGGGTCTTGGGCCCTTTCCCCTCTCTAGAGACAGAGAAATAGGGCTTC
 10 GGGCGCCAGCGTTTCTGTGGCCTCTGGGACCTCTTGGCCAGGGACAAGGACCCGTGAC
 TTCCTTGCTTGCTGTGTGGCCCCGGGAGCAGCTCAGACGCTGGCTCCTTCTGTCCCTCTGC
 CCGTGACATTAGCTCAAGTCACTGATCAGTCACAGGGGTGGCCTGTGAGGTGAGGCGGG
 CGGCTCAGGCGGAAGAGCGTGGAGAGCAGGCACCTGCTGACCAGCCCTTCCCCTCCCAG
 GACAACCTCCCCAGATACCCCGTGGGCAAGTTCTTCCAATATGACACCTGGAAGCAGTCC
 15 ACCCAGCGCCTGCGCAGGGGCTGCTGCCCTCCTGCGTGCCCGCCGGGGTACGTGCTC
 GCCAAGGAGCTCGAGGCGTTCAGGGAGGCCAAACGTCACCGTCCCCTGATTGCTCTACCC
 ACCCAAGACCCCGCCACGGGGGCGCCCCCCAGAGATGGCCAGCAATCGGAAGTGAGCA
 AAACGCGCAAGTCTGCAGCCCGGCGCCACCATCCTGCAGCCTCCTCCTGACCACGGAC
 GTTTCATCAGGTTCCATCCCGAAAATCTCTCGGTTCCACGTCCCCCTGGGGCTTCTCCT
 20 GACCCAGTCCCCGTGCCCCGCTCCCCGAAACAGGCTACTCTCCTCGGCCCCCTCCATCG
 GGCTGAGGAAGCACAGCAGCATCTTCAAACATGTACAAAATCGATTGGCTTTAAACACCC
 TTCACATACCCTCCCCCAAATTATCCCCAATTATCCCCACACATAAAAAATCAAAACAT
 TAAACTAACCCCTTCCCCCCCCCCCCACAACAACCTCTTAAACTAATTGGCTTTTTAG
 AAACACCCCAAAAAGCTCAGAAATTGGCTTTAAAAAAAACAACCACCAAAAAAATCAA
 25 TTGGCTAAAAAAAAGTATTAAAAACGAATTGGCTGAGAAACAATTGGCAAAATAAAG
 GAATTTGGCACTCCCCACCCCTCTTTCTCTTCTCCCTTGGAATTTGAGTCAAATTGGC
 CTGGACTTGAGTCCCTGAACCAGCAAAGAGAAAAGAAGGACCCAGAAATCACAGGTGGG
 CACGTGCTGCTACCGCCATCTCCCTTCTCACGGGAATTTTCAGGGTAAACTGGCCATCC
 GAAAATAGCAACAACCCAGACTGGCTCCTCACTCCCTTTTCCATCACTAAAAATCACAGA
 30 GCAGTCAGAGGGACCCAGTAAGACCAAAGGAGGGGAGGACAGAGCATGAAAACCAAATC
 CATGCAAATGAAATGTAATTGGCAGCACCCTCACCCCAAATCTTACATCTCAATTCCCA
 TCCTAAAAAGCACTCATACTTTATGCATCCCCGAGCTACACACACACAACACACAGCAC
 ACGCATGAACACAGCACACACACGAGCACAGCACACACACAAACGCACAGCACACACAGC
 ACACAGATGAGCACACAGCACACACACAAACGCACAGCACACACACGCACACACATGCAC
 35 ACACAGCACACAAACGCACGGCACACACACGCACACACATGCACACACAGCACACACACA
 AACGCACAGCACACACAAACGCACAGCACACACAGCACACACAGCACACACAGGACACAC
 AGCACACAAACGCACAGCACACAGCACACACATGCACACACAGCACACACACTAGCACACA
 GCACACACACAAAGACACAGCACACACATGCACACACAGCACACACACGGAACACAGCA
 CACACGAACACAGCACACACAGCACACACACAAACACAGCACACACATGCACACAGCACA
 40 CGCACACACAGCACACACATGAACACAGCACACACAGCACACACATGCACACACAGCACA
 CGCATGCACAGCACACATGAACACAGCACACACACAAACACACAGCACACACATGCACAC
 ACAGCACACACACTCATGCGCAGCACATACATGAACACAGCTCACAGCACACAAACACGC
 AGCACACACGTTGCACACGCAAGCACCCACCTGCACACACACATGCGCACACACACGCAC
 ACCCCCAAAAATTGGATGAAAACAATAAGCATATCTAAGCAACTACGATATCTGTATGG
 45 ATCAGGCCAAAGTCCCGCTAAGATTCTCCAATGTTTTTCATGGTCTGAGCCCCGCTCCTGT
 TCCCATCTCCACTGCCCCCTCGGCCCTGTCTGTGCCCTGCCTCTCAGAGGAGGGGGCTCAG
 ATGGTGCGGCTGAGTGTGCGGCCGGCGGCATTTGGGATACACCCGTAGGGTGGGCGGGG
 TGTGTCCCAGGCCTAATTCCATCTTTCCACCATGACAGAGATGCCCTTGTGAGGCTGGCC
 TCCTTGGCGCCTGTCCCCACGGCCCCCGCAGCGTGAGCCACGATGCTCCCCATACCCAC
 50 CCATTCCCGATACACCTTACTTACTGTGTGTTGGCCCAGCCAGAGTGAGGAAGGAGTTTG
 GCCACATTGGAGATGGCGGTAGCTGAGCAGACATGCCCCACGAGTAGCCTGACTCCCTG
 GTGTGCTCCTGGAAGGAAGATCTTGGGGACCCCCCACCGGAGCACACCTAGGGATCATC
 TTTGCCCGTCTCCTGGGGACCCCCCAAGAAATGTGGAGTCCTCGGGGGCCGTGCACTGAT
 GCGGGGAGTGTGGGAAGTCTGGCGGTTGGAGGGGTGGGTGGGGGGCAGTGGGGGCTGGGC
 55 GGGGGGAGTTCTGGGGTAGGAAGTGGTCCCGGAGATTTTGGATGGAAAAGTCAGGAGGA
 TTGACAGCAGACTTGCAGAATTACATAGAGAAATTAGGAACCCCCAAATTTTCATGTCAAT
 TGATCTATTCCCCCTCTTTGTTTCTTGGGGCATTTTTCTTTTTTTTTTTTTTTTGT
 TTTTTTACCCCTCCTTAGCTTTATGCGCTCAGAAACCAAATTAAACCCCCCCCCCATGTA
 ACAGGGGGGAGTGACAAAAGCAAGAAGCACGAAGCCAGCCTGGAGACCACACGTCCT
 60 GCCCCCGCCATTTATCGCCCTGATTGGATTTTGTTTTTTCATCTGTCCCTGTTGCTTGGG
 TTGAGTTGAGGGTGGAGCCTCCTGGGGGGCACTGGCCACTGAGCCCCCTTGGAGAAGTCA
 GAGGGGAGTGGAGAAGGCCACTGTCCGGCCTGGCTTCTGGGGACAGTGGCTGGTCCCCAG

AAGTCCTGAGGGCGGAGGGGGGGGTTGGGCAGGGTCTCCTCAGGTGTCAGGAGGGTGCTC
 GGAGGCCACAGGAGGGGGCTCCTGGCTGGCCTGAGGCTGGCCGGAGGGGAAGGGGCTAGC
 AGGTGTGTAAACAGAGGGTTCCATCAGGCTGGGGCAGGGTGGCCGCCTTCCGCACACTTG
 AGGAACCCCTCCCCTCTCCCTCGGTGACATCTTGCCCGCCCCCTCAGCACCCCTGCCTTGTCT
 5 CCAGGAGGTCCGAAGCTCTGTGGGACCTCTTGGGGGCAAGGTGGGGTGAGGCCGGGGAGT
 AGGGAGGTGAGGCGGGTCTGAGCCACAGAGCAGGAGAGCTGCCAGGTCTGCCCATCGAC
 CAGGTTGCTTGGGCCCCGGAGCCACGGGTCTGGTGATGCCATAGCAGCCACCACCGCGG
 CGCCTAGGGCTGCGGCAGGGACTCGGCCTCTGGGAGGTTTACCTCGCCCCCACTTGTGCC
 CCCAGCTCAGCCCCCTGCACGCAGCCCGACTAGCAGTCTAGAGGCCTGAGGCTTCTGGG
 10 TCCTGGTGACGGGGCTGGCATGACCCCGGGGGTTCGTCCATGCCAGTCCGCCTCAGTCGCA
 GAGGGTCCCTCGGCAAGCGCCCTGTGAGTGGGCCATTTCGGAACATTGGACAGAAGCCCAA
 AGAGCCAAATTGTACAAATTGTGGAACCCACATTGGCCTGAGATCCAAAACGCTTCGAGG
 CACCCCAAATTACCTGCCCATTCGTGAGGACACCCACCCACCCAGTGTTATATTCTGCCT
 CGCCGGAGTGGGTGTTCCCGGGGGCACTTGCCGACCAGCCCCCTTGCCTCCCCAGGTTTGC
 15 AGCTCTCCCCTGGGCCACTAACCATCCTGGCCCCGGGCTGCCTGTCTGACCTCCGTGCCTA
 GTCGTGGCTCTCCATCTTGTCTCCTCCCCGTGTCCCCAATGTCTTCAGTGGGGGGCCCCC
 TCTTGGGTCCCCTCCTCTGCCATCACCTGAAGACCCCCACGCCAAACACTGAATGTCACC
 TGTGCCTGCCGCCTCGGTCCACCTTGCGGCCCGTGTGTTGACTCAACTCAACTCCTTTAAC
 GCTAATATTTCCGGCAAAATCCCATGCTTGGGTTTTGTCTTTAACCTTGTAACGCTTGCA
 20 ATCCCAATAAAGCATTAAAAGTCATGATCTTCTGAGTGTTCCACTCTCTGACTTGGGTAC
 TGGACTGCCAGAGGGAGGGAAGGGGCTGAGCACCTGGAAGCAGGCAGAGGGGGATAGAAG
 AGGGAAGGGGAAGGAAGGCCTTAGGGGTGTGGACACCTCTCTCCGTCCCCTGATCACATA
 CATGGAGAAATGAGAGAGCTGGAAGCCAGACTCTCAGACTCACTGTCTGTCACCTGAAGC
 CAGGGGGTCTGGGACAGTGTGAGGCACCAAGTTCTCAAAGATGGGGGTGCCACGAAGGGT
 25 AGGAGCCTGGGGGGCTTTTTTCAGAGAAAAAGCAAAGTACCATCAGTACCAACTCCAGGGA
 ATGCCTCCCCCACCACAGCCTTAGAGGACTGGGGCTGGGCAACCTCTAAAAGGTTCTGG
 AAACCGTATCTGTGGCTGGAGATGGGGGCTCAGGGCCACTCTCACCCAGGGACTCAGCCC
 CCTTCCAAGGTTGAGGCTGCCCAGATGTCATTAGTACCACTGCCTCCTGCCAGGGCTCAG
 CCTGTACCCACCTGTCCCAAGGGTGCTGGCCTCTAGCTTTCAAGGGTCCCTGAGCATGGG
 30 AGGAGGGGTAGGCTGGGCTGCTGGGAGCCTGG

SEQ ID NO:20

IGF2 exon 9 sequence, Ensemble exon entry ENSE00001488587 (Human GRCh37,
 February 2009)

GACAACTTCCCCAGATACCCCGTGGGCAAGTTCTTCCAATATGACACCTGGAAGCAGTCCACCCAGCGCCTGCG
 CAGGGGCCTGCCTGCCCTCCTGCGTGCCCGCCGGGGTACAGTGCTCGCCAAGGAGCTCGAGGCGTTTCAGGGAGG
 CCAAACGTCACCGTCCCCTGATTGCTCTACCCACCCAAGACCCCGCCACGGGGGCGCCCCCCCCAGAGATGGCC
 AGCAATCGGAAGTGAGCAAACTGCCGCAAGTCTGCAGCCCGGCGCCACCATCCTGCAGCCTCCTCCTGACCAC
 40 GGACGTTTCCATCAGGTTCCATCCCGAAAATCTCTCGGTTCCACGTCCCCCTGGGGCTTCTCCTGACCCAGTCC
 CCGTGCCCCGCTCCCCGAAACAGGCTACTCTCCTCGGCCCCCTCCATCGGGCTGAGGAAGCACAGCAGCATCT
 TCAAACATGTACAAAATCGATTGGCTTTAAACACCCCTTCACATACCCTCCCCCAAATTATCCCCAATTATCCC
 CACACATAAAAAATCAAAACATTAACTAACCCCTTCCCCCCCCCCCCACAACAACCCTCTTAAAACTAATTGG
 CTTTTTTAGAAACACCCACAAAAGCTCAGAAATTGGCTTTAAAAAAAACAACCACCAAAAAAATCAATTGGCT
 45 AAAAAAAAAAAGTATTA AAAACGAATTGGCTGAGAAACAATTGGCAAAATAAAGGAATTTGGCACTCCCCACCC
 CCCTCTTTCTCTTCTCCCTTGGACTTTGAGTCAAATTGGCCTGGACTTGAGTCCCTGAACCAGCAAAGAGAAAA
 GAAGGACCCAGAAATCACAGGTGGGCACGTGCTGCTACCGCCATCTCCCTTCTCACGGGAATTTTCAGGGTA
 AACTGGCCATCCGAAAATAGCAACAACCCAGACTGGCTCCTCACTCCCTTTTCCATCACTAAAAATCACAGAGC
 AGTCAGAGGGACCCAGTAAGACCAAAGGAGGGGAGGACAGAGCATGAAAACCAAATCCATGCAAATGAAATGT
 50 AATTGGCAGGACCTCACCCCCAAATCTTACATCTCAATTCCCATCCTAAAAAGCACTCATACTTTATGCATCC
 CCGCAGCTACACACACACAACACACAGCACACGCATGAACACAGCACACACACGAGCACAGCACACACACAAAC
 GCACAGCACACACAGCACACAGATGAGCACACAGCACACACACAAACGCACAGCACACACACGACACACATGC
 ACACACAGCACACAAACGCACGGCACACACACGACACACATGCACACACAGCACACACACAAACGCACAGCAC
 ACACAAACGCACAGCACACACGACACACACAGCACACACACGAGCACACAGCACACAAACGCACAGCACAGCAC
 55 ACACATGCACACACAGCACACACACTAGCACACAGCACACACACAAAGACACAGCACACACATGCACACACAGC
 ACACACACGCGAACACAGCACACACGAACACAGCACACACAGCACACACACAAACACAGCACACACATGCACAC
 AGCACACGCACACACAGCACACACATGAACACAGCACACAGCACACACATGCACACACAGCACACACGCGATGCA
 CAGCACACATGAACACAGCACACACACAAACACACAGCACACACATGCACACACAGCACACACACTCATGCGCA
 GCACATACATGAACACAGCTCACAGCACACAAACACGACAGCACACACGTTGCACACGCAAGCACCCACCTGCAC
 60 ACACACATGCGCACACACACGACACACCCCCACAAAATTGGATGAAAACAATAAGCATATCTAAGCAACTACGAT

ATCTGTATGGATCAGGCCAAAGTCCCGCTAAGATTCTCCAATGTTTTTCATGGTCTGAGCCCCGCTCCTGTTCCC
 ATCTCCACTGCCCCCTCGGCCCTGTCTGTGCCCTGCCTCTCAGAGGAGGGGGCTCAGATGGTGCGGCCTGAGTGT
 GCGGCCGCGGCATTTGGGATACACCCGTAGGGTGGGCGGGGTGTGTCCCAGGCCTAATTCCATCTTTCCACCA
 TGACAGAGATGCCCTTGTGAGGCTGGCCTCCTTGGCGCCTGTCCCCACGGCCCCCGCAGCGTGAGCCACGATGC
 5 TCCCCATACCCCAACCATTTCCCGATACACCTTACTTACTGTGTGTTGGCCCAGCCAGAGTGAGGAAGGAGTTTG
 GCCACATTGGAGATGGCGGTAGCTGAGCAGACATGCCCCACGAGTAGCCTGACTCCCTGGTGTGCTCCTGGAA
 GGAAGATCTTGGGGACCCCCCACCAGGAGCACACCTAGGGATCATCTTTGCCCGTCTCCTGGGGACCCCCCAAG
 AAATGTGGAGTCTCGGGGGCCGTGCACTGATGCGGGGAGTGTGGGAAGTCTGGCGGTTGGAGGGGTGGGTGGG
 GGGCAGTGGGGGCTGGGCGGGGGGAGTTCTGGGGTAGGAAGTGGTCCCCGGGAGATTTTGGATGGAAAAGTCAGG
 10 AGGATTGACAGCAGACTTGCAGAATTACATAGAGAAATTAGGAACCCCCAAATTTTCATGTCAATTGATCTATTC
 CCCCTCTTTGTTTTCTTGGGGCATTTTTTCTTTTTTTTTTTTTTTTTTTTGTTTTTTTTTTTTACCCCTCCTTAGCTTTAT
 GCGCTCAGAAACCAAATTAACCCCCCCCCCATGTAACAGGGGGGAGTGACAAAAGCAAGAAGCACGAAGCC
 AGCCTGGAGACCACACGTCTGCCCCCGCCATTTATCGCCCTGATTGGATTTTGTTTTTTCATCTGTCCCTGT
 TGCTTGGGTTGAGTTGAGGGTGGAGCCTCCTGGGGGGCACTGGCCACTGAGCCCCCTTGGAGAAGTCAGAGGGG
 15 AGTGGAGAAGGCCACTGTCCGGCCTGGCTTCTGGGGACAGTGGCTGGTCCCCAGAAGTCTTGAGGGCGGAGGGG
 GGGGTTGGGCAGGGTCTCCTCAGGTGTGAGGAGGGTGCTCGGAGGGCCACAGGAGGGGGCTCCTGGCTGGCCTGA
 GGCTGGCCGGAGGGGAAGGGGCTAGCAGGTGTGTAAACAGAGGGTTCCATCAGGCTGGGGCAGGGTGGCCGCCT
 TCCGCACACTTGAGGAACCTCCCCTCTCCCTCGGTGACATCTTGCCCGCCCCCTCAGCACCTGCCTTGTCTCC
 AGGAGGTCCGAAGCTCTGTGGGACCTCTTGGGGGCAAGGTGGGGTGAGGCCGGGAGTAGGGAGGTGAGGCGGG
 20 TCTGAGCCCACAGAGCAGGAGAGCTGCCAGGTCTGCCCATCGACCAGGTTGCTTGGGCCCCGGAGCCACGGGT
 CTGGTGATGCCATAGCAGCCACCACCGCGCGCCTAGGGCTGCGGCAGGGACTCGGCCTCTGGGAGGTTTACCT
 CGCCCCACTTGTGCCCCCAGCTCAGCCCCCCTGCACGCAGCCGACTAGCAGTCTAGAGGCTGAGGCTTCTG
 GGTCTTGGTGACGGGGCTGGCATGACCCCGGGGGTTCGTCCATGCCAGTCCGCCTCAGTCGCAGAGGGTCCCTCG
 GCAAGCGCCCTGTGAGTGGGCCATTGGAACATTGGACAGAAGCCCAAAGAGCCAAATTGTACAATTGTGGAA
 25 CCCACATTGGCCTGAGATCCAAAACGCTTCGAGGCACCCCAAATTACCTGCCCATTCGTCAGGACACCCACCCA
 CCCAGTGTTATATTCTGCCTCGCCGGAGTGGGTGTTCCCGGGGGCACTTGCCGACCAGCCCCCTTGCCTCCCCAG
 GTTTCAGCTCTCCCCTGGGCCACTAACCATCCTGGCCCCGGGCTGCCTGTCTGACCTCCGTGCCTAGTCTGTGGC
 TCTCCATCTTGTCTCCTCCCCGTGTCCCAATGTCTTCAGTGGGGGGCCCCCTCTTGGGTCCCCTCCTCTGCCA
 TCACCTGAAGACCCCCACGCCAAACACTGAATGTCACCTGTGCCTGCCGCCTCGGTCCACCTTGCGGCCCGTGT
 30 TTGACTCAACTCAACTCCTTTAACGCTAATATTTCCGGCAAATCCCATGCTTGGGTTTTGTCTTTAACCTTGT
 AACGCTTGCAATCCCAATAAAGCATTTAAAGTCATGATCTTC

SEQ ID NO:21**Synth 1**

35 GCGGCCGCTTAATACGACTCACTATAGGGAGAACCCTCCGACCGTGCTTCCGGACAACCTTCCCCAGATACCC
 CGTGGGCAAGTTCTTCCAATATGACACCTGGAAGCAGTCCACCCAGCGCCTGCGCAGGGGGCTGCCTGCCCTCC
 TGCGTGCCCCGCGGGGTACGTGCTCGCCAAGGAGCTCGAGGCGTTTCCAGGGAGGCCAAACGTACCGTCCCCTG
 ATTGCTCTACCCACCCAAGACCCCGCCACGGGGGCGCCCCCCCCAGAGATGGCCAGCAATCGGAAGTGAGCAAA
 40 ACTGCCGCAAGTCTGCAGCCCGGCGCCACCATCCTGCAGCCTCCTCCTGACCACGGACGTTTCCATCAGGTTCC
 ATCCCGAAAATCTCTCGGTTCCACGTCCCCCTGGGGCTTCTCCTGACCCAGTCCCCGTGCCCCGCTCCCCGAA
 ACAGGCTACTCTCCTCGGCCCCCTCCATCGGGCTGAGGAAGCACAGCAGCATCTTCAAACATGTACAAAATCGA
 TTGGCTTTAAACACCCTTCACATACCCTCCCCCCAAATTATCCCCAATTATCCCCACACATAAAAAATCAAAAC
 ATTAACCTAACCCCCCTTCCCCCCCCCCCCACAACAACCCTCTTAAACTAATTGGCTTTTTTAGAAACACCCACA
 45 AAAGCTCAGAAATTGGCTTTAAAAAAAACAACCACCAAAAAAATCAATTGGCTAAAAAAAAGTATTAAAA
 ACGAATTGGCTGAGAAACAATTGGCAAAATAAAGGAATTTGGCACTCCCCACCCCCCTCTTCTCTTCTCCCTT
 GGACTTTGAGTCAAATTGGCCTGGACTTGAGTCCCTGAACCAGCAAAGAGAAAAGAAGGACCCAGAAATCACA
 GGTGGGCACGTGCTGCTACCGCCATCTCCCTTCTCACGGGAATTTTTCAGGGTAAACTGGCCATCCGAAAATAG
 CAACAACCCAGACTGGCTCCTCACTCCCTTTTCCATCACTAAAAATCACAGAGCAGTCAGAGGGACCCAGTAAG
 50 ACCAAAGGAGGGGAGGACAGAGCATGAAAACCAAATCCATGCAAATGAAATGTAATTGGCACGACCCTCACC
 CCAAATCTTACATCTCAATTCCCATCCTAAAAAGCACTCATACTTTATGCATCCCCGCCTCATGCGCAGCACAT
 ACATGAACACAGCTCACAGCACACAAACACGCAGCACACACGTTGCACACGCAAGCACCCACCTGCACACACAC
 ATGCGCACACACACGCACACCCCCACAAAATTGGATGAAAACAATAAGCATATCTAAGCAACTACGATATCTGT
 ATGGATCAGGCCAAAGTCCCGCTAAGATTCTCCAATGTTTTTCATGGTCTGAGCCCCGCTCCTGTTCCCATCTCC
 55 ACTGCCCTCGGCCCTGTCTGTGCCCTGCCTCTCAGAGGAGGGGGCTCAGATGGTGCGGCCTGAGTGTGCGGCC
 GCGGCATTTGGGATACACCCGTAGGGTGGGCGGGGTGTGTCCCAGGCCTAATTCCATCTTTCCACCATGACAG
 AGATGCCCTTGTGAGGCTGGCCTCCTTGGCGCCTGTCCCCACGGCCCCCGCAGCGTGAGCCACGATGCTCCCCA
 TACCCACCCATTCCCGATACACCTTACTTACTGTGTGTTGGCCCAGCCAGAGTGAGGAAGGAGTTTGGCCACA
 TTGGAGATGGCGGTAGCTGAGCAGACATGCCCCACGAGTAGCCTGACTCCCTGGTGTGCTCCTGGAAGGAAGA
 60 TCTTGGGGACCCCCCACCAGGAGCACACCTAGGGATCATCTTTGCCCGTCTCCTGGGGACCCCCCAAGAAATGT

5 GGAGTCCTCGGGGGCCGTGCACTGATGCGGGGAGTGTGGGAAGTCTGGCGGTTGGAGGGGTGGGTGGGGGGCAG
 TGGGGGCTGGGCGGGGGGAGTTCTGGGGTAGGAAGTGGTCCCGGGAGATTTTGGATGGAAAAGTCAGGAGGATT
 GACAGCAGACTTGCAGAATTACATAGAGAAATTAGGAACCCCCAAATTTTCATGTCAATTGATCTATTCCCCCTC
 TTTGTTTCTTGGGGCATTTTTCTTTTTTTTTTTTTTTTTTTGTTTTTTTTTTTACCCCTCCTTAGCTTTATGCGCTC
 10 AGAAACCAAATTAAACCCCCCCCCCATGTAAACAGGGGGGAGTGACAAAAGCAAGAACGCACGAAGCCAGCCTG
 GAGACCACACGTCCTGCCCCCGCCATTTATCGCCCTGATTGGATTTTGTTCATCTGTCCCTGTTGCTTG
 GGTGAGTTGAGGGTGGAGCCTCCTGGGGGGCACTGGCCACTGAGCCCCCTTGGAGAAGTCAGAGGGGAGTGGA
 GAAGGCCACTGTCCGGCCTGGCTTCTGGGGACAGTGGCTGGTCCCCAGAAGTCTTGAGGGCGGAGGGGGGGGTT
 GGGCAGGGTCTCCTCAGGTGTGAGGAGGGTGCTCGGAGGCCACAGGAGGGGGCTCCTGGCTGGCCTGAGGCTGG
 15 CCGGAGGGGAAGGGGCTAGCAGGTGTGTAAACAGAGGGTTCCATCAGGCTGGGGCAGGGTGGCCGCCTTCCGCA
 CACTTGAGGAACCTCCCCTCTCCCTCGGTGACATCTTGCCCGCCCCCTCAGCACCTTGCTTGTCTCCAGGAGG
 TCCGAAGCTCTGTGGGACCTCTTGGGGGCAAGGTGGGGTGAGGCCGGGGAGTAGGGAGGTGAGGCGGGTCTGAG
 CCCACAGAGCAGGAGAGCTGCCAGGTCTGCCCATCGACCAGGTTGCTTGGGCCCCGGAGCCACGGGTCTGGTG
 ATGCCATAGCAGCCACCACCGCGCGCCTAGGGCTGCGGCAGGGACTCGGCCTCTGGGAGGTTTACCTCGCCCC
 20 CACTTGTGCCCCCAGCTCAGCCCCCTGCACGCAGCCGACTAGCAGTCTAGAGGCTGAGGCTTCTGGGTCTCCT
 GGTGACGGGGCTGGCATGACCCCGGGGGTTCGTCCATGCCAGTCCGCCTCAGTCGCAGAGGGTCCCTCGGCAAGC
 GCCCTGTGAGTGGGCCATTTCGGAACATTGGACAGAAGCCCAAAGAGCCAAATTGTCACAATTGTGGAACCCACA
 TTGGCCTGAGATCCAAAACGCTTCGAGGCACCCCAAATTACCTGCCCATTCGTGAGGACACCCACCCACCCAGT
 GTTATATTCTGCCTCGCCGAGTGGGTGTTCCCGGGGGCACTTGCCGACCAGCCCCCTTGCGTCCCCAGGTTTGC
 25 AGCTCTCCCCTGGGCCACTAACCATCCTGGCCCCGGGCTGCCTGTCTGACCTCCGTGCCTAGTCGTGGCTCTCA
 TCTTGTCTCCTCCCCGTGTCCCCAATGTCTTCAGTGGGGGGCCCCCTCTTGGGTCCCCTCCTCTGCCATCACCT
 GAAGACCCCCACGCCAAACACTGAATGTCACCTGTGCCTGCCGCCTCGGTCCACCTTGCGGCCCGTGTGTTGACT
 CAACTCAACTCCTTTAACGCTAATATTTCCGGCAAATCCCATGCTTGGGTTTTGTCTTTAACCTTGTAACGCT
 TGCAATCCCAATAAAGCATTAAGTCATGATCTTCGGCGGCCGCT

SEQ ID NO:22

CA repeat-rich region from SEQ ID NO:20

30 AGCTACACACACACAACACACAGCACACGCATGAACACAGCACACACACGAGCACAGCACACACACAAACGCAC
 AGCACACACAGCACACAGATGAGCACACAGCACACACACAAACGCACAGCACACACACGCACACACATGCACAC
 ACAGCACACAAACGCACGGCACACACACGCACACACATGCACACACAGCACACACACAAACGCACAGCACACAC
 AAACGCACAGCACACACGCACACACAGCACACACACGAGCACACAGCACACAAACGCACAGCACACGCACACAC
 ATGCACACACAGCACACACACTAGCACACAGCACACACACAAAGACACAGCACACACATGCACACACAGCACAC
 35 ACACGCGAACACAGCACACACGAACACAGCACACACAGCACACACAAACACAGCACACACATGCACACAGCA
 CACGCACACACAGCACACACATGAACACAGCACACAGCACACACATGCACACACAGCACACACGCATGCACAGC
 ACACATGAACACAGCACACACACAAACACACAGCACACACATGCACACACAGCACACACA

SEQ ID NO:23

40 Synth 2 sequence

GGCGGCCGCTTAATACGACTCACTATAGGGAGAACCCCTCCGACCGTGCTTCCGGACAACCTTCCCCAGATACCC
 CGTGGGCAAGTTCTTCCAATATGACACCTGGAAGCAGTCCACCCAGCGCCTGCGCAGGGGGCCTGCCTGCCCTCC
 TGCGTGCCCCGCCGGGGTACGTGCTCGCCAAGGAGCTCGAGGCGTTCAGGGAGGCCAAACGTACCCGTCCCCTG
 45 ATTGCTCTACCCACCCAAGACCCCGCCACGGGGGCGCCCCCCCCAGAGATGGCCAGCAATCGGAAGTGAGCAAA
 ACTGCCGCAAGTCTGCAGCCCGGTGCCACCATCCTGCAGCCTCCTCCTGACCACGGACGTTTCCATCAGGTTCC
 ATCCCGAAAATCTCTCGGTTCCACGTCCCCCTGGGGCTTCTCCTGACCCAGTCCCCGTGCCCGCCTCCCCGAA
 ACAGGCTACTCTCCTCGGCCCCCTCCATCGGGCTGAGGAAGCACAGCAGCATCTTCAAACATGTACAAAATCGA
 TTGGCTTTAAACACCCCTTCACATACCCTCCCCCCAAATTATCCCCAATTATCCCCACACATAAAAAATCAAAAC
 50 ATTAAACTAACCCCTTCCCCCCCCCCCCACAACAACCCTCTTAAACTAATTGGCTTTTTTAGAAACACCCCA
 AAAGCTCAGAAATTGGCTTTAAAAAAAACAACCACCAAAAAAATCAATTGGCTAAAAAAAAGTATTAAAA
 ACGAATTGGCTGAGAAACAATTGGCAAAATAAAGGAATTTGGCACTCCCCACCCCCCTCTTCTCTTCTCCCTT
 GGACTTTGAGTCAAATTGGCCTGGACTTGAGTCCCTGAACCAGCAAAGAGAAAAGAAGGGCCCCAGAAATCACA
 GGTGGGCATGTGCTGCTACCGCCATCTCCCTTCTCACGGGAATTTTCAGGGTAAACTGGCCATCCGAAAATAG
 55 CAACAACCCAGACTGGCTCCTCACTCCCTTTTCCATCACTAAAAATCACAGAGCAGTCAGAGGGACCCAGTAAG
 ACCAAAGGAGGGGAGGACAGAGCATGAAAACCAAAATCCATGCAAATGAAATGTAATTGGCACGACCCCTCACCC
 CCAAATCTTACATCTCAATTCCCATCCTAAAAAGCACTCATACTTTATGCATCCCCGCCTCATGCGCAGCACAT
 ACATGAACACAGCTCACAGCACACAAACACGCAGCACACACGTTGCACACGCAAGCACCCACCTGCACACACAC
 ATGCGCACACACACGCACACCCCCACACAATTAGATGAAAACAATAAGCATATCTAAGCAACTACGATATCTGT
 60 ATGGATCAGGCCAAAGTCCCGCTAAGATTCTCAATGTTTTTCATGGTCTGAGCCCCCCTCCTGTTCCCATCTCC

ACTGCCCCTCGGCCCTGTCTGTGCCCTGCCTCTCAGAGGAGGGGGCTCAGATGGTGCGGCCCTGAGTGTGCGGCC
 GCGGCATTTGGGATACACCCGTAGGGTGGGCGGGGTGTGTCCCAGGCCTAATTCCATCTTTCCACCATGACAG
 AGATGCCCTTGTGAGGCTGGCCTCCTTGGCGCCTGTCCCCACGGCCCCCGCAGCGTGAGCCACGATGCTCCCCA
 TACCCACCCATTCCCGATACACCTTACTTACTGCGTGTTGGTCCAGCCAGAGTGAGGAAGGAGTTTGGCCACA
 5 TTGGAGATGGCGGTAGCTGAGCAGACATGCCCCACGAGTAGCCTGACTCCCTGGTGTGCTCCTGGAAGGAAGA
 TCTTGGGGACCCCCCACCGGAGCACACCTAGGGATCATCTTTGCCCATCTCCTGGGGACCCCCCAAGAAATGT
 GGAGTCCTCGGGGGCCGTGCACTGATGTGGGGAGTGTGGGAAGTCTGGCGGTTGGAGGGGTGGGTGGGGGGCAG
 TGGGGGCTGGGCGGGGGGAGTTCTGGGGTAGGAAGTGGTCCCGGGAGATTTTGGATGGAAAAGTCAGGAGGATT
 GACAGCAGACTTGCAGAATTACATAGAGAAATTAGGAACCCCCAAATTTTCATGTCAATTGATCTATTCCCCCTC
 10 TTTGTTTCTTGGGGCAGTTTTCTTTTTTTTTTTTTTTTTTGTTTTTTTTTTACCCCTCCTTAGCTTTATGCGCTC
 AGAAACCAAATTAACCCCCCCCCCATGTAACAGGGGGGCAGTGACAAAAGCAAGAACGCACGAAGCCAGCCTG
 GAGACCACCACGTCTTCCCCCGCCATTTATCGCCCTGATTGGATTTTGTTTTTTCATCTGTCCCTGTTGCTTG
 GGTGAGTTGAGGGTGGAGCCTCCTGGGGGGCACTGGCCACTGAGCCCCCTTGGAGAAGTCAGAGGGGAGTGGA
 GAAGGCCACTGTCCGGCCTGGCTTCTGGGGACAGTGGCTGGTCCCCAGAAGTCTGAGGGCGGAGGGGGGGGTT
 15 GGGCAGGGTCTCCTCAGGTGTGAGGAGGGTGCTCGGAGGCCACAGGAGGGGGCTCCTGGCTGGCCTGAGGCTGG
 CCGGAGGGGAAGGGGCTAACAGGTGTGTAACAGAGGGTTCCATCAGGCTGGGGCAGGGTGGCCGCCTTCCGCA
 CACTTGAGGAACCCTCCCCCTCTCCCTCGGTGACATCTTGCCCGCCCCCTCAGCACCTGCCTTGTCTCCAGGAGG
 TCCGAAGCTCTGTGGGACCTCTTGGGGGCAAGGTGGGGTGAGGCCGGGGAGTAGGGAGGTGAGGCGGGTCTGAG
 CCCACAGAGCAGGAGAGCTGCCAGGTCTGCCCATCGACCAGGTTGCTTGGGCCCCGGAGCCACGGGTCTGGTG
 20 ATGCCATAGCAGCCACCACCGCGGCACCTAGGGCTGCGGCAGGGACTCGGCCTCTGGGAGGTTTACCTCGCCCC
 CACTTGTGCCCCCAGCTCAGCCCCCCTGCACGCAGCCCGACTAGCAGTCTAGAGGCCTGAGGCTTCTGGGTCTT
 GGTGACGGGGCTGGCATGACCCCGGGGGTTCGTCCATGCCAGTCCGCCTCAGTCGCAGAGGGTCCCTCGGCAAGC
 ACCCTGTGAGTGGGCCATTTCGGAACATTGGACAGAAGCCCAAAGAGCCAAATTGTACAATTGTGGAACCCACA
 TTGGCCTGAGATCCAAAACGCTTCGAGGCACCCCAAATTACCTGCCCATTTCGTCAGGACACCCACCCACCCAGT
 25 GTTATATTCTGCCTCGCCGGAGTGGGTGTTCCCGGGGGCACTTGCCGACCGGCCCTTGCGTCCCCAGGTTTGC
 AGCTCTCCCCTGGGCCACTAACCATCCTGGCCCGGGCTGCCTGTCTGACCTCCGTGCCTAGTCGTGGCTCTCCA
 TCTTGTCTCCTCCCCGTGTCCCAATGTCTTCAGTGGGGGGCCCCCTCTTGGGTCCCCTCCTCTGCCATCACCT
 GAAGACCCCCACGCCAAACACTGAATGTACCTGTGCCTGCCGCCTCGGTCCACCTTGCGGCCCGTGTGTTGACT
 CAACTCAGCTCCTTTAACGCTAATATTTCCGGCAAATCCCATGCTTGGGTTTTGTCTTTAACCTTGTAACGCT
 30 TGCAATCCCAATAAAGCATTAAGATCATGATCTTCGGCGGCCGCT

WHAT IS CLAIMED IS:

1 1. A method of determining loss-of-imprinting in the Insulin Growth
2 Factor-2 (IGF2) gene of an individual, the method comprising,
3 detecting the SNP genotype of the IGF2 gene in the individual, wherein the
4 genotype of at least three SNPs selected from the group consisting of SEQ ID NOs: 1, 2, 3,
5 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and 16 is determined, thereby determining whether the
6 individual is heterozygous or homozygous at each of the at least three SNPs;
7 quantifying in a sample from the individual the amount of RNA comprising
8 two polymorphic options of at least one heterozygous SNP;
9 determining a ratio of the amount of RNA comprising two polymorphic
10 options of at least one heterozygous SNP; and
11 correlating the RNA ratio to loss of imprinting of the IGF2 gene.

1 2. The method of claim 1, wherein at least one SNP in the detecting step
2 is selected from the group consisting of SEQ ID NO:1, 2, 3, 4, 5, and 6.

1 3. The method of claim 1, wherein the correlating step further comprises
2 correlating the relative amount of RNA comprising the polymorphic options of the at least
3 one heterozygous SNP to an increased risk of cancer, a diagnosis or prognosis of cancer, or
4 a prediction of efficacy of a drug for ameliorating, treating or preventing cancer.

1 4. The method of claim 1, wherein at least two of the detected SNPs are
2 heterozygous and the quantifying step comprises quantifying the amount of RNA
3 comprising two polymorphic options at the at least two heterozygous SNPs.

1 5. The method of claim 1, wherein the sample is a blood, stool, cell
2 scrape or tissue sample.

1 6. The method of claim 1, wherein the RNA is reverse transcribed into
2 cDNA and the quantity of cDNA comprising each polymorphic option is used to determine
3 the amount of RNA comprising the two polymorphic options.

1 7. The method of claim 6, wherein the amount of allele-specific cDNA
2 is quantified in a method comprising contacting the cDNA with at least one allele-specific
3 detection polynucleotide.

1 8. The method of claim 6, comprising contacting the cDNA with a
2 sufficient number of allele-specific detection polynucleotides such that the polymorphic
3 option for each heterozygous SNP from the group is determined.

1 9. The method of claim 8, comprising contacting the cDNA with a
2 number of different allele-specific detection polynucleotides, wherein the number is equal
3 to or greater than the number of heterozygous SNPs in the group such that at least one
4 different allele-specific detection polynucleotide is used to detect each different
5 heterozygous SNP.

1 10. The method of claim 7, wherein the at least one allele-specific
2 detection polynucleotide is hybridized to the cDNA and extended in a template-dependent
3 manner through the polymorphic position of the SNP in the cDNA.

1 11. The method of claim 10, wherein the at least one allele-specific
2 detection polynucleotide comprises at least 8 (e.g., at least 10, 12, 15) contiguous
3 nucleotides at the 3' end of the allele-specific detection polynucleotide, wherein the at least
4 8 contiguous nucleotides are either:

5 100% complementary to at least 8 (e.g., at least 10, 12, 15) nucleotides
6 directly 3' (or is 2 or 3 nucleotides 3') of the polymorphic position of the SNP region set
7 forth in the SEQ ID NO:; or

8 100% identical to at least 8 (e.g., at least 10, 12, 15) nucleotides directly 5'
9 (or is 2 or 3 nucleotides 5') of the polymorphic position of the SNP region set forth in the
10 SEQ ID NO:.

1 12. The method of claim 7, wherein the at least one allele-specific
2 detection polynucleotide comprises a sequence 100% identical to at least 8 (e.g., at least 10,
3 12, 15) contiguous nucleotides, or the complement thereof, of at least one heterozygous
4 SNP, and the sequence consists of at least 8 (e.g., at least 10, 12, 15) contiguous
5 nucleotides, or the complement thereof, of the SNP, wherein one of the positions of the
6 sequence corresponds to the variable position of the SNP.

1 13. The method of claim 1, wherein the detecting step comprises
2 detecting the SNP genotype of each polymorphic option of each of:

3 SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and 16; or

4 SEQ ID NOs: 1, 5, 8, 9, 10, 11, 14, 15, and 16; or
5 SEQ ID NOs: 1, 5, 8, 9, 10, 11, 12, 14, 15, and 16; or
6 SEQ ID NOs: 1, 2, 4, 5, 8, 9, 10, 12, 13, 14, 15, and 16.

1 14. The method of claim 1, wherein the detecting step comprises
2 detecting at least 4 (e.g., 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15) SNPs selected from the
3 group.

1 15. The method of claim 1, wherein the detecting step comprises
2 contacting the sample with a first, second and third polynucleotides of any of claims 17-19
3 or 27.

1 16. The method of claim 3, further comprising providing a risk
2 classification of cancer, diagnosis of cancer, or prognosis based on the correlating step,
3 and/or submitting the individual to a disease screening procedure (e.g., colonoscopy) based
4 on the correlating step, and/or submitting a sample from the individual to further diagnostic
5 or prognostics assays based on the correlating step and/or changing a drug or other
6 treatment regimen of the individual based on the correlating step.

1 17. A reaction mixture comprising,
2 a first polynucleotide of between 8-100 nucleotides, wherein the first
3 polynucleotide distinguishes between one polymorphic option of a first SNP (or
4 complement thereof) and the other polymorphic option of the first SNP (or complement
5 thereof) in a hybridization reaction,
6 a second polynucleotide of between 8-100 nucleotides, wherein the second
7 polynucleotide distinguishes between one polymorphic option of a second SNP (or
8 complement thereof) and the other polymorphic option of the second SNP (or complement
9 thereof) in a hybridization reaction, and
10 a third polynucleotide of between 8-100 nucleotides, wherein the third
11 polynucleotide distinguishes between one polymorphic option of a third SNP (or
12 complement thereof) and the other polymorphic option of the third SNP (or complement
13 thereof) in a hybridization reaction, wherein the first and second and third SNP is selected
14 from the group consisting of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and
15 16, wherein at least one SNP is 1, 2, 3, 4, 5, or 6.

1 18. The reaction mixture of claim 17, wherein at least one, at least two,
2 or three of the first, second, and third polynucleotide comprise a sequence 100% identical to
3 at least 8 (e.g., at least 10, 12, 15, 20) contiguous nucleotides, or the complement thereof, of
4 the SEQ ID NO: corresponding to the first and second and third SNP, respectively.

1 19. The reaction mixture of claim 18, wherein the sequence consists of at
2 least 8 (e.g., at least 10, 12, 15, 20) contiguous nucleotides, or the complement thereof, of
3 the SNP, wherein one of the positions of the sequence corresponds to the variable position
4 of the SNP.

1 20. The reaction mixture of claim 17, further comprising a sample
2 comprising nucleic acids from a human.

1 21. The reaction mixture of claim 17, further comprising a polymerase.

1 22. The reaction mixture of claim 20, wherein the polymerase is a
2 thermostable polymerase.

1 23. The reaction mixture of claim 17, wherein at least one of the first and
2 second and third polynucleotides are detectably labeled.

1 24. The reaction mixture of claim 20, wherein the detectable label is a
2 fluorescent label.

1 25. The reaction mixture of claim 20, wherein the first and second
2 polynucleotides are detectably labeled with different labels such that the different labels can
3 be differentially detected based on different wavelength of fluorescence of the labels or
4 different mass of the labels.

1 26. The reaction mixture of claim 17, comprising a plurality of different
2 allele-specific detection polynucleotide of between 8-100 nucleotides, such that at least one
3 polynucleotide of the plurality distinguishes between one allele of a SNP (or complement
4 thereof) and the other allele of the SNP (or complement thereof) in a hybridization reaction
5 for each of:

6 SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and 16; or

7 SEQ ID NOs: 1, 5, 8, 9, 10, 11, 14, 15, and 16; or

8 SEQ ID NOs: 1, 5, 8, 9, 10, 11, 12, 14, 15, and 16; or
9 SEQ ID NOs: 1, 2, 4, 5, 8, 9, 10, 12, 13, 14, 15, and 16.

1 27. A reaction mixture comprising,
2 a first allele-specific detection polynucleotide of between 8-100 nucleotides,
3 a second allele-specific detection polynucleotide of between 8-100
4 nucleotides,
5 a third allele-specific detection polynucleotide of between 8-100 nucleotides,
6 wherein each of the first, second, and third polynucleotides comprise at least
7 8 (e.g., at least 10, 12, 15, 20) contiguous nucleotides at the 3' end of the allele-specific
8 detection polynucleotide, wherein the at least 8 contiguous nucleotides are either:
9 100% complementary to at least 8 (e.g., at least 10, 12, 15, 20) nucleotides
10 directly 3' (or is 2 or 3 nucleotides 3') of the polymorphic position of a SNP region; or
11 100% identical to at least 8 (e.g., at least 10, 12, 15, 20) nucleotides directly
12 5' (or is 2 or 3 nucleotides 5') of the polymorphic position of a SNP region [or, e.g., 100%
13 identical to at least 8 (e.g., at least 10, 12, 15, 20) nucleotides directly 3' (or is 2 or 3
14 nucleotides 3') of the polymorphic position of the complement of the SNP region],
15 wherein the SNP region corresponding to each of the first, second, and third
16 polynucleotides is different and the SNP regions are selected from the group consisting of
17 SEQ ID NOs:1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and 16, wherein at least one SNP
18 region is SEQ ID NO:1, 2, 3, 4, 5, or 6.

1 28. The reaction mixture of claim 27, further comprising a sample
2 comprising nucleic acids from a human.

1 29. The reaction mixture of claim 27, further comprising a polymerase.

1 30. The reaction mixture of claim 29, wherein the polymerase is a
2 thermostable polymerase.

1 31. The reaction mixture of claim 27, wherein at least one of the first and
2 second and third polynucleotides are detectably labeled.

1 32. The reaction mixture of claim 31, wherein the detectable label is a
2 fluorescent label.

1 33. The reaction mixture of claim 27, wherein the first and second and
2 third polynucleotides are detectably labeled with different labels such that the different
3 labels can be differentially detected based on different wavelength of fluorescence of the
4 labels or different mass of the labels.

1 34. The reaction mixture of claim 27, comprising a plurality of different
2 allele-specific detection polynucleotides, wherein each of the plurality of polynucleotides
3 comprise at least 8 (e.g., at least 10, 12, 15, 20) contiguous nucleotides at the 3' end of the
4 allele-specific detection polynucleotide, wherein the at least 8 contiguous nucleotides are
5 either:

6 100% complementary to at least 8 (e.g., at least 10, 12, 15, 20) nucleotides
7 directly 3' (or is 2 or 3 nucleotides 3') of the polymorphic position of a SNP region; or

8 100% identical to at least 8 (e.g., at least 10, 12, 15, 20) nucleotides directly
9 5' (or is 2 or 3 nucleotides 5') of the polymorphic position of a SNP region,

10 wherein the plurality includes a sufficient number of polynucleotides such at
11 least one polynucleotide corresponds to each of the following SNP regions:

12 SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and 16; or

13 SEQ ID NOs: 1, 5, 8, 9, 10, 11, 14, 15, and 16; or

14 SEQ ID NOs: 1, 5, 8, 9, 10, 11, 12, 14, 15, and 16; or

15 SEQ ID NOs: 1, 2, 4, 5, 8, 9, 10, 12, 13, 14, 15, and 16.

1 35. A kit comprising,

2 a first polynucleotide of between 8-100 nucleotides, wherein the first
3 polynucleotide distinguishes between one polymorphic option of a first SNP (or
4 complement thereof) and the other polymorphic option of the first SNP (or complement
5 thereof) in a hybridization reaction,

6 a second polynucleotide of between 8-100 nucleotides, wherein the second
7 polynucleotide distinguishes between one polymorphic option of a second SNP (or
8 complement thereof) and the other polymorphic option of the second SNP (or complement
9 thereof) in a hybridization reaction,

10 a third polynucleotide of between 8-100 nucleotides, wherein the third
11 polynucleotide distinguishes between one polymorphic option of a third SNP (or
12 complement thereof) and the other polymorphic option of the third SNP (or complement
13 thereof) in a hybridization reaction, wherein the first and second and third SNP is selected

14 from the group consisting of SEQ ID NOs:1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and
15 16, wherein at least one SNP is selected from SEQ ID NO:1, 2, 3, 4, 5, or 6.

1 36. The kit of claim 35, wherein at least one, at least two, or three of the
2 first, second, and third polynucleotide comprise a sequence 100% identical to at least 8
3 (e.g., at least 10, 12, 15, 20) contiguous nucleotides, or the complement thereof, of the SEQ
4 ID NO: corresponding to the first and second and third SNP, respectively.

1 37. The kit of claim 36, wherein the sequence consists of at least 8 (e.g.,
2 at least 10, 12, 15, 20) contiguous nucleotides, or the complement thereof, of the SNP,
3 wherein one of the positions of the sequence corresponds to the variable position of the
4 SNP.

1 38. The kit of claim, further comprising a polymerase.

1 39. The kit of claim 38, wherein the polymerase is a thermostable
2 polymerase.

1 40. The kit of claim 35, wherein at least one of the first and second and
2 third polynucleotides are detectably labeled.

1 41. The kit of claim 40, wherein the detectable label is a fluorescent
2 label.

1 42. The kit of claim 40, wherein the first and second and third
2 polynucleotides are detectably labeled with different labels such that the different labels can
3 be differentially detected based on different wavelength of fluorescence of the labels or
4 different mass of the labels.

1 43. The kit of claim 35, comprising a plurality of different allele-specific
2 detection polynucleotide of between 8-100 nucleotides, such that at least one polynucleotide
3 of the plurality distinguishes between one allele of a SNP (or complement thereof) and the
4 other allele of the SNP (or complement thereof) in a hybridization reaction for each of:

5 SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and 16; or

6 SEQ ID NOs: 1, 5, 8, 9, 10, 11, 14, 15, and 16; or

7 SEQ ID NOs: 1, 5, 8, 9, 10, 11, 12, 14, 15, and 16; or

8 SEQ ID NOs: 1, 2, 4, 5, 8, 9, 10, 12, 13, 14, 15, and 16.

1 44. A kit comprising,
2 a first allele-specific detection polynucleotide of between 8-100 nucleotides,
3 a second allele-specific detection polynucleotide of between 8-100
4 nucleotides,
5 a third allele-specific detection polynucleotide of between 8-100 nucleotides,
6 wherein each of the first, second, and third polynucleotides comprise at least
7 8 (e.g., at least 10, 12, 15, 20) contiguous nucleotides at the 3' end of the allele-specific
8 detection polynucleotide, wherein the at least 8 contiguous nucleotides are either:
9 100% complementary to at least 8 (e.g., at least 10, 12, 15, 20) nucleotides
10 directly 3' (or is 2 or 3 nucleotides 3') of the polymorphic position of a SNP region; or
11 100% identical to at least 8 (e.g., at least 10, 12, 15, 20) nucleotides directly
12 5' (or is 2 or 3 nucleotides 5') of the polymorphic position of a SNP region [or, e.g., 100%
13 identical to at least 8 (e.g., at least 10, 12, 15, 20) nucleotides directly 3' (or is 2 or 3
14 nucleotides 3') of the polymorphic position of the complement of the SNP region],
15 wherein the SNP region corresponding to each of the first, second, and third
16 polynucleotides is different and the SNP regions are selected from the group consisting of
17 SEQ ID NOs:1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and 16, wherein at least one SNP
18 region is SEQ ID NO:1, 2, 3, 4, 5, or 6.

1 45. The kit of claim 44, further comprising a sample comprising nucleic
2 acids from a human.

1 46. The kit of claim 44, further comprising a polymerase.

1 47. The kit of claim 46, wherein the polymerase is a thermostable
2 polymerase.

1 48. The kit of claim 44, wherein at least one of the first and second and
2 third polynucleotides are detectably labeled.

1 49. The kit of claim 48, wherein the detectable label is a fluorescent
2 label.

1 50. The kit of claim 44, wherein the first and second and third
2 polynucleotides are detectably labeled with different labels such that the different labels can

be differentially detected based on different wavelength of fluorescence of the labels or different mass of the labels.

51. The kit of claim 44, comprising a plurality of different allele-specific detection polynucleotides, wherein each of the plurality of polynucleotides comprise at least 8 (e.g., at least 10, 12, 15, 20) contiguous nucleotides at the 3' end of the allele-specific detection polynucleotide, wherein the at least 8 contiguous nucleotides are either:

100% complementary to at least 8 (e.g., at least 10, 12, 15, 20) nucleotides directly 3' (or is 2 or 3 nucleotides 3') of the polymorphic position of a SNP region; or

100% identical to at least 8 (e.g., at least 10, 12, 15, 20) nucleotides directly 5' (or is 2 or 3 nucleotides 5') of the polymorphic position of a SNP region [or, e.g., 100% identical to at least 8 (e.g., at least 10, 12, 15, 20) nucleotides directly 3' (or is 2 or 3 nucleotides 3') of the polymorphic position of the complement of the SNP region],

wherein the plurality includes a sufficient number of polynucleotides such at least one polynucleotide corresponds to each of the following SNP regions:

SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and 16; or

SEQ ID NOs: 1, 5, 8, 9, 10, 11, 14, 15, and 16; or

SEQ ID NOs: 1, 5, 8, 9, 10, 11, 12, 14, 15, and 16; or

SEQ ID NOs: 1, 2, 4, 5, 8, 9, 10, 12, 13, 14, 15, and 16.

52. A computer-implemented method for determining loss-of-imprinting in the Insulin Growth Factor-2 (IGF2) gene, the method comprising:

(a) receiving, at a host computer, genotype values for at least three SNPs selected from the group consisting of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and 16, wherein the genotype is determined from a sample from an individual; and

(b) receiving, at a host computer, a value representing the amount of RNA comprising each polymorphic option of at least one heterozygous SNP selected from the group consisting of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and 16, wherein the RNA is from a sample from an individual; and

(c) determining, at a host computer, a ratio of the amount of RNA comprising two polymorphic options of at least one heterozygous SNP; and

(d) outputting to a human the RNA ratio or correlating in the host computer, the RNA ratio to loss of imprinting of the IGF2 gene, and optionally outputting to a human the result of the correlating step.

1 53. The computer-implemented method of claim 52, wherein at least one
2 SNP is selected from SEQ ID NO: 1, 2, 3, 4, 5, or 6.

1 54. The computer-implemented method of claim 52, wherein the
2 correlating step further comprises correlating the relative amount of RNA comprising the
3 polymorphic options of the at least one heterozygous SNP to an increased risk of cancer, a
4 diagnosis or prognosis of cancer, or a prediction of efficacy of a drug for ameliorating,
5 treating or preventing cancer.

1 55. The computer-implemented method of claim 52, wherein the
2 receiving step (a) comprises receiving a value representing the amount of RNA having each
3 polymorphic option of each of
4 SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and 16; or
5 SEQ ID NOs: 1, 5, 8, 9, 10, 11, 14, 15, and 16; or
6 SEQ ID NOs: 1, 5, 8, 9, 10, 11, 12, 14, 15, and 16; or
7 SEQ ID NOs: 1, 2, 4, 5, 8, 9, 10, 12, 13, 14, 15, and 16.

1 56. The computer-implemented method of claim 52, wherein the
2 receiving step (a) comprises receiving a value representing the amount of RNA having each
3 polymorphic option of each of at least 4 (e.g., 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15) SNPs
4 selected from the group.

1 57. A computer program product for determining loss-of-imprinting in
2 the Insulin Growth Factor-2 (IGF2) gene, the computer readable product comprising:
3 a computer readable medium encoded with program code, the program code
4 including:
5 program code for receiving genotype values for at least three SNPs
6 selected from the group consisting of SEQ ID NOs:1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,
7 15, and 16, wherein the genotype is determined from a sample from an individual;
8 program code for receiving a value representing the amount of RNA
9 comprising each polymorphic option of at least one heterozygous SNP selected from the
10 group consisting of SEQ ID NOs:1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and 16,
11 wherein the RNA is from a sample from an individual;
12 program code for determining a ratio of the amount of RNA
13 comprising two polymorphic options of at least one heterozygous SNP; and

14 optionally, program code for correlating in the host computer, the
15 RNA ratio to loss of imprinting of the IGF2 gene.

1 58. The computer program product of claim 57, at least one SNP is
2 selected from SEQ ID NO: 1, 2, 3, 4, 5, or 6.

1 59. The computer program product of claim 57, comprising program
2 code for correlating the relative amount of RNA comprising the polymorphic options of the
3 at least one heterozygous SNP to an increased risk of cancer, a diagnosis or prognosis of
4 cancer, or a prediction of efficacy of a drug for ameliorating, treating or preventing cancer.

1 60. The computer program product of claim 57, comprising program
2 code for receiving information representing the presence or absence of each polymorphic
3 option of the at least three SNPs in genomic DNA in the sample; and program code for
4 rdetermining whether the individual is heterozygous for the at least two SNPs.

1 61. The computer program product of claim 57, comprising program
2 code for receiving a value representing the amount of RNA having each polymorphic option
3 of each of
4 SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and 16; or
5 SEQ ID NOs: 1, 5, 8, 9, 10, 11, 14, 15, and 16; or
6 SEQ ID NOs: 1, 5, 8, 9, 10, 11, 12, 14, 15, and 16; or
7 SEQ ID NOs: 1, 2, 4, 5, 8, 9, 10, 12, 13, 14, 15, and 16.

1 62. The computer program product of claim 57, comprising program
2 code for receiving a genotype value representing for each of at least 4 (e.g., 4, 5, 6, 7, 8, 9,
3 10, 11, 12, 13, 14, 15) SNPs selected from the group.

1 63. A pair of control isolated nucleic acid members, substantially free of
2 cellular nucleic acids, wherein both members of the pair comprise at least two Insulin Growth
3 Factor-2 (IGF2) single nucleotide polymorphism (SNP) sequences, wherein:

4 (a) one member of the pair comprises a polynucleotide that comprises one
5 allele of the at least two *IGF2* SNPs, wherein the nucleic acid sequence adjacent to the first
6 SNP is substantially identical to at least 15 contiguous nucleotides of the corresponding
7 region of SEQ ID NO:17, 18, 21, or 23, or the complement thereof, and the nucleic acid
8 sequence adjacent to the second SNP is substantially identical to at least 15 contiguous

9 nucleotides of the corresponding region of SEQ ID NO:17, 18, 21, or 23, or the complement
10 thereof; and

11 (b) the second member of the pair comprises a polynucleotide comprising
12 an alternate allele of the at least two *IGF2* SNPs; wherein the nucleic acid sequence adjacent
13 to the first SNP is substantially identical to at least 15 contiguous nucleotides of the
14 corresponding region of SEQ ID NO:17, 18, 21, or 23, or the complement thereof; and the
15 nucleic acid sequence adjacent to the second SNP is substantially identical to at least 15
16 contiguous nucleotides of the corresponding region of SEQ ID NO:17, 18, 21, or 23, or the
17 complement thereof.

1 64. The pair of claim 63, wherein at least one of the SNPs is selected from
2 the group consisting of the SNP as shown in SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12,
3 13, 14, 15, and 16.

1 65. The pair of claim 63, wherein at least two of the SNPs are selected
2 from the group consisting of the SNP as shown in SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,
3 11, 12, 13, 14, 15, and 16.

1 66. The pair of claim 63, wherein at least one of the SNPs is selected from
2 the group consisting of the SNP as shown in SEQ ID NOs: 1, 2, 3, 4, 5, and

1 67. The pair of claim 63, wherein the at least two *IGF2* SNPs comprise
2 three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen or
3 sixteen *IGF2* SNPs.

1 68. The pair of claim 67, wherein the SNPs comprise the SNPs as shown
2 in:

3 SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and 16;

4 SEQ ID NOs: 1, 5, 8, 9, 10, 11, 14, 15, and 16;

5 SEQ ID NOs. 1, 5, 8, 9, 10, 11, 12, 14, 15, and 16; or

6 SEQ ID NOs. 1, 2, 4, 5, 8, 9, 10, 12, 13, 14, 15, and 16.

1 69. The pair of claim 63, wherein the first member of the pair comprises a
2 polynucleotide that has at least 15 contiguous nucleotides of one allele of SEQ ID NO:1, 2, 3,
3 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16, or the complement thereof; and the second
4 member of the pair comprises a polynucleotide that has at least 15 contiguous nucleotides of

5 the alternative allele of SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16, or the
6 complement thereof.

1 70. The pair of claim 63, wherein one of the members of the pair
2 comprises at least two minor alleles of the SNPs.

1 71. The pair of claim 63, wherein the pair of isolated nucleic acid members
2 are RNA.

1 72. The pair of claim 63, wherein the pair of isolated nucleic acid members
2 are DNA.

1 73. The pair of claim 63, wherein the polynucleotide of (a) is operably
2 linked to a promoter and the polynucleotide of (b) is operably linked to a promoter.

1 74. The pair of claim 63, wherein the members of the pair comprise less
2 than 500 nucleotides of the sequence set forth in SEQ ID NO:22.

1 75. The pair of claim 63, wherein the members of the pair are separated.

1 76. The pair of claim 63, wherein the members of the pair are in a mix
2 together.

1 77. A mixture comprising the pair of isolated nucleic acid members of any
2 one of the preceding claims.

1 78. The mixture of claim 77, wherein the members of the pair are present in
2 equimolar amounts.

1 79. The mixture of claim 77, further comprising a second pair of isolated
2 nucleic acids, substantially free of cellular nucleic acids, wherein both members of the second
3 pair comprise at least one *IGF2* SNP sequence and wherein the at least one *IGF2* SNP
4 sequence in the second pair is different from the *IGF2* SNPs in the first pair; and

5 (c) one member of the second pair comprises one allele of the at least one
6 *IGF2* SNP, wherein the nucleic acid sequence adjacent to the at least one SNP is substantially
7 identical to at least 15 contiguous nucleotides of the corresponding region of SEQ ID NO:17,
8 18, 21, or 23, or the complement thereof; and

9 (d) the other member of the second pair comprises an alternate allele of the at
10 least one *IG2F* SNP; wherein the nucleic acid sequence adjacent to the at least one SNP is

11 substantially identical to at least 15 contiguous nucleotides of the corresponding region of
12 SEQ ID NO:17, 18, 21, or 23, or the complement thereof

1 80. A kit comprising the pair of isolated nucleic acid members of any one
2 of claims 63 to 76.

1 81. The kit of claim 80, wherein one member of the pair is in a separate
2 container without the second member of the pair.

1 82. A kit comprising a mixture of any one of claims 77 to 79.

1 83. The kit of claim 80, further comprising a second pair of isolated
2 nucleic acids, substantially free of cellular nucleic acids, wherein both members of the second
3 pair comprise at least one *IGF2* SNP sequences and wherein the at least one *IGF2* SNP
4 sequence in the second pair is different from the *IGF2* SNPs in the first pair; and

5 (c) one member of the second pair comprises one allele of the at least one
6 *IGF2* SNP, wherein the nucleic acid sequence adjacent to the at least one SNP is substantially
7 identical to at least 15 contiguous nucleotides of the corresponding region of SEQ ID NO:17,
8 18, 21, or 23, or the complement thereof and

9 (d) the other member of the second pair comprises an alternate allele of the at
10 least one *IGF2* SNP; wherein the nucleic acid sequence adjacent to the at least one SNP is
11 substantially identical to at least 15 contiguous nucleotides of the corresponding region of
12 SEQ ID NO:17, 18, 21, or 23, or the complement thereof.

1 84. The kit of claim 83, wherein the second pair of isolated nucleic acids is
2 a separate container from the first pair of nucleic acids.

1 85. A method of determining loss-of-imprinting (LOI) in an *IGF2* gene
2 from an individual, the method comprising,

3 (a) quantifying in a sample from the individual, the amount of maternal (first)
4 and paternal (second) copy of *IGF2* RNA, wherein the quantifying step comprises contacting
5 the sample RNA, or a sample cDNA thereof, with one or more oligonucleotides that
6 distinguish between a first possible SNP allele and a second possible SNP allele in the first
7 and second copy, respectively; and

8 (b) providing a control mix comprising a known ratio of the pair of nucleic
9 acids of any one of claims 63 to 76 that comprise polynucleotides having the first possible
10 SNP allele and the second possible SNP allele in step (a);

11 (c) quantifying in the control mix the amount of each member of the pair of
12 nucleic acids;
13 (d) comparing the ratio of the pair of nucleic acids present in the control mix
14 measured in step (c) to the amounts of the first and second copy of *IGF2* RNA, or a sample
15 cDNA thereof, measured in step (a), thereby determining the presence or absence of *IGF2*
16 LOI.

1 86. A method of providing a control standard in an *IGF2* loss-of-
2 imprinting (LOI) assay to confirm the viability of the reaction conditions, the method
3 comprising,
4 providing a control mix comprising a known ratio of the pair of nucleic acids
5 of any one of claims 63 to 76; and
6 quantifying in the control mix the measured ratio of each member of the pair
7 of nucleic acid, thereby confirming viability of the reaction conditions of the assay.


Figure 1. *IGF2* Gene Model

Figure 2. Diagram of *IGF2* Genotype and Allele-specific Gene Expression Measurement Strategy.




Figure 3. Informativity of Combinations of SNPs in *IGF2* Exon 9




Figure 4. Informativity of Various Optimal Combinations of SNPs in *IGF2* Exon 9 Across All Ethnic Groups




Figure 5. Example of Restriction Enzyme Based Assay for Genotyping SEQ ID NO: 8.




Figure 6. Example of Restriction Enzyme Based Assay for Detecting LOI of *IGF2*.




Figure 7. Diagram of Single Nucleotide Primer Extension Assay.





Figure 8. Single Nucleotide Primer Extension Genotyping of SEQ ID NO: 8.


Figure 9. Single Nucleotide Primer Extension Assay Detects LOI of *IGF2*.









Figure 10. Quantitative Single Nucleotide Primer Extension Assays.**A.****B.****C.****D.****E.****F.****G.****H.**






Figure 11. Quantitative Single Nucleotide Primer Extension Assays.**A.****B.****C.****D.****E.**


Figure 12. Multiplexed Assay of *IGF2* Genotype and Imprinting Status.

Figure 13. Diagram of IGF2 LOI Assay Details as Related to Synth1 and Synth2 Controls.




Figure 14. Use of DNA Controls to Determine the Quantitative Linearity of an *IGF2* LOI Assay.









Figure 15. Use of RNA Controls to Determine the Quantitative Linearity of an *IGF2* LOI Assay.

A.**B.****C.****D.****E.****F.**